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Sphingolipid-metabolizing enzymes control the critical balance of the cellular 
levels of sphingolipids, including the apoptotic inducing ceramide (Cer) and 
the proliferative inducing sphingosine 1-phosphate (S1P). Many evidences 
indicate that sphingosine kinases (SphKs)  play a critical role in regulating 
cellular processes in the body but pharmacological inhibition of SphK has been 
somehow an untested field due to lack of research into development of 
inhibitors of SphK. The presence of two isoforms of SphK also complicated 
the development process as current inhibitors of SphKs were non-specific. In 
this project, a number of novel and specific inhibitors of human recombinant 
SphKs were identified and these compounds demonstrated inhibition of SphKs 
at micromolar concentrations. A structure activity relationship (SAR) study 
was also conducted to identify the key functionalities that give rise to 
inhibitory activity. A fluorescence method for testing the effectiveness of SphK 
inhibitors was developed to enhance the process in identifying potential 
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Chapter 1: Introduction 
 
1.1  Sphingolipid Pathway 
Cell membrane mainly consists of the phospholipid bilayer; which separates 
the intracellular components of a cell from the extracellular environment. This 
phospholipid bilayer consists of two continuous layers of lipid molecules 
surrounding the entire cell. Each of the phospholipid molecules found in the 
plasma membranes has a polar region (hydrophilic head) and a long non-polar 
hydrocarbon chain region (hydrophobic tail) (Figure 1-1). The hydrocarbon 
chains usually contain between 14 to 24 carbon atoms. Often the hydrocarbon 
chain is a long alkyl, unbranched chain.  These lipid molecules are held 
together by weak hydrophobic bonding and van der Waals’ forces, which give 
the structure a liquid like form. The molecules are aligned in such a way that 
the polar heads form the surfaces of the membrane and the non-polar tails are 
pointing inward. (Figure 1-1) The cell membrane contains proteins, which are 
involved in carrying out many of the active functions of the membranes such as 
acting as receptors and transportation routes for various substances into or out 
of the membrane. Phospholipids have recently also shown importance in their 




Figure 1-1. Phospholipid Membrane Bilayer. 
2 
 
Sphingolipids or metabolites of membrane phospholipid sphingomyelin 
(Figure 1-2), are emerging as signalling molecules with pleiotropic effects on 
important cellular processes including cancer progression.
2
 Among the 
sphingomyelin metabolites, ceramide, sphingosine, and sphingosine-1-
phosphate (S1P) belong to a new class of potent bioactive molecules involved 
in regulation of cell proliferation, survival and apoptosis.
3,4,5
 Ceramide is 
produced either de novo, or by the enzymatic breakdown of sphingomyelin
6
. 
Sphingosine, however, can only be formed by the deacylation of ceramide by 
ceramidases, and can further undergo either phosphorylation by sphingosine 
kinases (SphKs) to S1P, or acylation to ceramide by ceramide synthase.
6
 
(Scheme 1-1)  In immune cells, the sphingolipid metabolism is closely 
associated with the development, differentiation, activation, and proliferation 
of immune cells,
7
 and its also has effects on physiological responses such as 











Figure 1-2. Structure of Sphingomyelin 
 
1.2 Sphingolipid Rheostat 
Ceramide and sphingosine have been linked to the mediation of cell cycle 
arrest, inhibition of proliferation, and the promotion of apoptosis.
4,10,11
 
Apoptosis is programmed cell death and leads to the resolution of 
inflammation without disgorgement of the cytotoxic contents. This cell suicide 
process is required for tissue homeostasis to prevent uncontrolled cell 
proliferation.
12
 In contrast, S1P stimulates growth and suppresses apoptosis in 
response to apoptotic stimuli such as tumor necrosis factor alpha (TNFα)13 and 
Fas ligand (FasL).
14
 Since these sphingolipid metabolites with opposing 
functions are inter-convertible within the cells, the balance between 
ceramide/sphingosine and S1P levels forms a ‘sphingolipid rheostat’,15 
whereby elevated levels of S1P pushes the cell towards cell survival and 
proliferation, and cell apoptosis is induced when the balance shifts towards 
increasing levels ceramide or sphingosine. There are several potential 
regulators of the sphingolipid rheostat, such as S1P-phosphatase and S1P 
lyase.
15
 However, SphKs are deemed to be important and are well-placed in the 
rheostat to be key regulators of this balance as they can increase S1P 





1.3 Sphingosine Kinases 
SphKs belong to a family of lipid kinases, whose roles are in various signal 
transduction pathways. Examples of other lipid kinases include diacylglycerol 
kinases (DAGKs), ceramide kinases (CERKs) and phosphatidylinositol 3-
kinases (PI3Ks).  These lipid kinases are involved in the phosphorylation 
process of the substrates of these enzymes using adenosine-5'-triphosphate 
(ATP) to form the phosphorylated substrate which is involved in further 
downstream signaling pathways and the formation of adenosine diphosphate 
(ADP). SphKs phosphorylate sphingosine to sphingosine-1-phosphate (S1P) at 
its conserved kinase catalytic domain that contains an ATP binding site and 
five conserved domains (C1 to C5).
7, 16, 17
 The five domains are said to be 





To date, two mammalian isoforms of SphKs, SphK 1
19,20
 and SphK 2,
21
 have 
been isolated and characterized. Both SphK 1 and SphK 2 are able to 
phosphorylate sphingosine to form S1P, but their functions differ much. SphK 
1 enhances growth and proliferation while suppressing apoptosis
22
, whereas the 
putative BH3-only protein SphK 2
23,24
 does exactly the opposite by inhibiting 
cell growth and enhancing apoptosis, preceded by cytochrome c release and 
activation of caspase-3
23,25
. In addition, Maceyka et al. have demonstrated that 
SphK 1 and SphK 2 have opposing roles in the ceramide biosynthesis, 
suggesting that the location of S1P production dictates its function.
24
 At the 
protein level, SphK 1 contains 200 amino acids less than SphK 2
6
. In terms of 





 SphKs are also highly specific in their substrate preference. Both SphK 1 
and SphK 2 are capable of phosphorylating erythrosphingosine and 
dihydrosphingosine (Figure 1-3); however, other phospholipids do not appear 




 Figure 1-3. Structure of erythrosphingosine and dihydrosphingosine. 
 
1.4 Sphingosine Kinases Distribution in Cells 
SphKs expression has been found to be in various cell types, a number of tissue 
cells and even in organs. High level of expression is found in the testis, 
intestinal and kidney cells
28





 For organs, SphK 1 is found to be most abundant in 
liver, spleen and lung, whereas SphK 2 is found to be present only in the liver 
and heart.
16, 31
 SphK 1 is usually localized in the cytoplasm of the cell with 
possible translocation to the plasma membranes
17
 but SphK 2 is localized in the 




1.5 Roles of Sphingosine Kinases in Cellular Processes 
1.5.1 Sphingosine kinase as a signaling molecule 
SphK is a signaling enzyme that can be activated via an agonist. Various 
external stimuli, such as epidermal growth factor (EGF), platelet derived 
growth factor (PDGF), nerve growth factor (NGF) and vascular endothelial 





 On top of these growth factors, cytokines, chemotactic peptides, Fc-receptors, 




1.5.2 Role of sphingosine kinases in calcium signaling 
The roles of SphK in various signaling processes have been widely studied. In 
the regulation of intracellular calcium signals, it has been shown that SphK 
activity plays a significant role.
17, 32, 37, 38
 Calcium signalling plays an important 
physiological role in the body as it is involved in many cellular processes such 
as cellular motility as well as exerting allosteric regulatory affects on many 
enzymes and proteins.
39
 The resting concentration of Ca
2+
 in the cytoplasm of 
the cell is normally maintained in the range of 10 – 100 nM. However this 
could be increase to 500 – 1000 nM due to external stimulus, resulting in 
cellular activities above the norm. Known external stimulus or intracellular 
second messengers which can trigger the increase in the cytosolic Ca
2+ 
concentration, include inositol 1,4,5-triphosphate (IP3), cyclic adenosine 5’-
diphosphoribose (cADPR), nitric oxide (NO), diacylglycerol (DAG), 




 Recent research also determined that 
SphK and its product, S1P, play a significant part in triggering the increase of 
Ca
2+ 




is a key second messenger in the 
leukocyte activation, upon engagement with immune receptors, Ca
2+
 
concentration in the immune cell is acutely increased. S1P can trigger an even 
higher increase in concentration, together with the stimulation by FcγRI 
aggregation in monocytes or mast cells.
17
 The sudden increase in Ca
2+
 






1.5.3 Sphingosine Kinases in Angiogenesis 
Angiogenesis is a physiological process involving the growth of new blood 
vessels from pre-existing vessels. Research has shown that SphK activity is 
high in human platelets and S1P is stored in high concentrations in the 
platelets.
41, 42
 Upon activation by external stimuli, S1P would be release from 
the platelets to engage in roles such as inflammation and angiogenisis. Recent 
findings have shown that a family of G-protein-coupled receptors (GPCR) of 
the endothelial differentiation gene (EDG) family serve as receptors for S1P. 
Furthermore, the EDG receptors appear to be S1P receptor subtypes with 
distinct signaling characteristics. In vascular endothelial cells, S1P acts on 
EDG-1 and EDG-3 subtypes of receptors to induce cell survival and 





1.6 Sphingosine Kinases in Diseases 
Diseases in which S1P has been established to be a key player include cancer, 
autoimmune diseases, allergy and cardiovascular diseases.
44
 SphK 1 and S1P 
regulate various processes important for cancer and inflammation, including 
proliferation, migration, invasion and angiogenesis, as demonstrated in both 
cell cultures and animals.
15
 SphK 1 has been found to be expressed in bronchial 
epithelial and airway smooth muscle cells,
45
 and this localization shows the 
involvement of SphK 1 in airway inflammation in bronchial asthma. Evidences 
also show S1P to be involved in the pathogenesis of bronchial asthma.
46
 
Nishiuma et al. have demonstrated that the inhalation of SphK inhibitors 
attenuates airway inflammation in asthmatic mouse model.
46
 Calcium release 
8 
 
from intracellular stores and enzyme degranulation via a novel pathway can 
also be inhibited by halting SphK 1 activity.
17
 A recent research has also found 
that SphK 1 was being up-regulated in stimulated human phagocytes and in 




Increased SphK 1 expression has been consistently found in various cancer 






 and head and 
neck squamous cell carcinoma.
50
 In addition, S1P has been implicated as a 
potent pro-angiogenic factor. S1P promotes endothelial cell migration, thereby 
promoting blood vessel formation.
51
 It is also a natural ligand to the G protein-
coupled receptor, S1P1, which has important functions in vascular maturation.
5
 
There is also evidence to show that the survival to serum deprivation or 
detachment from the extracellular matrix in endothelial cells over-expressing 
SphK 1 is enhanced, implying the important role SphK 1 plays in vascular 
phenomena under stressed conditions.
52
 Thus, SphK 1 makes a suitable cancer 
chemotherapeutic target, for several reasons. Firstly, SphK 1 has been 
established to be an oncogene, as exemplified in NIH3T3 fibroblasts, where 
overexpression of SphK 1 induces cell transformation and the capability to 
form tumors in nude mice
53
. Secondly, SphK 1 upregulation in prostate cancer 
cells results in resistance to chemotherapy
54
 and radiation therapy
55
, suggesting 
that SphK 1 plays a role in protection against therapy. Thirdly, SphK 1 is also 
found to be overexpressed in various tumors.
56
 Fourthly, S1P has been 
described as a potent pro-angiogenic factor.
57
 Lastly, SphK 1 is a key controller 
of the ‘sphingolipid rheostat,15 thus inhibition of SphK 1 will lower S1P 
9 
 
production while increasing sphingosine and ceramide ultimately induces 
cancer cell death.  
 
1.7 Current Developments in Sphingosine Kinases Inhibitors 
These findings suggest that inhibition of SphK 1 could potentially be used in 
therapeutic treatment against different allergic and inflammatory responses or 
cancers. Due to the lack of structural information on SphKs, analogues of 
natural sphingosine kinase’s substrate, sphingosine, were explored as SphK 1 
inhibitors. Three sphingosine analogues (Figure 1-4), N,N-dimethylsphingosine 
(DMS), d,l-threo-dihydrosphingosine (DHS) and N,N,N-trimethylsphingoine 
(TMS) were known to inhibit SphK activity. These compounds inhibit both 
isoforms of SphK
6
 as well as other kinases such as protein kinase C (PKC)
 58,59
, 
sphingosine-dependent protein kinase, such as DAG Kinases (DAGKs)
60
, as 
well as casein kinase II.
61
 Several research groups also reported developments 
of inhibitors of SphKs, but the compounds reported thus far have either 
targeted both SphKs or information on the isoform of SphK being targeted was 
insufficient. Besides that compounds also seem to inhibit other enzymes as 
well. These compounds are namely ABC294640 and ABC747080 by Maines 
et al.,
62
 F12509a and B5354C by Kono et al.,
63
 S-15183a/b by Kono et al.,
64
 
compounds 9ab and 12aa by Xiang et al.
65
 and compounds 23 and 28 by 
Matthews et al.
66




Figure 1-4. Structure of SphK inhibitors that resemble the natural substrate of 
SphKs. 
 
Recently, specific inhibitors of SphK 1 began to emerge. Paugh et al. have 
reported the synthesis of a SphK 1 specific inhibitor, SK1-I (Figure 1-5) that 
induces apoptosis in U937 human leukaemia cells and reduced tumour size in a 
mouse model of acute myeloid leukaemia.
67
 French et al. have also reported a 
SphK 1 inhibitor, SKI-II (Figure 1-5) that was shown to inhibit recombinant 












Figure 1-5. Structures of SphK 1 and 2 inhibitors. 
  
1.8 Objectives of our studies 
The significant roles that SphKs play in inflammation and carcinogenesis 
provide us with a potential therapeutic target to devise new and more specific 
drug candidates to treat auto-immune diseases and cancers.  Modulating the 
sphingolipid rheostat by inhibiting SphK, serve as a new strategy to tackle the 
various diseases. More research is needed to understand the full functions and 
applications of SphKs and their product, S1P, in human health and diseases. 
12 
 
The focus of this thesis is on the synthesis and evaluation of sphingosine 
analogues as inhibitors of sphingosine kinases and its applications. With the 
information gather via inhibitory studies of the sphingosine analogues, we also 
aim to develop a structure activity relationship in the inhibitors of SphK 1. 
Another purpose of our study is to develop a fluorometric based SphK assay to 
simplify the process of evaluating SphK activity of potential SphK inhibitors. 
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Chapter 2: Synthesis and Evaluation of Sphingosine Analogues as 
Sphingosine Kinase Inhibitor 
 
2.1 Introduction 
Earlier studies have shown that SphKs can be inhibited by a number of organic 
compounds.
1-3
 Analogues of sphingosine, a natural substrate of sphingosine 
kinase were often explored as SphK’s inhibitors. The two sphingosine 
analogues (Figure 2-1) are N,N-dimethylsphingosine (DMS) and d,l-threo-
dihydrosphingosine (DHS). These compounds inhibit both isoforms of SphK,
4
 
as well as other kinases such as protein kinase C (PKC),
5,6
 sphingosine-
dependent protein kinase, such as DAG Kinases (DAGKs),
7
 as well as casein 
kinase II.
8
 To better understand the roles of the different isoforms of SphK, it 
would be highly desirable to obtain inhibitors which inhibit specifically only 
one of the SphK isoforms. Thus, as part of our efforts to develop and evaluate 
the role of the different SphKs, we set out to develop sphingosine analogues as 
novel and specific SphK inhibitors, which can be used as laboratory reagents 
and potentially as novel drug candidates. In our inhibitor design, we have 
included the N-alkyloxycarbonyl functionality, as earlier studies of some of 
these compounds have shown favorable inhibition of either of the SphK 
isoforms.
9, 10
 Analogues of DMS were not explored because we perceive such 
analogues would most probably exhibit similar physiological effects as DMS.
6
 
In this study, we have investigated the role in the inhibition of either isoforms 
of SphKs, the specific functionality to the inhibitory function cytotoxicity and 











N, N-dimethylsphingosine (DMS) Dihydrosphingosine (DHS)  
Figure 2-2. Structure of SphK inhibitors, DMS and DHS  
2.2 Synthetic Strategy 
Compounds 2-4a and 2-4b were prepared from S-(-)-1,1-dimethylethyl-4-
formyl-2,2-dimethyloxazolidine-3-carboxylate 2-1 using the synthetic strategy  
shown in Scheme 2-1. Acetylides of various chain lengths, obtained by treating 
alkynes with n-butyllithium (BuLi, 1.6 M in hexanes), were coupled with 2-1. 
According to an earlier reported procedure
11
, this coupling reaction does not 
occur stereo-selectively thus giving both the erythro isomer 2-2a and the threo 
isomer 2-2b in nearly equal quantities.  To obtain specifically the naturally 




have reported the use of 
hexamethyl phosphine triamide (HMPT) as an additive. Since HMPT is an 
unpleasant reagent, we sought to develop a more benign procedure for this 
reaction. We found that temperature is a contributing factor in determining the 
stereoselectivity of the reaction (Table 2-1). Lowering the reaction temperature 
to -15ºC and using 1.16 eq of BuLi gave solely the threo-isomer 2-2b (Table 2-
1, entry 1) whilst decreasing the reaction temperature further provided 
predominantly the erythro-isomer 2-2a (Table 2-1, entries 2 - 5). These 
observations could be explained using the Felkin-Anh model
14 
(Figure 2-2a) 
which has been commonly used to demonstrate the stereoselective reaction of a 
carbonyl group with an adjacent stereogenic centre. According to the Felkin-
Anh transition state, the most reactive conformation has the electronegative 
nitrogen atom lying perpendicular to the carbonyl group (ie G1 and G2 in 
19 
 
Figure 2-2a). At low temperatures, the gauche conformer G1 is preferred as it 
would enable the nucleophile to approach the carbonyl group at the Bürgi–
Dunitz angle via the least hindered trajectory. Hence 2-2a, the kinetic control 
Felkin-Anh product, is predominant. However at a higher reaction temperature, 
the reverse in stereoselectivity (Table 2-1, entry 1) could be attributed to the 
gauche conformer G2 which undergoes nucleophilic addition via a 
thermodynamically more stable transition state. When temperature decreases 
further (Table 2-1, entries 4 -5), chelation effect starts to occur and leads to the 
chelation model (Figure 2-2b) co-exists with the gauche conformer G1 
transition state, giving rise to increasing amount of threo-isomer being formed .   
 
Subsequent ring opening of 2-2a and 2-2b using strongly acidic, macroreticular 
resin with sulfonic acid functionality yielded 2-3a and 2-3b respectively, in 
high yields.
15
 Attempts to remove the Boc protecting group by treating 2-3a 
and 2-3b with 4M HCl resulted in a complex mixture which was difficult to 
purify. Hence a mixture of 1M trimethylsilane chloride and 1M phenol in 
dichloromethane
16
 was used and this gave the deprotected product 2-4a and 2-














2-2a: 2-2b Alkyne BuLi
a
 
1 1.36 eq 1.16 eq -15 2-2b only 
2 1.36 eq 1.16 eq -23 3:1 
3 1.36 eq 1.16 eq -40 2-2a only 
4 1.36 eq 1.16 eq -50 9:1 
5 1.36 eq 1.16 eq -78 7:1 
a 
1.6 M BuLi in hexanes 
 





















































Figure 2-2. Proposed transition state of reaction. (a) Felkin-Anh model; (b)  




Compounds 2-2a and/or 2-2b were also oxidized with manganese dioxide to 
give compound 2-5 in good yields
15 
(Scheme 2-1). Treatment of 2-5 with the 
strongly acidic, macroreticular resin with sulfonic acid functionality, however, 
did not provide the ring opened product 2-8. To circumvent this problem, we 
proceeded to oxidize 2-3a and/or 2-3b using manganese dioxide which 
provided compound 2-8 in good yields. To further increase the diversity of the 
analogues, the C≡C bond in 2-5a was selectively reduced to C-C bond17 giving 
2-6a in over 83% yield. Using this synthetic strategy, 19 analogues of 
sphingosine were synthesized (Figure 2-3) and evaluated for their inhibitory 
activity against SphK 1 and 2.  
 
Scheme 2-1. Synthetic Route (a) Synthesis of Sphingosine Analogues. (b) 























































2-2a1: R = C4H9 (80%)
2-2a2: R = C8H17 (81%)
2-2a3: R = C13H27 (70%)
2-2b1: R = C4H9 (90%) 2-5a: R = C4H9 (74%)
2-5b: R = C8H17 (86%)
2-5c: R = C13H27(70%)
2-8a: R = C4H9 (87%)
2-8b: R = C8H17 (70%)
2-8c: R = C13H27 (84%)
2-6a: R = C4H9 
(85%)
2-3a1: R = C4H9 (quant.)
2-3a2: R = C8H17 (85%)
2-3a3: R = C13H27 (quant.)
2-3b1: R = C4H9 (quant.)
2-4a1: R = C4H9 (95%)
2-4a2: R = C8H17 (quant.)
2-4a3: R = C13H27 (quant.)







































































































































2.3 Results and Discussions 
2.3.1 SphK Assay 
Tables 2-2 and 2-3 show the results of the inhibitory function tests of the 
compounds on SphK 1 and SphK 2.  The compounds were tested, in an initial 
SphK assay, at a standard 10 µM concentration to filter out potential inhibitors. 
Potential inhibitors were determined by their ability to inhibit SphKs by at least 
50% at 10 µM concentration. 
 






1 2-2a3 111.93 ± 9.80 
2 2-3b1 117.21 ± 3.92 
3 2-4a1 131.64 ± 6.20 
4 2-4a2 86.34 ± 4.53 
5 2-4a3 75.63 ± 7.26  
6 2-4b1 95.15 ± 8.82 
7 2-5a 90.92 ± 9.55 
8 2-5b 84.85 ± 5.13 
9 2-5c 45.34 ± 2.00 
10 2-6a1 95.29 ± 1.50 







Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 1 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. 
 
Table 2-3. SphK 2 Assay results of compounds at 10 µM with DMS as 
comparison. 
12 2-8b 95.80 ± 5.80 
13 2-8c  43.06 ± 9.17 





1 2-2a3 123.36 ± 15.10 
2 2-3b1 111.03 ± 5.89 
3 2-4a1 108.86 ± 7.62 
4 2-4a2 116.46 ± 12.45 
5 2-4a3 152.49 ± 8.16 
6 2-4b1 95.71 ± 15.33 
7 2-5a 114.70 ± 12.29 
8 2-5b 62.81 ± 14.85 
9 2-5c 117.06 ± 3.86 








Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 2 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. 
 
From Tables 2-2 and 2-3, it can be seen that only 2-5c (Table 2-2, Entry 9) and 
2-8c (Table 2-2 and Table 2-3, Entry 13) met the initial criterion of 50% at 10 
µM concentration. 2-5c showed potential specificity on the inhibition of SphK 
1 only, whereas 2-8c showed inhibition for both isoforms of SPHK. The rest of 
the compounds either showed little or no inhibition. This initial screen, using a 
fixed concentration of 10 µM, only provided a rapid identification of 
compounds that show potential ability to inhibit SphK.  
 
The effects of compounds 2-5c and 2-8c were determined at multiple 
concentrations and the IC50 values for each compound were calculated using 
the Graphpad Prism software. As shown in Table 2-4, compounds 2-5c and 2-
8c demonstrated IC50 values at low micro-molar range for the inhibition of 
SphK 1. In fact, their IC50 values are lower than that of DMS, making them 
more potent SphK inhibitors than DMS. 
 
 
11 2-8a 117.27 ±  4.41 
12 2-8b 89.88 ± 7.31 
13 2-8c 45.88 ± 9.14 
14 DMS 66.97 ± 12.63 
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Note: Data represent the concentrations required to inhibit SphK 1’s activity by 
50% and are the mean ± standard deviation of triplicate experiments. Freshly 
prepared transfected cell lysate was used for individual testing. 
 
 
From Table 2-2 (Entry 3) and Table 2-3, it can be seen that some of the data 
from the SphK assay showed an increase in the sphingosine kinase’s activity. 
This phenomenon is especially noticeable in the SphK 2 assay result for 2-4a3 
(Table 2-3, Entry 5) and has been attributed to the formation of sphingosine-1-
phosphate (S1P) during the SphK assay. Earlier studies have shown that S1P is 
capable of activating the kinase through specific G-protein coupled receptors 
(GPCR).
18
 Though not a part of this current research project, it is worth 
mentioning that there is a growing list of agonists that have been reported to 
increase SphK activity.
18
 This phenomenon however was not observed in 
compounds that could inhibit the enzyme because there is a possibility that 
these potential inhibitors could block or bypass the agonist-induced effects. 
Another plausible reason for the activation of the sphingosine kinase could be 
due to the compound binding to allosteric site on the SphK enzyme instead of 
inhibiting SphKs, thus enhancing the SphK activity. To understand the full 
Entry Compound IC50 (µM) 
1 2-5c 3.3 ± 0.2 
2 2-8c  1.2 ± 0.1 
3 DMS  5.7 ± 1.5 
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potentials of the compounds’ abilities to function as sphingosine kinases 
inhibitors, cytoxicity tests and PKC specificity test were performed. 
 
2.3.2 MTT Assay 
Figure 2-4 shows the results of MTT assay using U937 cells, a human 
monocytic cell line, for DMS, 2-5c, 2-8c at three different incubation timings. 
Concentration of the test compounds was set as 10 µM. Blank and 
dimethylsulfoxide (DMSO) were also included to serve as controls as the test 
compounds were dissolved in DMSO. The amount of DMSO used in the assay 
was controlled at 0.5% of the total volume. This is to ensure that DMSO does 
not result in cytotoxicity of cells. Compound 2-5c is shown to be the less toxic 
compound amongst the two compounds. Its cytoxicity is comparable with, if 
not less toxic than that of DMS. However it is observed that compound 2-8c is 
very cytotoxic to cells (Figure 2-4). To confirm our observation that 2-5c is a 
better inhibitor than DMS, we subjected 2-5c in another MTT assay testing, 
using the HL60 cell line, a human promyelocytic leukemia cell line. From 
Figure 2-5, it was observed that 2-5c is less toxic towards HL 60 cells as 
compared to DMS. Both MTT assay results, using two different cell lines, 
allowed us to determine that 2-5c is not toxic towards cells and remains as a 
potential candidate as a SphK 1 inhibitor.  In the MTT assay testing, it was 
observed that the proliferation rate of both cell lines, when subjected to 10 µM 
of 2-5c, was moderately down regulated. In comparison with control, it was 
observed that the proliferation rate of cells was slowed by at least 10%, when 
the incubation period was extended from 24 to 72 h. We hypothesized that 2-5c 
could be anti-proliferative. This could be an important finding because SphK 1 
28 
 
is often found to be over-expressed in cancer cells, thus 2-5c may be an 
effective therapeutic agent against resistant cancer tumours. Though not part of 
our research focus, more work will be needed to prove our hypothesis.  
 
Having eliminated 2-8c as a potential inhibitor of SPHK through the MTT 
assay, 2-5c is then subjected to a testing in a protein kinase C (PKC) assay to 
determine its specificity towards SphK 1. 
 
 
Figure 2-4. MTT assay results at various incubation timing using U937 cell 




Figure 2-5. MTT assay results at various incubation timing using HL60 cell 
line. Note: Compounds were added at 10 µM concentration.    
 
 
2.3.3 PKC Assay 
A non-radioactive assay was chosen to evaluate the compounds activity against 
PKC. Pure human PKC alpha protein was incubated with a PKC specific 
peptide with or without the presence of 2-5c or DMS. 2-5c as well as DMS as a 
control, were tested at five concentrations: 10 µM, 25 µM, 50 µM, 75 µM, 100 
µM in this assay. Procedures used are provided in the experimental section. 
Electrophoresis was used to separate the incubation product. The 
phosphorylation process of compounds by protein kinase C protein changes the 
phosphorylated peptide’s net charge from +1 to -1. This change in the net 
charge of the substrate allows the phosphorylated and non-phosphorylated 




Figure 2-6. Gel photograph of the PKC assay for DMS and compound 2-5c. 
Note: Inhibition of PKC activity results in decreased intensity of the 
phosphorylated substrate/band and an increased intensity of the non-
phosphorylated band and vice versa. 
 
The intensity of the bands obtained were calculated and the percentage 
inhibition of the PKC protein by DMS and 2-5c were calculated and plotted 
(Figure 2-7) for comparison. It can be seen that significant inhibition of the 
PKC protein by 2-5c only occurred at concentrations above 100 µM (Figure 2-
7) whereas DMS was reported to show inhibition of the PKC protein at 50 
µM.
6
 From the PKC assay results, it could be postulated that 2-5c does not 





Figure 2-7. Comparison of inhibitory activity between DMS and 2-5c. Note: 
Relative percentage inhibition is calculated by taking the difference between 
the absolute inhibition value due to added compound and that of when no 




SphK 1 has been shown to be critically important in the regulation of cancer 
cell proliferation and apoptosis.
19
 More recently, we have shown a pivotal role 
for SphK 1 in experimental arthritis
20
 and allergic asthma.
21
 Thus SphK 1 
represents a potential novel therapeutic target to treat a wide range of diseases, 
ranging from cancer, to autoimmune disease such as rheumatoid arthritis and 
allergies such as asthma.
19-22
 In our work, we have demonstrated a facile and 
stereoselective synthesis of analogues of sphingosine and have identified 
several compounds that potently inhibit SphKs. One of the compounds, 2-5c, 
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was shown to be less toxic than DMS. Compound 2-5c is a SphK 1 specific 
inhibitor and had shown potential uses in drug development. Current efforts are 
ongoing to develop compound 2-5c as a lead compound. Understanding the in 
vivo effects of this new class of compound will be crucial in evaluating their 
clinical potential. 
 
2.5 Experimental Section 
2.5.1 Chemistry 
General Procedures.  All chemical reagents and solvents were obtained from 
Sigma Aldrich, Merck, Lancaster, or Fluka and were used without further 
purification. Analytical TLC was carried out on pre-coated silica plates (Merck 
silica gel 60, F254) and visualized with UV light or stained with 
phosphomolybdic acid (PMA) stain. Flash column chromatography was 
performed with silica (Merck, 70-230 mesh). The purities of the compounds 
were determined via HPLC using a Shimadzhu LCMS-IT-TOF system with a 
Phenomenex Luma C18 column (50 x 3.0 mm, 5 µm). Detection was 
conducted at 220 nm and integration was obtained with a Shimadzhu LCMS 
solution software. The mobile phase was a gradient with solvent B from 30% 
to 100% over 9 minutes and a flow rate of 0.8 mL/min. Solvent A was 0.1% 
trifluoroacetic acid in water, and solvent B was 0.1% trifluoroacetic acid in 





C NMR spectra were measured on a Bruker ACF 300 or AMX 
500 Fourier Transform spectrometer. Chemical shifts were reported in parts per 
million (ppm), relative to the internal standard of tetramethylsilane (TMS). The 
signals observed were described as follows: s (singlet), d (doublet), t (triplet), 
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m (multiplet). The number of protons (n) for a given resonance was indicated 
as nH. Mass spectra were performed on a Finnigan/MAT LCQ mass 
spectrometer under electron spray ionization (ESI). Optical rotations were 
determined with a JASCO DCP-1000 digital polarimeter and were the average 
of at least 10 measurements with an RSD value of less than -100%.  
 
General Procedure for the Synthesis of (S)-tert-Butyl-4-((R)-1-hydroxy-3-
alkyl-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate compound (2-2a)  
Garner’s aldehyde 2-1 (0.432 mL, 2 mmol) in tetrahydrofuran (12 mL) was 
added, via a cannula, to a solution of the respective alkyne (2.72 mmol) and 
BuLi (1.45 mL, 2.32 mmol, 1.6 M in hexanes) in tetrahydrofuran (25 mL), at -
40 ºC. The reaction mixture was stirred under nitrogen for 4 h at -40 ºC. When 
TLC monitoring indicated the complete consumption of the starting materials, 
the reaction mixture was quenched with distilled water (10 mL) and extracted 
with ethyl acetate. The combined organic layer was washed with ammonium 
chloride, dried over magnesium sulfate, filtered, concentrated and purified by 




carboxylate (2-2a1). [α]25 = -44.28° (c = 99.5 x 10-3 g/mL, CH2Cl2); 
1
H NMR 
(300 MHz, C6D6) δ 5.10-5.12 (m, 1H, CHOH), 4.60 (br s, 1H, CHOH), 4.12-
4.18 (m, 1H, OCH2CHN), 3.80-3.84 (m, 2H, OCH2CH), 2.05-2.09 (t, 2H, J = 
5.1 Hz, 6.7 Hz, C≡CCH2), 1.75 (s, 3H, OCCH3), 1.53 (s, 3H, NCCH3), 1.46 (s, 
9H, OC(CH3)3), 1.27-1.41 (m, 4H, CH2(CH2)2CH3), 0.86-0.91 (t, 3H, J = 6.9 
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Hz, 7.1 Hz, CH2CH3); 
13
C NMR (125 MHz, C6D6) δ 154.8, 95.6, 86.6, 81.3, 
80.1, 64.8, 63.8, 63.1, 30.4, 28.9, 27.8, 27.7, 25.6, 25.3, 21.6, 18.2, 13.2; 




carboxylate (2-2a2). [α]25 = -44.62° (c = 43.5 x 10-3 g/mL, CH2Cl2); 
1
H NMR 
(300 MHz, C6D6) δ 5.05-5.12 (m, 1H, CHOH), 4.60 (br s, 1H, CHOH), 4.03-
4.07 (m, 1H, OCH2CHN), 3.62-3.78 (m, 2H, OCH2CH), 2.02-2.07 (t, 2H, J = 
6.3 Hz, 6.5 Hz, C≡CCH2), 1.68 (s, 3H, OCCH3), 1.44 (s, 3H, NCCH3), 1.37 (s, 
9H, OC(CH3)3), 1.15-1.28 (m, 12H, CH2(CH2)6CH3), 0.91-0.93 (t, 3H, J = 6.9 
Hz, 7.0 Hz, CH2CH3); 
13
C NMR (75 MHz, C6D6) δ154.8, 95.6, 86.6, 81.3, 80.1, 
65.9, 65.5, 64.8, 64.2, 63.9, 62.9, 32.8, 30.2, 30.1, 29.8, 29.6, 29.0, 26.7, 23.6, 
19.7, 14.9; HRMS (ESI, M + Na) calcd for C21H37O4NNa: 390.2615; found 
390.2621. Yield: 81%. 
 
 (S)-tert-Butyl-4-((R)-1-hydroxyhexadec-2-ynyl)-2,2-dimethyloxazolidine-
3-carboxylate (2-2a3). [α]25 = -40.09° (c = 26.0 x 10-3 g/mL, CH2Cl2); 
1
H 
NMR (300 MHz, C6D6) δ 5.11-5.12 (m, 1H, CHOH), 4.60 (br s, 1H, CHOH), 
4.09-4.10 (m, 1H, OCH2CHN), 3.65-3.71 (m, 2H, OCH2CH), 2.05-2.08 (t, 2H, 
J = 5.7 Hz, 7.0 Hz, C≡CCH2), 1.68 (s, 3H, OCCH3), 1.44 (s, 3H, NCCH3), 
1.37 (s, 9H, OC(CH3)3), 1.22-1.30 (m, 22H, CH2(CH2)11CH3), 0.87-0.92 (t, 3H, 
J = 6.6 Hz, 7.0 Hz, CH2CH3); 
13C NMR (75 MHz, C6D6) δ 154.8, 94.6, 85.6, 
80.2, 79.7, 79.2, 65.0, 64.2, 63.8, 63.2, 62.8, 61.9, 32.0, 29.8, 29.6, 29.4, 29.2, 
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28.9, 28.7, 28.0, 25.8, 25.4, 23.2, 22.7, 18.7, 14.0; HRMS (ESI, M + Na) calcd 
for C26H47O4NNa: 460.3397; found 460.3406. Yield: 70%. 
 
General Procedure for the Synthesis of (S)-tert-Butyl-4-((S)-1-hydroxy-3-
alkyl-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate compound (2-2b)  
Garner’s aldehyde 2-1 (0.432 mL, 2 mmol) in tetrahydrofuran (12 mL) was 
added, via a cannula, to a solution of the respective alkyne (2.72 mmol) and 
BuLi (1.45 mL, 2.32 mmol, 1.6 M in hexanes) in tetrahydrofuran (25 mL), at -
15 ºC. The reaction mixture was stirred under nitrogen for 4 h at -15 ºC. When 
TLC monitoring indicated the complete consumption of the starting materials, 
the reaction mixture was quenched with distilled water (10 mL) and extracted 
with ethyl acetate. The combined organic layer was washed with ammonium 
chloride, dried over magnesium sulfate, filtered, concentrated and purified by 
column chromatography (ethyl acetate: hexane = 1:5 with 2% acetic acid) to 
yield  2-2b. 
 
(S)-tert-Butyl-4-((S)-1-hydroxyhept-2-ynyl)-2,2-dimethyloxazolidine-3-
carboxylate (2-2b1). [α]25 = -49.16° (c = 84.0 x 10-3 g/mL, CH2Cl2); 
1
H NMR 
(300 MHz, C6D6) δ 5.15-5.18 (m, 1H, CHOH), 4.62 (br s, 1H, CHOH), 4.07-
4.08 (m, 1H, OCH2CHN), 3.74-3.80 (m, 2H, OCH2CH), 1.99-2.03 (t, 2H, J = 
5.1 Hz, 6.7 Hz, C≡CCH2), 1.61 (s, 3H, OCCH3), 1.41 (s, 3H, NCCH3), 1.36 (s, 
9H, OC(CH3)3), 1.26-1.32 (m, 4H, CH2(CH2)2CH3), 0.74-0.79 (t, 3H, J = 6.9 
Hz, 7.1 Hz, CH2CH3); 
13C NMR (75 MHz, C6D6) δ 154.8, 95.6, 86.6, 81.3, 
80.1, 65.9, 64.7, 64.2, 31.6, 29.1, 28.9, 28.8, 26.7, 26.4, 22.8, 19.3, 14.3; 
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HRMS (ESI, M + Na) calcd for C17H29O4NNa: 334.1994; found 334.1987. 
Yield: 90%. 
 
General Procedure for the Synthesis of tert-Butyl-(2S,3R)-1,3- 
dihydroxyalk-4-yn-2-ylcarbamate compound (2-3a) and tert-Butyl-(2S,3S)-
1,3-dihydroxyalk-4-yn-2-ylcarbamate compound (2-3b). 
Compound 2-2a (0.2534 mmol) or 2-2b (0.5692 mmol) was dissolved in 
anhydrous methanol (15 mL). Amberlyst 15 resin (1.2 wt. eq) was added and 
the reaction mixture was shaken for 48 h. After which, the reaction mixture 
was filtered and concentrated to give 2-3a or 2-3b. 
 
tert-Butyl-(2S,3R)-1,3-dihydroxynon-4-yn-2-ylcarbamate (2-3a1). [α]25 = -
13.55° (c = 1.100 x 10
-3
 g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 5.33-
5.36 (d, 1H, J = 8.1 Hz, CHOH), 4.60 (s, 1H, CHOH), 4.06-4.09 (m, 1H, 
OCH2CHN), 3.74-3.76 (m, 2H, OCH2CH), 2.19-2.24 (t, 2H, J = 5.4 Hz, 7.1 Hz, 
C≡CCH2), 1.35-1.51 (m, 2H, CH2CH2CH3), 1.44 (s, 9H, OC(CH3)3), 1.24-1.25 
(m, 2H, CH2CH2CH3), 0.87-0.92 (t, 3H, J = 7.1 Hz, 7.2 Hz, CH2CH3); 
13
C 
NMR (125 MHz, CDCl3) δ 156.2, 88.1, 80.0, 77.9, 64.7, 62.8, 55.7, 30.5, 28.3, 
21.9, 18.3, 13.5; HRMS (ESI, M + Na) calcd for C14H25O4NNa: 294.1676; 
found 294.1681. Yield: 100%. 
 
tert-Butyl-(2S,3R)-1,3-dihydroxytridec-4-yn-2-ylcarbamate (2-3a2). [α]25 = 
-20.57° (c = 1.060 x 10
-3
 g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 5.36-
5.39 (d, 1H, J = 8.4 Hz, CHOH), 4.57 (s, 1H, CHOH), 4.01-4.06 (m, 1H, 
OCH2CHN), 3.70-3.73 (m, 2H, OCH2CH), 2.17-2.21 (t, 2H, J = 5.4 Hz, 7.0 Hz, 
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C≡CCH2), 1.43 (s, 9H, OC(CH3)3), 1.24-1.33 (m, 12H, CH2(CH2)6CH3), 0.84-
0.88 (t, 3H, J = 6.3 Hz, 7.0 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 156.2, 
87.9, 80.0, 64.3, 62.6, 55.8, 31.7, 29.1, 29.0, 28.8, 28.4, 28.2, 22.5, 18.6, 14.0; 
HRMS (ESI, M + Na) calcd for C18H33O4NNa: 350.2302; found 350.2314. 
Yield: 85%. 
 
tert-Butyl-(2S,3R)-1,3-dihydroxyoctadec-4-yn-2-ylcarbamate (2-3a3). [α]25 
= -63.31° (c = 0.420 x 10
-3
 g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 5.35-
5.38 (d, 1H, J = 8.0 Hz, CHOH), 4.58 (s, 1H, CHOH), 4.02-4.07 (m, 1H, 
OCH2CHN), 3.69-3.73 (m, 2H, OCH2CH), 2.17-2.22 (t, 2H, J = 7.0 Hz, 7.3 Hz, 
C≡CCH2), 1.44 (s, 9H, OC(CH3)3), 1.24-1.33 (m, 22H, CH2(CH2)11CH3), 0.84-
0.89 (t, 3H, J = 6.3 Hz, 7.0 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 156.2, 
88.0, 80.0, 64.4, 63.6, 62.6, 55.8, 31.8, 29.6, 29.3, 29.0, 28.8, 28.5, 28.3, 22.6, 
18.6, 14.0HRMS (ESI, M + Na) calcd for C23H43O4N Na: 420.3084; found 
420.3088. Yield: 100%. 
 
tert-Butyl-(2S,3S)-1,3-dihydroxynon-4-yn-2-ylcarbamate (2-3b1). [α]25 = -
26.17° (c = 1.150 x 10
-3
 g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 5.35-
5.37 (d, 1H, J = 8.0 Hz, CHOH), 4.58 (s, 1H, CHOH), 4.04-4.07 (m, 1H, 
OCH2CHN), 3.73-3.74 (m, 2H, OCH2CH), 2.18-2.24 (t, 2H, J = 6.8 Hz, 7.1 Hz, 
C≡CCH2), 1.34-1.51 (m, 2H, CH2CH2CH3), 1.44 (s, 9H, OC(CH3)3), 1.24-1.25 
(m, 2H, CH2CH2CH3), 0.87-0.92 (t, 3H, J = 7.1 Hz, 7.2 Hz, CH2CH3); 
13
C 
NMR (75 MHz, CDCl3) δ 156.3, 87.9, 80.0, 77.9, 64.4, 62.7, 55.8, 30.5, 28.3, 
21.9, 18.3, 13.5; HRMS (ESI, M + Na) calcd for C14H25O4NNa: 294.1676; 
found 294.1671. Yield: 100%. 
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General Procedure for the Synthesis of (2S,3R)-2-Aminoalk-4-yne-1,3-diol 
compound (2-4a) and (2S,3S)-2-Aminoalk-4-yne-1,3-diol compound (2-4b) 
Phenol (0.47g, 5 mmol) in dichloromethane (5 mL) was mixed with 
trimethylsilane chloride (0.635 mL, 5 mmol) in dichloromethane (5 mL). The 
mixture solution was added to compound 2-3a (0.0777 mmol) or 2-3b (0.2925 
mmol) and stirred for 1 h. Thereafter the reaction mixture was purified by 
column chromatography (ethyl acetate: hexane = 1:1 followed by chloroform: 
methanol: ammonium hydroxide = 130:25:4) to yield 2-4a or 2-4b. 
 
(2S,3R)-2-Aminonon-4-yne-1,3-diol (2-4a1). [α]25 = -168.67° (c = 0.150 x 10-
3
 g/mL, DMSO); 
1
H NMR (300 MHz, CD3OD) δ 4.38-4.40 (m, 1H, CHOH), 
3.57-3.72 (m, 2H, CH2OH), 2.86-2.89 (m, 1H, CH2CHCHOH), 2.24-2.27 (t, 
2H, J = 6.9 Hz, 7.0 Hz, C≡CCH2), 1.29-1.54 (m, 4H, CH2(CH2)2CH3), 0.92-
0.95 (t, 3H, J = 7.0 Hz, 7.6 Hz, CH2CH3); 
13
C NMR (125 MHz, CD3OD) δ 
87.8, 79.1, 64.3, 63.3, 58.6, 31.8, 22.9, 19.0, 13.8; HRMS (ESI, M + H) calcd 
for C9H17O2N: 171.1332; found 172.1339. Yield: 95%. 
 
(2S,3R)-2-Aminotridec-4-yne-1,3-diol (2-4a2). [α]25 = -58.70° (c = 0.385 x 
10
-3
 g/mL, DMSO); 
1
H NMR (300 MHz, CD3OD) δ 4.56 (br s, 1H, CHOH), 
3.72-3.86 (m, 2H, CH2OH), 3.19 (br s, 1H, CH2CHCHOH), 2.24-2.28 (t, 2H, J 
= 6.6 Hz, 7.0 Hz, C≡CCH2), 1.49-1.55 (m, 2H, C≡CCH2CH2), 1.40-1.43 (m, 
2H, CH2CH3), 1..31 (s, 8H, (CH2)4CH2), 0.88-0.92 (t, 3H, J = 5.4 Hz, 7.0 Hz, 
CH2CH3); 
13
C  NMR (75 MHz, CD3OD) δ 89.0, 77.7, 61.6, 60.7, 58.6, 32.9, 
30.3, 30.2, 29.9, 29.6, 23.6, 19.3, 14.3; HRMS (ESI, M + H) calcd for 
C13H25O2N: 227.1885; found 228.1958. Yield: 100%. 
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(2S,3R)-2-Aminooctadec-4-yne-1,3-diol (2-4a3). [α]25 = -29.67° (c = 0.765 x 
10
-3
 g/mL, DMSO); 
1
H NMR (300 MHz, CD3OD) δ 4.59 (br s, 1H, CHOH), 
3.70-3.90 (m, 2H, CH2OH), 3.21 (br s, 1H, CH2CHCHOH), 2.23-2.28 (t, 2H, J 
= 5.4 Hz, 7.1 Hz, C≡CCH2), 1.48-1.57 (m, 2H, C≡CCH2CH2), 1.40-1.42 (m, 
2H, CH2CH3), 1.29 (s, 18H, (CH2)9CH2), 0.88-0.92 (t, 3H, J = 6.4 Hz, 6.9 Hz, 
CH2CH3); 
13C  NMR (75 MHz, CD3OD) δ 89.1, 77.6, 64.3, 61.4, 60.4, 58.6, 
33.0, 30.7, 30.6, 30.4, 30.2, 29.9, 29.6, 23.7, 23.1, 19.3, 14.4; HRMS (ESI, M 
+ H) calcd for C18H35O2N: 297.2668; found 298.2735. Yield: 100%. 
(2S,3S)-2-Aminonon-4-yne-1,3-diol (2-4b1). [α]25 = -16.57° (c = 0.99 x 10-3 
g/mL, DMSO); 
1
H NMR (300 MHz, CD3OD) δ 4.58-4.60 (m, 1H, CHOH), 
3.73-3.85 (m, 2H, CH2OH), 3.19-3.22 (m, 1H, CH2CHCHOH), 2.24-2.29 (t, 
2H, J = 6.3 Hz, 6.6 Hz, C≡CCH2), 1.42-1.52 (m, 4H, CH2(CH2)2CH3), 0.90-
0.95 (t, 3H, J = 7.0 Hz, 7.0 Hz, CH2CH3); 
13
C NMR (75 MHz, CD3OD) δ 89.0, 
77.7, 61.5, 60.6, 58.5, 31.6, 22.9, 19.0, 13.8; HRMS (ESI, M + H) calcd for 
C9H17O2N: 171.1259; found 172.1337. Yield: 92%. 
 
General Procedure for the Synthesis of (S)-tert-Butyl-4-alk-2-ynoyl-2,2-
dimethyloxazolidine-3-carboxylate compound (2-5) 
Compound 2-2a or 2-2b (0.1182 mmol) and anhydrous dichloromethane (4mL) 
were placed in a dry round bottom flask. Manganese dioxide (0.2055g, 2.369 
mmol) was added and the reaction mixture was stirred at room temperature for 
3 h. The reaction mixture was then filtered through Celite powder and purified 





Purified using ethyl acetate: hexane = 1:6. [α]25 = -23.02° (c = 1.060 x 10-3 
g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 4.33-4.36 (m, 1H, OCH2CH), 
4.04-4.22 (m, 2H, OCH2CH), 2.36-2.41 (t, 2H, J = 6.9 Hz, 7.1 Hz, C≡CCH2), 
1.70 (s, 3H, OCCH3), 1.54 (s, 3H, NCCH3), 1.42 (s, 9H, OC(CH3)3), 1.45-1.50 
(m, 4H, CH2(CH2)2CH3), 0.88-0.93 (t, 3H, J = 7.2 Hz, 7.2 Hz, CH2CH3); 
13
C  
NMR (75 MHz, CDCl3) δ 186.2, 130.8, 98.1, 95.3, 80.7,66.5, 65.7, 65.3, 29.6, 
29.5, 28.3, 28.1, 25.1, 24.2, 21.9, 18.7, 13.3; HRMS (ESI, M + Na) calcd for 
C17H27O4NNa: 332.1832; found 332.1843. Yield: 74%. 
 
(S)-tert-Butyl-4-undec-2-ynoyl-2,2-dimethyl-oxazolidine-3-carboxylate (2-
5b). Purified using ethyl acetate: hexane = 1:4. [α]25 = -22.61° (c = 0.69 x 10-3 
g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 4.33-4.36 (m, 1H, OCH2CH), 
4.04-4.23 (m, 2H, OCH2CH), 2.35-2.40 (t, 2H, J = 7.1 Hz, 7.2 Hz, C≡CCH2), 
1.70 (s, 3H, OCCH3), 1.54 (s, 3H, NCCH3), 1.44-1.50 (m, 4H, CH2(CH2)2CH3), 
1.42 (s, 9H, OC(CH3)3), 0.86-0.89 (t, 3H, J = 5.7 Hz, 6.9 Hz, CH2CH3); 
13
C 
NMR (125 MHz, CDCl3) δ 186.2, 128.8, 98.2, 95.3, 80.7, 66.6, 65.7, 65.4, 31.8, 
29.0, 28.9, 28.8, 28.3, 28.2, 27.5, 25.2, 24.2, 22.6, 19.1, 14.1; HRMS (ESI, M 
+ Na) calcd for C21H35O4NNa: 388.2458; found 388.2470. Yield: 86%. 
 
(S)-tert-Butyl-4-hexadec-2-ynoyl-2,2-dimethyloxazolidine-3-carboxylate (2-
5c). Purified using ethyl acetate: hexane = 1:4. [α]25 = -24.77° (c = 0.965 x 10-
3 g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 4.33-4.36 (m, 1H, OCH2CH), 
4.04-4.22 (m, 2H, OCH2CH), 2.36-2.41 (t, 2H, J = 6.9 Hz, 7.1 Hz, C≡CCH2), 
1.69 (s, 3H, OCCH3), 1.54 (s, 3H, NCCH3), 1.49-1.50 (m, 4H,  
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CH2(CH2)9CH2), 1.42 (s, 9H, OC(CH3)3), 1.24 (s, 18H, CH2(CH2)9CH2), 0.85-
0.89 (t, 3H, J = 5.6 Hz, 7.0 Hz, CH2CH3); 
13
C  NMR (75 MHz, CDCl3) δ 186.2, 
127.9, 98.1, 95.3, 80.6, 66.5, 65.7, 65.3, 51.6, 31.8, 29.5, 29.4, 29.3, 28.9, 28.8, 
28.3, 28.1, 27.5, 26.1, 25.1, 25.0, 24.2, 22.6, 19.0, 14.0; HRMS (ESI, M + Na) 
calcd for C26H45O4NNa: 458.3241; found 458.3220. Yield: 70%. HPLC, tR= 
13.66 mins (98.0%). 
 
General Procedure for the Synthesis of (S)-tert-Butyl-4-alkanoyl-2,2-
dimethyloxazolidine-3-carboxylate compound (2-6) 
Compound 2-5 (0.0934 mmol) and anhydrous methanol (4 mL) were placed in 
a dry round bottom flask. 10% Pd/C powder (0.0029g, 10% wt. eq.) and 
diphenyl sulphide (0.1537µl, 0.000934 mmol) were added in the stated order 
and the reaction mixture was purged twice with hydrogen gas. A hydrogen 
balloon was attached to the reaction flask and the mixture was stirred at room 
temperature for 24 h. After which, the reaction mixture was filtered through 
Celite powder and purified by column chromatography (ethyl acetate: hexane = 
1:5, 2% acetic acid) to yield 2-6. 
 
(S)-tert-Butyl-4-heptanoyl-2,2-dimethyloxazolidine-3-carboxylate (2-6a).  
[α]25 =  -15.31°(c= 1.195 x 10-3 g/mL, DMSO); 1H NMR (300 MHz, CDCl3) δ 
4.30-4.44 (dd, 1H, J = 5.2 Hz, 6.3 Hz, OCH2CH), 4.13 (dt, 2H, J = 9.1 Hz, 9.4 
Hz, OCH2CH), 2.46-2.50 (t, 2H, J = 4.9 Hz, 6.6 Hz, C(O)CH2), 1.70 (s, 3H, 
OCCH3), 1.58-1.64 (m, 2H, C(O)CH2CH2), 1.52-1.56 (m, 2H, CH2CH3), 1.49 
(s, 3H, NCCH3), 1.40 (s, 9H, OC(CH3)3), 1.26-1.32 (m, 4H, CH2(CH2)2CH2), 
0.86 (t, 3H, J = 4.5 Hz, 6.3 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ 208. 
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8, 155.6, 95.1, 80.5, 65.6, 65.3, 65.1, 39.0, 38.3, 31.5, 29.6, 28.9, 28.8, 28.2, 
26.1, 25.3, 24.8, 23.6, 23.0, 22.4, 13.9; HRMS (ESI, M + Na) calcd for 
C17H31O4NNa: 336.2151; found 336.2155. Yield: 85%. 
 
General Procedure for the Synthesis of (S)-tert-Butyl-1-hydroxy-3-oxoalk-
4-yn-2-ylcarbamate compound (2-8)  
Compound 2-3a or 2-3b (0.273 mmol) and anhydrous dichloromethane (4 mL) 
were placed in a dry round bottom flask. Manganese dioxide (0.2055g, 5.46 
mmol) was added and the reaction mixture was stirred at room temperature for 
3 h. The reaction mixture was then filtered through Celite powder and purified 
by column chromatography (ethyl acetate: hexane = 1:3) to yield 2-8. 
 
(S)-tert-Butyl-1-hydroxy-3-oxonon-4-yn-2-ylcarbamate (2-8a). [α]25 = -
16.28° (c = 1.640 x 10
-3
 g/mL, DMSO); 
1
H NMR (500 MHz, CDCl3) δ 5.61 (s, 
1H, CH2OH), 4.41 (s, 1H, OCH2CH), 4.01-4.11 (m, 2H, OCH2CH), 2.39-2.42 
(t, 2H, J = 7.0 Hz, 7.6 Hz, C≡CCH2), 1.55-1.60 (m, 2H, CH2CH2CH3), 1.44 (s, 
9H, OC(CH3)3), 1.41-1.45 (m, 2H, CH2CH3), 0.91-0.93 (t, 3H, J = 7.0 Hz, 7.6 
Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ 184.3, 155.8, 99.0, 80.3, 78.9, 
63.5, 63.1, 29.5, 28.2, 21.9, 18.8, 13.4; HRMS (ESI, M + Na) calcd for 
C14H23O4NNa: 292.1519; found 292.1520. Yield: 87%. 
 
(S)-tert-Butyl-1-hydroxy-3-oxotridec-4-yn-2-ylcarbamate (2-8b). [α]25 = -
88.53° (c = 0.340 x 10
-3
 g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 5.59 (s, 
1H, CH2OH), 4.42 (s, 1H, OCH2CH), 4.03-4.15 (m, 2H, OCH2CH), 2.38-2.43 
(t, 2H, J = 7.0 Hz, 7.3 Hz, C≡CCH2), 1.57-1.66 (m, 2H, CH2(CH2)2-5cH3), 1.46 
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(s, 9H, OC(CH3)3), 1.25-1.27 (m, 10H, CH2(CH2)2-5cH3), 0.86-0.90 (t, 3H, J = 
5.9 Hz, 7.0 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 184.0, 155.8, 99.1, 
80.4, 78.8, 63.6, 63.2, 31.7, 29.6, 29.0, 28.9, 28.8, 28.2, 27.5, 22.6, 19.1, 14.0; 
HRMS (ESI, M + Na) calcd for C18H31O4NNa: 348.2145; found 348.2159. 
Yield: 70%. 
 
(S)-tert-Butyl-1-hydroxy-3-oxooctadec-4-yn-2-ylcarbamate (2-8c). [α]25 = -
49.15° (c = 0.47 x 10
-3
 g/mL, DMSO); 
1
H NMR (300 MHz, CDCl3) δ 5.60 (s, 
1H, CH2OH), 4.43 (s, 1H, OCH2CH), 4.06-4.15 (m, 2H, OCH2CH), 2.38-2.42 
(t, 2H, J = 7.1 Hz, 7.2 Hz, C≡CCH2), 1.55-1.62  (m, 2H, CH2(CH2)9CH2), 1.45 
(s, 9H, OC(CH3)3), 1.35-1.42 (m, 2H, CH2CH3) (1.21-1.29 (m, 18H, 
CH2(CH2)9CH2), 0.85-0.90 (t, 3H, J = 6.4 Hz, 7.1 Hz, CH2CH3); 
13
C NMR (75 
MHz, CDCl3) δ 184.0, 155.8, 99.2, 80.4, 78.8, 63.6, 63.2, 60.3, 33.4, 31.9, 29.6, 
29.5, 29.4, 29.3, 29.2, 28.9, 28.8, 28.2, 27.5, 24.7, 23.8, 22.6, 19.1, 14.0; 
HRMS (ESI, M + Na) calcd for C23H41O4NNa: 418.2928; found 418.2934. 
Yield: 84%. 
 
 2.5.2 Sphingosine kinase 1 or 2 DNA plasmid preparation 
Culture Growing: Human SphK 1 plasmid was established, in which SphK 1 
gene was fused with an enhanced green fluorescence protein gene (EGFP-
SphK 1) (Figure 2-8). The structure was constructed with restrictive enzymes 






Figure 2-8. Map of EGFP-SPHK 1 plasmid. EGFP-SphK 1 gene is inserted 
into pcDNA3.1 plasmid. 
 
Human SphK 2 clone, which contained SphK 2 plasmid, was produced by 
Open Biosystems and purchased from iDNA Technology. SphK 2 gene was 
inserted into the site constructed by two restriction enzymes NotI and SalI 
using pCMV-SPORT6 vector. There is no reporter system such as GFP or his-
tag within this plasmid. The SphHK 1 and 2 bacteria cells were removed from 
the freezer, and warmed to room temperature. 200 μL of LB medium was 
transferred into 50mL Falcon Tubes and then 20 μL of the warmed bacteria 
cells (SphK 1 and 2) were added. The mixtures were shaken gently and 50 μL 
of each of the mixture was pipetted into individually prepared culture plates 
(pre-coated with AMP) and evenly spread out using a bent glass pipette. The 
culture plates (containing SphK 1 and 2 cells individually) were then turned 
upside down and placed overnight in an incubator at 37 °C, 5% CO2 in a water 
saturated environment. This environment will allow the cells to grow into 
single colonies. After the single cell colonies have grown, a single colony was 
picked using a micropipette tip and dropped into a falcon tube containing LB 
medium. The tube was placed in an incubator shaker set at 270 rpm for 7 h or 
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more. The tube was then checked for cloudiness before more medium was 
added to the tube and the shaking was continued at 280 rpm for an additional 
17 h or more. Extraction and Purification: The cultured bacteria (containing the 
DNA-plasmids encoding for SphK 1 and SphK 2 genes) were centrifuged 
down and the supernatant liquid poured away. The pellet obtained was re-
dissolved in medium and purified using QIAfilter Plasmid Midi kit, following 
the protocol listed in the kit, yielding the DNA plasmids for SphK 1 and 2. The 
concentration of the DNA plasmids is obtained using the Thermo Scientific 
NanoDrop
TM
 1000 Spectrophotometer. 
 
2.5.3 Mammalian Cell Transfection 
Cell line used for the transfection process in this project was the Chinese 
Hamster Ovary (CHO) cell line. The cell line was cultured using Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Bovine 
Serum (FBS), 1% 2mM L-glutamine, 10 mg/mL streptomycin and 10 µL/mL 
penicillin. The cell line was maintained in an incubator at 37 °C, with 5% CO2 
in a water saturated environment. 1 x 10
6
 cells were plated in a 10 cm well 
plate in 15 mL of DMEM a day before actual transfection. On day of 
transfection, the medium in the cell culture was removed, the cells washed with 
sterile phosphate buffered saline (PBS) and 10 mL of plain DMEM was added 
as medium. SphK 1 or 2 DNA plasmids obtained were diluted in Opti-MEM I 
Reduced Serum Medium and mixed gently (24 µg plasmid in 1.5 mL Opti-
MEM/ per 10 cm well). Lipofectamine 2000 reagent was diluted in Opti-MEM, 
mixed gently and incubated for 5 minutes (60 µl Lipofectamine 2000 reagent 
in 1.5 mL Opti-MEM/ per 10 cm well). The diluted DNA and Lipofectamine 
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reagent were combined, shaken gently and incubated for 30 minutes. 100µl of 
the combined DNA-Lipofectamine 2000 complex was added to the wells 
containing the CHO cells and DMEM medium and the culture plates were 
placed in the incubator for 48 h at 37 °C with 5% CO2 in a water saturated 
environment. After 24 h, the cells were scrapped and transferred to 2.0 mL 
eppendorf tubes. Cell lysates are obtained by freeze-thawing the eppendorf 
tubes using liquid nitrogen for at least 10 times consecutively. The tubes were 
then centrifuged at 13000 rpm for about 5 minutes and the supernatant liquid 
was transferred to a 50 mL centrifuge tube. Concentrations of the cell lysates 
were measured using the Bradford Test template, following the protocol listed 
for Bradford Test.
23
 The success of the transfection process was checked by 
running the SphK assay using the cell lysates obtained (Figure 2-10).  
 
 







P based Sphingosine Kinase (SphK) Assay 
1mM of sphingosine-BSA complex was prepared by adding of 20µl of natural 
occurring erythro-sphingosine (50 mM) drop-wise into a glass tube containing 
1 mL of BSA solution (4 mg/mL). The glass tube was continually vortexed 
during the addition. After which, the reaction mixture was sonicated for a 
minute and stored on ice. The reaction mixture for the sphingosine kinase assay 
was prepared by first placing the compounds at 0, 10, 25, 50 and 100 μM 
concentrations into glass tubes containing the cell lysates (40µg/ per tube). The 
total volume was topped up to 180 µL using sphingosine kinase buffer. 10 µL 
of the prepared 1 mM sphingosine-BSA complex was added to the tubes. The 
reaction mixture in the glass tubes was then vortexed. 10 µL of the ATP 
solution (cold and hot ATP combined) was added to each of the samples and 
the mixture was then vortexed. The tubes were then placed in a rack in a 37
o
C 
water bath to be incubated for 30 minutes. After which, the rack was removed 
from the water bath and placed on ice. 20 μL of 1N HCl and 0.8 mL of 
chloroform: methanol: HCl (100:200:1, v/v/v) were added and the mixture was 
vortexed and allowed to stand for 5-10 minutes. 240 μL of chloroform and 240 
μL of 2N KCl were added; the mixture was vortexed and again allowed to 
stand for 5-10 minutes. The glass tubes were then centrifuged for 5-10 minutes. 
75 μL of the organic phase (bottom phase, chloroform) was spotted on the TLC 
plates with three lanes dedicated to each sample tube (i.e. to obtain triplicate 
readings). Upon drying, the plates were placed in a TLC glass chamber 
containing the eluent solvent system (1-butanol: methanol: acetic acid: water, 
80:20:10:20, v/v). The plates were exposed individually to a phosphor imager 
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screen for at least 3 h and the screen was read in a phosphor imager (Typhoon 
scanner).  
 
2.5.5 MTT Assay 
U937 cells/ HL60 cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 medium containing 10% Fetal Bovine Serum (FBS) and 1% L-
glutamine. 50000 cells were placed in wells of three 96 wells plates with a cell 
density of 1x10
6
 cells/ mL. The compound of interest was added into each well 
at concentration of 10 μM. Dimethylsphingosine was also added in at the 10 
μM to serve as a control. Wells containing plain DMSO served as a vehicular 
control. The plate was then placed in the incubator for 24, 48 and 72 h of 
incubation timing at 37°C with 5% CO2 in a water saturated environment. At 
the end of each individual incubation time point, MTT reagent solution (For 
200 samples) was prepared by dissolving 4 mg of 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) in 1 mL of plain RPMI 1640 
medium and 50 μL of the MTT solution was added into each sample well. The 
plate was then incubated again in the dark for 2 h and centrifuged at 3000 rpm 
for 5 minutes. The supernatant was removed using a pipette and care was taken 
not to disturb the crystal formation. The crystals were then dissolved in 200 μL 
(per well) of DMSO/ glycine buffer solution (190 μL of DMSO + 10 μL of 
glycine buffer). The plate was then gently shaken using a vortemp machine for 






2.5.6 Protein Kinase C (PKC) Assay 
The assay was performed in accordance to the Promega’s PepTag® Assay’s 
protocol provided. Protein Kinase C (PKC) Alpha protein and PKC protein 
were diluted to 2.5 μg/uL. The PKC 5X Solution was activated using probe 
sonicator for 25 seconds. Master Mix containing PKC Reaction 5X Buffer, C1 
Peptide, PKC Activator 5X Solution and Peptide Protection Solution was 
prepared. The master mix solution was then aliquot into individual 0.6 mL 
eppendorf tubes (16 μL each) and kept on ice till PKC enzyme is added. 
Inhibitors of various concentrations were added and deionised water is used to 
top up volume of solution in eppendorf to 21 μL. (25 μL for negative control 
assay). The eppendorfs was incubated in a 30 
o
C water bath for 2 minutes. 4 μL 
of PKC alpha or PKC protein was then added into eppendorfs to Standard or 
Positive Control Assay respectively. The eppendorfs were further incubated in 
a 30 
o
C water bath for 30 minutes. At the end of the incubation time, the 
eppendorfs were placed in a 95 
o
C heating block for 10 minutes to stop the 
reaction. The eppendorfs were placed on ice and in dark till loading begins. 
Add 1 μL of 80% glycerol to each eppendorfs before loading onto gel. Gel 
Preparation/ Separation: The horizontal agarose gel apparatus was assembled 
accordingly. 0.8% agarose solution (1.6 g in 200 mL 50 mM Tris-HCl, pH 8.0) 
was prepared and heated in microwave for 2 minutes and 10 seconds until all 
the agarose has dissolved. The mixture was allowed to cool to 60 
o
C and 
subsequently poured into gel tray, ensuring no bubble was formed in the 
process. The gel was allowed to solidify before the comb was removed. The 
gel was placed in the electrophoresis chamber and 50 mM Tris-HCl (pH 8.0) 
solution was poured onto the gel. The PKC assay samples was then loaded into 
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the well (10 uL per well) and the electrophoresis was started at 120 V for about 
30 minutes or till the separation was completed. The gel was then removed and 
the photo of the gel was taken using Kodax Imaging Machine.  
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Chapter 3: Synthesis and Structure Activity Relationship of Sphingosine 
Kinase 1 Inhibitors 
 
3.1 Introduction 
In chapter 2, we have described our work on the development of a SphK 1 
specific inhibitor, 3-1, which does not inhibit either SphK 2 or PKC
1
 (Figure 3-
1). In this project, we sought to further optimize 3-1 as our lead SphK 1 
inhibitor. Since no structural information of SphK 1 is available to allow the 
use of computational docking methods for the design of inhibitors,
2
 we have 
thus used information from our earlier inhibitor studies to carry out a ligand-
based design that is centred on compound 3-1. 
 
Through this project, we also sought to understand the Structure-Activity-
Relationship (SAR) of SphK 1 inhibitors. Herein we report the synthesis of 
SphK 1 specific inhibitors by using 3-1 as our lead compound. We also 
demonstrate an SAR approach in improving the selectivity and potency 
towards SphK 1. Besides that, we showed that the new compound is a 
significant improvement to 3-1, when subjected to biological testing. 
 
3.2 Synthetic Strategy 
Using our lead compound, (S)-tert-butyl 4-hexadec-2-ynoyl-2,2-
dimethyloxazolidine-3-carboxylate, 3-1, as a guide, we sought to further 
enhance the potency of the targeted inhibitors of SphK 1. Previous studies have 
shown that the inclusion of an N-alkoxylcarbonyl pharmacophore,
3,4
 as well as 
a 4,5-trans double bond
4
 proved to yield potent inhibitors. The inhibitor design 
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employed in this project includes the modification of the lead compound at 





D C B A
A: Alkyl chain modification
B: Saturation group modification
C: Carbonyl group modification
D: Polar head group modification
 
Figure 3-1: Structure of 3-1 and sectional modification areas. 
 
3.2.1 Modification of alkyl chain length (A-1)  
The chain length of sphingosine analogues have been the focus of other 
research groups,
 2,4
 as it is expected to have an impact on the inhibition on 
SphK 1. We have previously synthesized analogues of the lead compound 3-1, 
with chain lengths of 6, 10 and 15 carbons.
1
 Optimizing the carbon chain 
length was essential for the design of more potent inhibitors. To perform a 
more detailed study on the effects of the length of alkyl chain on inhibition, 
compounds 3-4a (19 carbons) and 3-4b (para-pentyl benzene) were 
additionally synthesized from (S)-1,1-dimethylethyl 4-formyl-2,2-
dimethyloxazolidine-3-carboxylate (also known as Garner’s aldehyde) 3-2 
using the synthetic strategy shown in Scheme 3-1. Paugh et. al have shown that 
the inhibitor SK1-I with a para-pentyl benzene replacing the alkyl chain gave 
rise to good inhibitory activity, thus the design of 3-4b incorporates a para-
pentyl benzene chain as well. The alkynes were treated with n-butyl lithium 
(1.6 M in hexanes), to yield the acetylides, which were coupled with 3-2. Only 











Scheme 3-1. Synthetic route of 3-4a and 3-4b. 
Reagents and conditions: (a) BuLi, alkyne, THF, -40 
o
C, 4 h; (b) DMP, 
NaHCO3, DCM, rt, 3 h 
 
3.2.2 Modification of alkyl chain terminus (A-2) 
To date, most modifications on the chain length involve the length of the chain. 
Polar substituents at the end of the alkyl chain have not received much 
attention. Billich et al. have devised a fluorometric method for analysis of 
SphK 1 assay, in which a sphingosine analogue (15-NBD-Sph) with a 
fluorescence tag attached at the end of the 12-carbon long alkyl chain acts as a 
substrate for SphK 1 in place of sphingosine.
6
 The attachment of a bulky and 
polar fluorophore at the end of the alkyl chain did not prevent this sphingosine 
analogue from acting as a substrate of SphK 1 (Figure 3-2). This suggests that 
modification of the chain terminus might not affect the binding efficacy 
towards SphK 1. The high hydrophobicity of the compounds that have been 
synthesized so far, could affect its chance in the further development into a 
therapeutic drug, as the hydrophobic nature of the compounds would 
significantly reduced the oral bio-availability. Thus we postulate that the chain 
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terminus could be modified with polar groups to increase oral bio-availability 
while not affecting the inhibition of SphK 1. To test this postulation, a series of 
analogues with polar substituents at the chain terminus were synthesized to 
explore the structure-activity space at the chain terminus  (Scheme 3-2). 
 
Figure 3-2. Structure of 15-NBD-Sph. 
 














3-9: R = COCH3 (50%)
3-10: R = SO2CH3 (63%)
3-5 3-6 (74%) 3-7 (77%)





Reagents and conditions: (a) BuLi, 3-2, THF, -40 
o
C, 4 h; (b) DMP, NaHCO3, 
DCM, rt, 3 h; (c) PPTS, EtOH, 55 
o
C, 8 h; (d) Ac2O, DMAP, TEA, rt, 17 h; (e) 
MsCl, TEA, DCM, rt, overnight.  
 




Reagents and conditions: (a) BuLi, 3-2, THF, -40 
o
C, 4 h; (b) DMP, NaHCO3, 
DCM, rt, 3 h. 
The protected alcohol 3-5 was prepared by following the method reported by 
Kozikowski et al.
7
 It was then treated with n-butyl lithium (BuLi, 1.6 M in 
hexane), to yield the acetylide, which was coupled with 3-2 at -40 
o
C to give 3-
6, which was further oxidised by DMP to yield 3-7.
8
 Deprotection of the THP 
group on 3-7 was then carried out using acid catalyst pyridinium p-
toluenesulfonate (PPTS) in ethanol to provide 3-8.
9
 The ester 3-9 was 
subsequently prepared by treating 3-8 with acetic anhydride in the presence of 
4-dimethylaminopyridine (DMAP)
10
 and stirring the mixture overnight at room 
temperature with triethylamine as solvent. Compound 3-8 was also mesylated 
by methanesulfonyl chloride to yield another analogue 3-10.
11
  Compound 3-13, 
with a methoxy group at the chain terminus, was synthesized by coupling 12-
methoxydodec-1-yne 3-11 to 2 to yield 3-12 which was in turn oxidized with 




For the synthesis of 3-19, we had initially attempted to displace the mesylate 
group on 3-10 with an azide ion. However this resulted in a complex mixture 
which could not be easily purified. The complexity of the reaction could be 
attributed to the ketone moiety which could also undergo a possible 
nucleophilic addition. Acetal protection of the ketone also proved to be 
difficult due to the stability of the conjugated ynone. Hence, to circumvent this 
problem, we proceeded to modify Ettmayer’s method whereby alcohol 3-6 was 
first acylated with acetic anhydride to yield 3-14
8,10
 which was then 





 Compound 3-15 was then mesylated by methanesulfonyl 
chloride to yield 3-16.
11
 An azide moiety was subsequently introduced at the 
chain terminus by treating 3-16 with sodium azide in DMF to yield 3-17.
13
 
Finally, deprotection of the acetyl protecting group using potassium carbonate 




Scheme 3-4. Synthetic route of 3-19. 
Reagents and conditions: (a) BuLi, 3-2, THF, -40 
o
C, 4 h; (b) Ac2O, DMAP, 
TEA, rt, 24 h; (c) PPTS, EtOH, 55 
o
C, 8 h; (d) MsCl, TEA, DCM, rt, overnight. 
(e) NaN3, DMF, 80 
o
C, 4 h; (f) K2CO3, MeOH, rt, 24 h; (g) DMP, NaHCO3, 
DCM, rt, 2 h. 
 
3.2.3 Modification of triple bond (B) 
Many of the known inhibitors such as DMS and SK1-I, as well as sphingosine 
itself, possess a 4,5-trans double bond. Furthermore, earlier studies by De 





Our lead compound, 3-1, possesses a triple bond in place of the double bond. 
Hence we hypothesized that unsaturation at this position appears to be 
necessary for inhibition. To verify our hypothesis, analogues of 3-1 with 
differing unsaturation at the 4,5-position were synthesized. Compound 3-20
1
 
was selectively reduced by sodium bis(2-methoxyethoxy)aluminumhydride 
(Red-Al
TM
) in THF over 2 hours to give solely the trans isomer
15
 3-21 
(Scheme 2.5) which was then oxidized with DMP to give 3-22. Compound 3-
23 was obtained by selectively reducing the triple bond of 3-1 to a single bond 




Scheme 3-5. Synthetic route of 3-22 and 3-23. 
 
Reagents and conditions: (a) Sodium bis(2-methoxyethoxy)aluminumhydride 
(Red-Al
TM
), THF, rt, 2 h; (b) DMP, NaHCO3, DCM, rt, 3 h; (c) H2  
(1 atm), 10% Pd/C, Ph2S, MeOH, rt, 24 h. 
 
3.2.4 Modification of carbonyl group at 3-position (C) 
A closer look at the widely-used inhibitors, DMS, DHS and TMS, as well as 
SK1-I identifies the hydroxyl group at the 3-position as a common 
pharmacophore. Substitution of the 3-hydroxyl group with a fluorine atom has 
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also been shown to yield potent inhibitors.
4
 These findings, together with the 
presence of a carbonyl group at the 3-position of 3-1, suggest the importance of 
an electronegative atom, possibly a hydrogen-bond acceptor (HBA), at the 3-
position. Thus, a series of analogues were synthesized by replacing the 
carbonyl group with isosteres.  
 
 Imines are planar and exhibit hydrogen-bond accepting abilities similarly to 
ketones. The key difference would be steric hindrance due to the N-substituted 
groups. To prepare the imine analogues, we had initially treated 3-1 with 
different amines in the presence of acetic acid as a catalyst and molecular 
sieves (4Å) as a dehydrating agent. However the reaction resulted in the 
formation of the Michael addition product. An alternative approach was thus 
carried out by reacting 3-1 with amines in the presence of titanium (IV) 
tetrachloride as a strong Lewis acid
17
 and this provided the desired compound 
3-24. Using this methodology, a variety of compounds with N-substituted alkyl, 
benzyl and hydroxyl groups were synthesized to probe the conformational 
space of the enzyme (Scheme 3-6). 
 









3-24a: R = CH(CH3)2 (65%)
3-24b: R = C3H7 (81%)
3-24c: R = C4H9 (95%)
3-24d: R = CH2C6H5 (80%)
3-24e: R = OH (60%)  
Reagents and conditions: Various amines, TiCl4, Et2O, rt, overnight. 
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Scheme 3-7. Synthetic route of various O-substituent analogues of 3-25 (a-d). 
 
Reagents and conditions: (a) NaH, DMSO, rt, 0.5 h; (b) RX, rt, 17 h (X = I or 
Br). 
 
Beside imines, we also looked at potential of placing a single bonded oxygen 
atom at the 3-position. Ethers possess an electronegative oxygen atom that 
could act as a HBA as well. Similar to the imines, steric hindrance from the 
alkyl group might interfere in binding as a HBA, and the change from planarity 
to a tetrahedral structure might also alter the degree of binding as well. 
Variation was made to the substituents at the oxygen with both benzyl and 
alkyl groups to accommodate SAR studies. Only erythro isomers were 
considered because of the similarity in structure to naturally-occurring erythro-
sphingosine.
18
 Synthesis of ethers by treating 3-20 with different alkyl halides 
under mild neutral conditions utilizing silver (I) oxide as a halophile resulted in 
very low yield (20%).
19
 Hence, Williamson ether synthesis was employed, 
whereby 3-20, was first deprotonated with sodium hydride and subsequently 
reacted with various alkyl halides to yield 3-25 (Scheme 3-7). 
 
Esters, although having poor metabolic stability, were included in the SAR 
study to provide additional data that could shed some light on the importance 
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of an electronegative substituent at the 3-position. Also, esters are often used as 
a form of pro-drug in drug development. The pro-drug, often a less active form 
of the pharmacological substrate, is administered and metabolised in-vivo in 
the body to the active form by enzyme. The advantages of a pro-drug are to 
increase selectivity towards the target and also to improve the oral 
bioavailability of the drug. The ester 3-26 was prepared with 3-20 and acetic 
anhydride in the presence of 4-dimethylaminopyridine (DMAP) as a 















Reagents and conditions: (a) Ac2O, DMAP, TEA, rt, 17 h. 
 







3-1 3-27 (56%)  
Reagents and conditions: (ai) CH3PPh3Br, THF, tBuOK, 0 
o
C, 0.5 h; (ii) 3-1, -
78 
o
C, 0.5 h; (iii) 0 
o
C, 1 h. 
 
To determine the importance of a HBA at the 3- position, it was necessary to 
introduce a non-HBA group at the position. An alkene moiety, being a non-
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HBA counterpart of a carbonyl group, was introduced via a Wittig reaction by 
reacting 3-1 with CH3PPh3Br under the strong base tBuOK.
20
 This compound 
3-27 would resemble 3-1 structurally with the key difference being the 
replacement of oxygen by a carbon atom, and would be an important gauge of 
the necessity for a HBA in the 3-position (Scheme 3-9), 
 
3.2.5 Modification of polar head of compound (D-1) 
The polar groups in the ring at the head of the compound are expected to play 
an important role in binding to the enzyme. Most inhibitors now closely 
resemble sphingosine in this aspect, with an alcohol and amine spanning the 
head. An advantage of closing the ring, as seen in the lead compound 3-1, 
would be rigidification of the polar head, which will reduce the amount of 
rotatable bonds at the polar head. Thus, this would reduce the amount of 
available conformations that the compound can have, while retaining the active 
conformation for optimal binding. Furthermore, Veber et al. reported a 
correlation between the bioavailability of a compound and the number of 
rotatable bonds.
21
 A significant disadvantage in 3-1 would be its high 
hydrophobic nature of the compound, thus to prevent the potential hurdle of 
having oral bioavailability problem, much more polar groups were introduced. 
Based on this argument, a series of analogues with higher rigidity and polarity 
were synthesized. Substitution of the 5-membered ring in 3-1 by aromatic rings 
of different ring sizes were considered and subsequently synthesized. 1-
pentadecyne was treated with n-butyl lithium (1.6 M in hexanes) to yield the 
acetylide, which was coupled to various aldehydes 3-28 at -23 
o
C to give 3-29. 
Compound 3-29 was either oxidised by DMP or manganese dioxide to yield 3-
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30 (a-l) in varying yields (Scheme 3-10a). Often drug candidates contained one 
or more kind of heteroatoms within the molecular structure, thus another series 
of analogues with two kinds of heteroatoms were synthesized. 1-pentadecyne 
was treated with n-butyl lithium (1.6 M in hexanes) to yield the acetylide, 
which was coupled to various aldehydes that contain two kind of heteroatom 3-
28 at -40
o
C, followed by oxidation by DMP to yield 3-30 (m-p) in varying 
yields (Scheme 3-10b). 
 
Scheme 3-10a. Synthetic route of various analogues 3-30 (a-k). 
 
Reagents and conditions: (a) BuLi, 1-pentadecyne, THF, -23 
o
C, 4 h; (b) DMP, 
NaHCO3,DCM, rt, 3 h (3-30a-h, l); (c) MnO2, DCM, rt, 24 h (3-30i-k). 
 




Reagents and conditions: (a)(i) BuLi, 1-pentadecyne, THF, -40 
o
C, 4 h; (a)(ii) 
DMP, NaHCO3,DCM, rt, 3 h. 
 
3.2.6 Modification of N-substituents. (D-2) 





 have included N-protected amides and 
carbamates as possible inhibitors of SphKs, with varying effects on inhibition. 
Well known inhibitors of Sphk 1 such as dimethylsphingosine (DMS) and 
trimethylsphingosine (TMS), possess substituted amine with alkyl groups. 
These results suggest that bulky hydrophobic groups around the amino group 
might enhance inhibition. Thus, two other analogues were synthesized for 
evaluation, using different carbamates to replace the tert-butyl carbamate 
moiety. The synthesis of 3-37a and 3-37b are illustrated in Scheme 3-11. First, 
L-serine methyl ester hydrochloride, 3-31, was deprotonated and protected 
using benzyl chloroformate or phenyl chloroformate in the presence of sodium 
carbonate to yield 3-32.
23
 Subsequent oxazolidine ring-closing with 2,2-
dimethoxypropane and boron trifluoride diethyl etherate as an acid catalyst 
gave 3-33 in good yield.
24
 Attempts to reduce the ester moiety using lithium 
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aluminium hydride resulted in a complex mixture that was difficult to purify. 
Instead, stirring 3-33 with the milder reducing agent, lithium borohydride in 
THF at 0 
o
C using an ice bath resulted in 3-34.
25
 3-34 was then oxidised to the 
aldehyde 3-35 using DMP. 1-Pentadecyne, was treated with n-butyl lithium 
(1.6 M in hexanes), to yield the acetylide, before coupling to 3-35 at -40 
o
C to 
obtain 3-36. Finally, oxidation of the secondary alcohols 3-36 with DMP 
resulted in the ketone 3-37.  
 
Scheme 3-11. Synthetic route of 3-37a and 3-37b. 
 
Reagents and conditions: (a) benzyl chloroformate, Na2CO3, THF, H2O, rt, 
overnight; (b) Phenyl chloroformate, Na2CO3, THF, H2O, rt, overnight; (c) 2,2-
dimethoxypropane, BF3.Et2O, Acetone, rt, 17 h; (d) LiBH4, THF, 0 
o
C, 2 h; (e) 
DMP, NaHCO3, DCM, rt, 1 h; (f) BuLi, 1-pentadecyne, THF, -40 
o
C, 4 h; (g) 





3.2.7 Modification of section D of compound (D-3) 
Till date, many inhibitors of SphK 1 are based on modification of the amino 
acid, serine.
1-3, 26
 Other than serine, there are 19 other natural occurring amino 
acids, thus a series of amino acid analogues of 3-1 were synthesized to evaluate 
their inhibitory abilities. The synthesis was illustrated in Scheme 3-12 and 3-13. 
Firstly, various BOC-protected amino acids were reduced using lithium 
aluminium hydride to yield 3-39. 3-39 was then oxidised to the aldehydes 3-40 
using DMP. 1-pentadecyne, was treated with n-butyl lithium (1.6 M in 
hexanes), to yield the acetylide, before coupling to various aldehydes 3-40 at -
40 
o
C and then subsequent oxidation with DMP resulted in the ketones 3-41. 
(Scheme 3-12) 
 




























a) R = CH3, R' = H
b) R = (CH3)2CH, R' = H
c) R = R' = CH2, R(CH2)R'
d) R = CH2Ph, R' = H
e) R = (CH3)2CHCH2, R' = H




Reagents and conditions: (a) LiAlH4, THF, rt, overnight; (b) DMP, NaHCO3, 
DCM, rt, 1.5 h; (c)(i) BuLi, 1-pentadecyne, THF, -40 
o
C, 4 h;(c)(ii) DMP, 




Scheme 3-13. Synthetic route of 3-47. 
 
Reagents and conditions: (a) (BOC)2O, TEA, THF, 55 
o
C, 2 h; (b) 2,2-
dimethoxypropane, BF3.Et2O, Acetone, rt, overnight (c) LiAlH4, THF, rt, 
overnight; (d) DMP, NaHCO3, DCM, rt, 1.5 h; (e)(i) BuLi, 1-pentadecyne, 
THF, -40 
o
C, 4 h;(e)(ii) DMP, NaHCO3, DCM, rt, 2 h. 
 
To generate the threonine analogue of 3-1, (2S, 3R)-threonine methyl ester 3-
42 was reacted with BOC anhydride in presence of TEA in THF at 55
o
C to 
yield 3-43. (2S, 3R) diastereoisomer of the threonine methyl ester was chosen 
and not the (2S, 3S) diastereoisomer, because previous study has shown that 
that having two chiral groups having different R,S configuration would give 
rise to better substrate binding activity.
27
 Oxazolidine ring-closing with 2,2-
dimethoxypropane and boron trifluoride diethyl etherate as an acid catalyst 
gave 3-44 in good yield.
24
 Lithium aluminium hydride was used to reduce 3-44 
to yield the alcohol 3-45. 3-45 was then oxidised to the aldehyde 3-46 using 
DMP. 1-Pentadecyne, was treated with n-butyl lithium (1.6 M in hexanes), to 
yield the acetylide, before coupling to 3-46 at -40 
o
C and then subsequent 
oxidation with DMP resulted in the ketone 3-47 (Scheme 3-13). 
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3.3 Results and Discussions 
3.3.1 SphK 1 inhibition - Chain length (A-1) 
The effects of chain length of the analogues on SphK 1 inhibition are shown in 
Table 3-1. Potency of the inhibitor is highest when the carbon chain length is 
15 (Table 3-a. Entry 3) and as the chain length decreases from 15 (Table 3-1, 
Entry 3) to 10 carbons (Table 3-1, Entry 2), and 6 carbons (Table 3-1, Entry 1), 
there is a drop in the inhibition of SphK 1. Elongation of the alkyl chain length 
to 19 carbons (Table 3-1, Entry 4), however, resulted in no significant 
inhibition of SphK 1. Comparing 3-1 to known inhibitors of SphK 1, a 
common feature present in them is the 15-carbon alkyl chain length. The 
natural substrate of SphK 1, sphingosine, also shares the same number of 
carbons as well. Thus, we could hypothesize that the optimal chain length for 
maximum inhibition is one with 15 carbons. Interestingly, substitution of the 
alkyl chain with a para-pentylbenzene (Table 3-1, Entry 5) resulted in 
comparable inhibition with 3-1. It is known that Paugh’s SK1-I also contains a 
para-pentylbenzene side chain on the selective SphK 1 inhibitor,
2
 thus this 
clearly shows that it is possible to replace the long alkyl chain with para-
substituted benzene group, giving us an alternative in the future design of 









Table 3-1.  Effect of chain length on SphK 1’s inhibition. 










86.90 ± 2.32 
3 3-1 
 
74.22 ± 7.14 
4 3-4a 
 
98.30 ± 0.04 
5 3-4b 
 
74.66 ± 6.36 
6 DMS 
 
68.89 ± 14.43 
 Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 1 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. Concentration of inhibitors used was fixed at 10 μM. 
 
 
3.3.2 SphK 1 inhibition - Chain terminus (A-2) 
Several observations were made from the substitution of the alkyl chain 
terminus with more polar substituents. Firstly, when bulky groups were 
inserted at the end of the chain, inhibition is adversely affected. The insertion 
of the mesylate moiety (Table 3-2, Entry 4) led to a decrease in inhibition of 
SphK 1 to only ~12% and the presence of an excessively bulky 
tetrahydropyran ring (Table 3-2, Entry 1) resulted in near no inhibition of 
SphK 1. Secondly, chain length appears again to be a key factor for maximal 
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inhibition and the observations from the compounds tested in this series 
confirmed our earlier hypothesis. A hydroxy (Table 3-2, Entry 2) and methoxy 
(Table 3-2, Entry 5) substituent with 13 and 14 atom chain lengths reduced 
inhibition to 9% and 11% respectively, whereas an acetyl substituent (Table 3-
2, Entry 3) with a chain length of 15 atoms resulted in a comparable inhibition 
with that of 3-1. 
 
Table 3-2. Effect of chain terminus on SphK 1’s inhibition.  





98.61 ± 3.00 
2 3-8 
 
91.36 ± 9.21 
3 3-9 
 
74.04 ± 10.33 
4 3-10 
 
87.61 ± 4.29 
5 3-13 
 
88.92 ± 3.32 
6 3-19 
 
86.24 ± 0.93 
7 3-1 
 
74.22 ± 7.14 
8 DMS 
 
68.89 ± 14.43 
Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 1 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 




The replacement of the last 3 carbons in the chain with 3 nitrogen atoms of the 
azide group (Table 3-2, Entry 6) reduced inhibition to 14%. This could be 
attributed to the linearity of the azide substituent, which restricts the flexibility 
of the chain terminus and affecting the binding efficacy of the inhibitor. Thus, 
the data shown in Table 3-2 appears to support the hypothesis that a 15 atoms 
chain length is optimal for inhibition, regardless of the electronegativity of the 
atoms at the chain terminus, whereas bulky substituents at the chain terminus 
are not desirable and flexibility of the chain terminus is important for inhibitory 
ability. In future inhibitor’s design, it would be desirable to incorporate a 15 
atoms alkyl chain length with polar group at the chain terminus to improve oral 
bio-availability, without affecting the inhibition ability of the compound. 
 
3.3.3 SphK 1 inhibition - Unsaturation (B) 
As previously mentioned, known inhibitors DMS and SK1-I, as well as 
sphingosine itself, possess a 4,5-trans double bond. 3-22 was synthesized with 
this in mind, and not surprisingly, displays inhibition ability similar to DMS 
and 3-1. However, when the triple bond in 3-1 was reduced to a single bond, as 
in 3-23, there was a significant decrease in inhibition of SphK 1 from 26% to 
only 8%. Since the molecular space differs greatly on changing from a linear 
triple bond to a double or single bond and little conformational similarities can 
be seen to account for the changes in inhibition, the plausible reasons for the 
difference in inhibitory activities are: (i) the conformations that the compounds 
with a triple (3-1) or trans double (3-22) bond can adopt, are more favourable 
for interaction with the enzyme as compared to the compound with a single 
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bond (3-23); and (ii) the electron rich unsaturated bond enhances interactions 
with the enzyme.  (Table 3-3) 
 









Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 1 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. Concentration of inhibitors used was fixed at 10 μM. 
 
3.3.4 SphK 1 inhibition - Carbonyl replacement (C) 
The results in Table 3-4 show that the replacement of the carbonyl group with 
different N-substituted imines affected the inhibition greatly. Not only was 
there no observable inhibition, but the imines displayed agonistic effects on 
SphK 1. This is especially true for the smaller N-substituted alkyl groups, as 
exemplified in compounds 3-24a and 3-24b which demonstrates 15% and 25% 
increase in SphK 1 activity respectively. Increase in SphK activity could be 
due to the binding of compounds to allosteric site on the SphK 1, which leads 





76.14 ± 11.08 
2 3-23 
 
92.18 ± 5.29 
3 3-1 
 
74.22 ± 7.14 
4 DMS 
 
68.89 ± 14.43 
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to the activation of SphK 1 and increase in affinity between the active binding 
site on SphK 1 and the sphingosine substrate. Another possible explanation for 
the poor inhibitory abilities of the imines is that the rigidity of the imines’ 
structure imposes steric constraints which could affect binding of the inhibitor 
and enzyme. 
 
In contrast to the imines, replacement of the planar carbonyl group with the 
tetrahedral ether moiety gave mixed results on SphK 1’s inhibiton. In general, 
the ethers showed inhibition, with the exception of 3-25a, which showed no 
inhibition (Table 3-4, Entry 6). For the case of 3-25a, the activation of SphK 1 
could be explained by the fact that the compound closely resemble the natural 
substrate sphingosine. A trend can be observed with the inhibitory activity 
increasing to a maximum with a propyl group (Table 3-4, Entry 7) and 
decreasing as the size increased. (Table 3-4, Entries 8 and 9) Replacement of 
the alkyl substituent with an electronegative acetyl substituent showed lower 
inhibition as well (Table 3-4, Entry 10). A possible explanation for this trend is 
the presence of a hydrophobic pocket at the active binding site that could 
accommodate a 3 to 4 carbon chain, which could serve to increase the stability 
of the bound complex. It was also particularly interesting to note the results 
obtained for 3-27 where a change from a carbonyl to an alkene moiety at the 3-
postion, rendered the compound with negligible SphK inhibitory activity 
(Table 3-4, Entry 11). The replacement of oxygen atom with a carbon atom and 
the corresponding reduction in SphK 1’s inhibitory activity, implies that a H-




Analysis of the data revealed the importance of an oxygen atom at the 3 
position, with inhibitory effects observed for only the carbonyl, ether or ester 
moiety. Replacement of the oxygen atom by a carbon atom or a nitrogen atom 
nullified all inhibition. Comparison with the known inhibitors DMS, DHS and 
SK1-I shows the common feature of having an oxygen at the 3 position as well, 
although in the form of a hydroxyl group. In addition, another SAR study on 
SphKs by De Jonghe et al.
 
demonstrated that the introduction of a fluorine 
atom at the 3 position resulted in substantial inhibition as well.
4
 Thus, the 
presence of a H-bond acceptor at the 3 position appears to be essential for 
inhibition of SphK 1.  
 
Table 3-4. Effect of carbonyl group replacement on SphK 1’s inhibition. 





114.56 ± 4.56 
2 3-24b 
 
125.28 ± 9.26 
3 3-24c 
 
103.97 ± 3.18 
4 3-24d 
 
109.12 ± 5.00 
5 3-24e 
 





111.69 ± 8.55 
7 3-25b 
 
78.30 ± 6.47 
8 3-25c 
 
80.46 ± 2.37 
9 3-25d 
 
90.74 ± 7.12 
10 3-26 
 
95.06 ± 3.31 
11 3-27 
 
98.85 ± 1.84 
12 3-1 
 
74.22 ± 7.14 
13 DMS 
 
68.89 ± 14.43 
Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 1 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. Concentration of inhibitors used was fixed at 10 μM. 
 
3.3.5 SphK 1 inhibition - Polar head (D-1) 
Replacement of the oxazolidine ring with various aromatic rings was done to 
see the effects of changes at the polar end of our lead compound, 3-1. A simple 
substitution with a hydrophobic benzene ring (Table 3-5, Entry 1) showed no 
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inhibitory effects at all. The incorporation of chloro and methoxy substituents 
on the para position of the benzene ring (Table 3-5, Entries 2 and 3) did not 
improve the inhibitory ability as well. Similarly, no SphK 1’s inhibition was 
observed when the number of methoxy groups on the benzene ring was 
increased. (Table 3-5, Entry 9)  In contrast, para-substitution with a nitro group 
(Table 3-5, Entry 4), reversed the trend and shows significant inhibition of 
SphK 1. The presence of 2 H-bond acceptors on the nitro substituent provides 
with possible hydrogen bonding with the enzyme. The hypothesis of having the 
need of H-bond acceptor in the polar region of the inhibitor is further 
substantiated in later part of this study. 
 
Substitution of the phenyl ring with a pyridine ring resulted in far more potent 
analogues (Table 3-5, Entries 5-7, 14 and 15) with percentage inhibition of up 
to 52% being obtained. These inhibition levels are significantly higher than that 
of 3-1 or DMS. This shows proof that a presence of an H-Bond acceptor in the 
polar region of the inhibitor is essential for SphK 1 inhibition. Furyl 
substitution (Table 3-5, Entries 8 and 10) yielded comparable inhibitory effects 
as well. Little inhibition was seen in 3-30k (Table 3-5, Entry 11), when the 
furan was substituted with its isostere, a thiophene, thus proving the hypothesis 
that H-bond acceptor atom is needed in the polar region of the inhibitor as 
mentioned earlier. Having two kind of heteroatoms also resulted in reduced 
inhibition (Entries 7, 14 and 15). All these observations lead to several 




Firstly, the presence of an electronegative heteroatom in the ring was required 
for inhibitory effects to be observed. The huge change in inhibition from 
benzaldehyde to pyridine highlights this postulation. In particular, presence of 
H-bonding possible atom within the ring results in inhibition. The replacement 
of the oxygen atom by another electronegative atom, such as sulfur, caused a 
four-fold decrease in percentage inhibition support the hypothesis. The increase 
in the size of the ring cannot explain this phenomenon given that 6-membered 
heterocycles also show high inhibitory rates. Having two kind of heteroatoms 
however, reduced the inhibitory ability and this could be explained by the fact 
that the incorporation of an extra heteroatom might have increase the overall 
size of the inhibitor thus reducing binding efficacy. This postulation is 
supported when the fluorine heteroatom is switched to chlorine; SphK 1’s 
inhibition is significantly reduced by about 17% (Entry 14 and 15).  
 
Secondly, in general, 6-membered rings appear to be more favorable for 
inhibition than 5-membered rings. Six-membered compounds, 3-30e–g and 3-
30o, show relatively higher inhibition (34% – 52%) as compared to five-
membered. furyl derivatives 3-30h and 3-30j (~28%), as well as the lead 
compound 3-1, which has a non-aromatic 5-membered oxazolidine ring (26%). 
It can be postulated that ring expansion here allows more favourable 
interactions between the binding groups with the corresponding binding 
regions, giving the inhibitors a better fit in the enzymatic pocket.  
 
Thirdly, the initial postulation that rigidification of the ring will improve 
binding appears to hold, with aromatic compounds (Table 3-5, Entries 5-8, 14 
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and 15) showing enhanced inhibitory effects on SphK 1 as compared to the 
lead compound 3-1. As aromatic rings are planar and adopt only one 
conformation, unlike saturated rings, they cannot undergo ring-flipping. This 
leads to their high rigidity while maintaining their active conformations. Here, 
conjugation and overlapping orbitals with the carbonyl group reduces rotation 
of the ring as well, thus effectively locking the polar head of the compound 
into a highly rigid planar conformation. However, having two aromatic rings 
(Table 3-5, Entry 12) give rise to undesirable solubility problems for the 
compound. 
 
Table 3-5. Effect of polar group replacement at section D of lead compound on 
SphK 1’s inhibition. 





98.34 ± 7.97 
2 3-30b 
 
100.84 ± 5.80 
3 3-30c 
 
98.75 ± 1.08 
4 3-30d 
 
72.81 ± 3.45 
5 3-30e 
 
62.91 ± 4.56 
6 3-30f 
 
66.23 ± 2.10 
7 3-30g 
 
47.55 ± 6.41 
8 3-30h 
 





105.31 ± 3.60 
10 3-30j 
 
71.98 ± 3.28 
11 3-30k 
 













77.36 ± 6.04 
15 3-30o 
 








74.22 ± 7.14 
18 DMS 
 
68.89 ± 14.43 
Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 1 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. Concentration of inhibitors used was fixed at 10 μM. 
a 
Compounds not soluble in DMSO at room temperature. 
 
Lastly, analysis of the 6-membered pyridine rings (Table 3-5, Entries 5-7) 
reveals that the position of the nitrogen atom in the ring affects the inhibitory 
ability. The potency of the inhibitory effects increase in the order 3-30f 
(nitrogen on 3
rd
 position) < 3-30e (nitrogen on 2
nd
 position) < 3-30g (nitrogen 
on 4
th
 position). This can be justified by the proximity of the nitrogen atom as a 
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H-bond acceptor to a possible H-bond donor at the active site of binding. In 
this case, a nitrogen atom on the 4
th
 position would be at the most optimal 
distance from the corresponding binding site for its interaction as an H-bond 
acceptor.  Any changes in the position of the nitrogen atom would move it to a 
further distance from the active site. This also supports the earlier hypothesis 
that a H-bond possible atom at the para-position of the ring give rise to SphK 1 
inhibition. 
 
3.3.6 SphK 1 inhibition - N-substituents (D-2) 
Replacement of the tert-butyl carbamate with a phenyl carbamate reduced 
inhibitory activity from 26% to 20%, whereas the benzyl substitution totally 
eliminated any inhibition. This implies the intolerance of lengthy substituents. 
The benzyl and phenyl group differ by only one carbon length, implying the 
steric constraints of the binding site of the enzyme that effectively limits the 
maximum size of the hydrophobic substituent to a phenyl group. Also, the 
benzyl substituent introduces an additional rotatable bond which increases the 
number of conformations it can take which might lead to the lack of inhibitory 
ability. In comparison with 3-1 and DMS, it can seen that the inhibitory ability 
of the compounds decrease with increasing size of the substituted group of the 
N-atom, confirming the fact that steric constraint of the binding site limits the 






Table 3-6. N-substituents and inhibition. Effect of N-substituent replacement of 
lead compound on SphK 1’s inhibition. 









80.00 ± 8.06 
3 3-1 
 
74.22 ± 7.14 
4 DMS 
 
68.89 ± 14.43 
Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 1 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. Concentration of inhibitors used was fixed at 10 μM. 
 
3.3.7 SphK 1 inhibition - Section D of compound (D-3) 
The effects of switching from inhibitor with serine based moiety to inhibitor of 
other amino acids based moiety on SphK 1 inhibition are shown in Table 3-7. 
It could be clearly seen that the switch resulted in minimal inhibition of SphK 1. 
In fact, out of the 7 compounds in the table, 5 of them (Table 3-7, Entries 2,3 
and 5-7) shown slight activation of SphK 1. Interestingly, addition of a methyl 
group at the 1
st
 position of our lead compound 3-1 (Table 3-7, Entry 7), give 
rise to activation instead of inhibition. Compound 3-47 and 3-1 differ by only 
one methyl group, implying the steric constraints of the binding site of the 
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enzyme that effectively limits the size of the polar head group that can be 
introduced. 
 
Table 3-7. Effect of modification of section D of lead compound on SphK 1’s 
inhibition. 





97.96 ± 3.03 
2 3-42b 
 
106.58 ± 2.13 
3 3-42c 
 
108.59 ± 3.10 
4 3-42d 
 
93.18 ± 6.04 
5 3-42e 
 
119.59 ± 1.17 
6 3-42f 
 
105.82 ± 2.04 
7 3-47 
 
107.31 ± 0.74 
8 3-1 
 
74.22 ± 7.14 
9 DMS 
 
68.89 ± 14.43 
Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 1 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. Concentration of inhibitors used was fixed at 10 μM. 
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3.3.8 SphK 2 inhibition 
From the results of the SphK 1 assay, five of the compounds, 3-30e, 3-30f, 3-
30g, 3-30n and 3-30o (Table 3-5, Entries 5-7, 14 and 15), were found to be 
more potent than both 3-1 and DMS, showing percentage inhibition up to 52% 
at 10 μM concentration of the respective compound. The resemblance between 
the two isoforms of SphK has rendered most of current inhibitors of SphK 1 to 
inhibit SphK 2 too. This is well exemplified in known inhibitors such as DMS 
and DHS. Thus in our effort to discover SphK 1 specific inhibitors, it is 
necessary to elucidate the selectivity of the inhibitors towards SphK 1. From 
Table 3-8, compounds 3-30e and 3-30f do not show significant inhibition of 
SphK 2 at this concentration, whereas compound 3-30g does not inhibit SphK 
2 at all. However, both 3-30n and 3-30o have significant inhibition against 
SphK 2, making the two compounds unsuitable for further testing. The other 
three compounds appear to be selective towards SphK 1 only, thus prompting 
us to screen their selectivity against the PKC enzyme. 
 
Table 3-8. SphK 2 assay results of five potential compounds, 3-30e, 3-30f, 3-
30g, 3-30n and 3-30o.   









100.95 ± 9.55 
3 3-30g 
 
110.79 ± 2.96 
4 3-30n 
 





95.42 ± 5.96 
6 3-1 
 
117.06 ± 3.86 
Note: Values are reported as percentages (%) and over the base level of 100% 
(maximum SphK activity from the SphK 2 over-expression cells). Compounds 
used are of 95% purity. Freshly prepared transfected cell lysate was used for 
individual testing. Concentration of inhibitors used was fixed at 10 μM. 
 
3.3.9 PKC inhibition 
SphK inhibitors are often implicated in PKC inhibition as well. Detection of 
PKC using a non-radioactive assay was chosen to evaluate compounds. Human 
PKCα protein was incubated with PKC specific peptide with or without the 
presence of the compounds in accordance to the procedures of PepTag® Assay 
for Non-Radioactive Detection of Protein Kinase C by Promega. 
Electrophoresis was used to separate incubation product. The phosphorylation 
process of the compounds by protein kinase C protein changes the 
phosphorylated peptide’s net charge from +1 to -1. This change in the net 
charge of the substrate allows the phosphorylated and non-phosphorylated 
substrate to migrate towards opposite electrodes. The intensity of the bands 
obtained was measured and the inhibition of PKC protein by the compounds 
was calculated for comparison. It can be seen that at 10 μM, none of the 
compounds show any significant inhibition of PKC (Figure 4). The SphK 2 and 





Figure 3-3. Gel photograph of the PKC assay results of three potential 
compounds, 3-30e, 3-30f and 3-30g. Note: PKC inhibition causes a decrease in 
intensity of the phosphorylated band and a corresponding increase in the 
intensity of the nonphosphorylated band. 
 
Table 3-9. PKC assay results of three potential compounds, 3-30e, 3-30f and 3-
30g.  
Entry Cpd Structure PKC activity (%) 
1 3-30e 
 
104.95 ± 4.77 
2 3-30f 
 
100.80 ± 4.40 
3 3-30g 
 
106.98 ± 4.07 
4 3-1 
 
101.79 ± 2.56 
Note: Concentration of inhibitors used was fixed at 10 M. 
 
3.3.10 IC50 Results 
IC50 of the three compounds were conducted using SphK 1 enzyme from over-
expressing HCT 116 cells with SphK 1 and the results obtained were shown in 
Table 4. From the table, we can see that the best candidates are 3-30e and 3-
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30g. Both compounds have significantly lower IC50 than our lead compound 3-
1. 
 
Table 3-10. IC50 results of three potential compounds, 3-30e, 3-30f and 3-30g 
with compound 3-1 as comparison. 
Compound IC50 Values (µM) 
3-30e 0.8 ± 0.4 
3-30f 7.8 ± 1.1 
3-30g 0.9 ± 0.3 
3-1 3.7 ± 0.2 
Note: Result is the representative of three independent experiments. Freshly 
prepared transfected cell lysate was used for individual testing.  
 
3.3.11 MTT Assay 
MTT assays were performed to understand the cytotoxic effects of the 
compounds against cell lines and two incubation timings, 24 h and 48 h for the 
assays were conducted. Dimethylsulfoxide (DMSO) was included as a 
vehicular control given that it was the solvent used to dissolve the compounds. 
The amount of DMSO used in the assay was controlled at 0.5% of the total 
volume to limit potential cytoxicity caused by DMSO.  
 
As shown in Figure 3-4a, all three compounds resulted in cytotoxicity of the 
U937 cells and much reduced absorbance intensity was observed. In contrast, 
compound 3-1 appears to show only less cytotoxicity. However, this is not a 
definite indication of the cytotoxicity of the compounds because the presence 
of SphK 1 inhibitors would also result in a decrease in the proliferation rate. As 
mentioned previously, SphK 1 enhances growth and proliferation, and is often 
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found to be over-expressed in cancer cells. High level of SphK 1 expression, in 
particular, was found in cancer cells.
18
 The decreased intensity observed in the 
MTT assay could also be attributed to the down-regulation of SphK 1. These 
observations were again observed when the MTT assays were repeated using 
HL 60 cells (Human promyelocytic leukemia cells) and HCT 116 cells (Human 
colorectal carcinoma cells) in Figures 5b and 5c. In order to confirm that the 
drop in absorbance values is due to compounds being anti-proliferative or 
causing apoptosis in cancerous cells, the MTT assay were repeated using MCF 
10a cell line, a non-tumorigenic epithelial cell line. As shown in Figure 3-4d, it 
can be seen that 3-30e causes cell apoptosis in normal cells, while 3-30f and 3-
30g do not. In fact, 3-30f and 3-30g are less cytotoxic towards non-cancerous 
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Figure 3-4. MTT Assay results of three potential compounds, 3-30e, 3-30f and 
3-30g with 3-1 as comparison, using different cell lines for testing. (a): U937; 
(b): HL 60; (c): HCT 116 cells; (d): MCF 10A. Note: Result is the 
representative of three independent experiments.  
 
3.3.12 Annexin V Apoptosis Assay 
From the results of the MTT assays and IC50, we could narrow down the lead 
candidate to compound 3-30g. 3-30g has a significantly much lower IC50 value 
of 0.9 µM, showed significant reduction in the amount of cancer cells in the 
three cancer cell lines tested and is less cytoxicity towards non-cancerous cell 
line, MCF-10A, as compared to 3-1. Annexin V apoptosis assay was conducted 
to understand whether the reduction of cancerous cells as shown in MTT assay 
was due to apoptosis of cancer cells caused by 3-30g. U937 cell line was used 
in the assay and the experiment is conducted over 48 h and the results obtained 
are shown in Figures 3-5 and 3-6. It can be seen that 3-30g caused almost 
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µM. (Figure 3-5c) Several of the known SphK inhibitors are pro-apoptotic 
towards cancer cells, thus this is a good indication of the efficacy of 3-30g and 
could be extremely useful in anti-cancer therapy.
2, 28
 The experiment was 
repeated using primary monocyte cells obtained from donated human blood 
over 18 h. The results (Figure 3-8) shows that cell death caused by 3-30g is 
kept to a minimum and is comparable to that caused by 3-1. This clearly 
indicates that 3-30g could be effective against cancer cells and results in 
minimal normal human cells’ death. 
 
 
Figure 3-5. Annexin V Assay results of 3-30g using U937 cell line for testing. 
(a): Blank; (b): Vehicle Control (DMSO); (c): 5 µM; (d): 10 µM; (e): 25 µM; 
(f): 50 µM. M1 region refers to percentage of apoptotic cells. Note: Result is 
the representative of three independent experiments.  
a) b) c) 




Figure 3-6. Analysed data obtained from Annexin V apoptosis assay of 3-30g 
on U937 cells over 48 h. Note: Result is the representative of three independent 
experiments. 
** 
refers to p-value <0.005. 
 
Figure 3-7. Annexin V Assay results of using primary monocyte cell line for 
testing. (a): Blank; (b): Vehicle Control (DMSO); (c): 10 µM 3-1; (d): 10 µM 
3-30g. M1 region refers to percentage of apoptotic cells. Note: Result is the 
representative of three independent experiments.  
a) b) c) 




Figure 3-8. Analysed data obtained from Annexin V apoptosis assay of 3-1 and 
3-30g on primary monocyte cells over 18 h. Note: Result is the representative 
of three independent experiments. 
 
3.3.13 BrdU Cell Proliferation Assay 
From the Annexin V assay results, we could conclude that 3-30g is apoptotic 
towards cancer cells. To understand the potential of 3-30g as a therapeutic drug, 
BrdU Cell proliferation assay was conducted to understand the mechanism of 
3-30g in cancer cells. U937 cell line was used in the assay and the experiment 
is conducted over 24 h and the results were as shown in Figure 3-7. It can be 
observed that the 3-30g caused no significant reduction in the cell proliferation 
rate of the cancer cells. A student t-test was conducted and the result coincided 
with our findings. It also showed comparable results with 3-1. This led us to 
believe that 3-30g works by acting on the apoptotic pathway of the cancer cell 
while not affecting the cell proliferation pathway. This is significant because 
by targeting cancer cell apoptosis and not affecting cell proliferation rate, the 
compound could be highly specific when used as an anti-cancer drug. It can 
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thus be concluded that 3-30g is a potential candidate as an effective and non-
toxic cancer drug.  
 
Figure 3-9. Analysed data obtained from BrdU cell proliferation assay of 3-30g 
at 10 µM concentration on U937 cells over 24 h. Note: Result is the 
representative of three independent experiments.  
 
3.3.14 Drug Likeness 
3-30g appears to be more drug-like when compared to 3-1, looking the various 
factors of drug-likeness and the rules of Lipinski’s Rule of Five.29 Table 3-11 
summaries the various factors often used in analyzing the drug likeness of a 
compound. Properties of 3-30g, as shown in the table, are often mid-range 
values, unlike the values for 3-1 which are more towards the maximum value 
or exceed the requirements. This makes 3-30g more drug-like as compared to 
3-1. Both compounds’ CLogP values have exceeded the recommended value, 
but 3-30g is more polar than 3-1, implying an increase in the oral 
bioavailability of the compound. Other than the factors mentioned in the table, 
observing the molecular structure of the compounds also shows that 3-30g is 
more drug-like than 3-1. 3-30g is more rigid in the structure, which means that 
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there is less free rotation of the bonds, thus allowing a better fit to enzyme. 
Reduction in the number of chiral center from 1 to 0 and the absence of 
functional groups that could be easy to metabolize or hydrolyze in 3-30g also 
reduces potential metabolism problems. Lower melting point and boiling point, 
due to its’ smaller molecular weight, allows easier formulation of 3-30g to 
liquid or aerosol form in drug development. 
 
Table 3-11. Comparison of factors used in analysis of drug likeness.
29
 








≤ 5 0 0 
Molecular Weight ≤ 500 313 435 
CLogP* ≤ 5 7.3 8.9 
Number of Atoms 
(NA) 




40≤ MR ≤130 99 128 
Polar Surface 
Area* (PSA) 
≤ 60 29 56 
Note: *values obtained from ChemBioDraw Software© 
 
3.4 Conclusions 
A series of sphingosine analogues based on the lead compound 3-1 were 
synthesized, with the discovery of several compounds which potently inhibit 
SphK 1.  In particular, three of the compounds, 3-30e, 3-30f and 3-30g 
inhibited SphK 1 more potently than 3-1 and DMS, and were further identified 
to be SphK 1 selective. IC50 testing of 3-30e, 3-30f and 3-30g were 0.8 µM, 7.8 
µM and 0.9 µM respectively. MTT assays performed on the three compounds 
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show that all three compounds are effective against cancerous cell lines, with 
3-30f and 3-30g being found to be less cytotoxic towards non-cancerous cell 
line as compared to 3-1. Further testing using Annexin v assay and BrdU cell 
proliferation assay confirmed that 3-30g targeted the cell apoptosis pathway 
and not cell proliferation pathway. Analysis of the compound shows that 3-30g 
is more drug-like as compared to 3-1. SAR studies performed on the analogues 
have shown several important functionalities that are essential for inhibitory 
activity on SphK 1, and are summarized in Figure 3-10. These SAR studies 
results will provide an important basis for further development of more potent 
inhibitors for SphK 1 that will be useful for clinical applications. 
  
Figure 3-10. Summary of Structure Activity Relationship (SAR) results. 
 
3.5 Experimental Section 
3.5.1 Chemistry 
General Procedures.  All chemical reagents and solvents were obtained from 
Sigma Aldrich, Merck, Lancaster, or Fluka and were used without further 
purification. Analytical TLC was carried out on pre-coated silica plates (Merck 
silica gel 60, F254) and visualized with UV light or stained with 
phosphomolybdic acid (PMA) stain. Flash column chromatography was 
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performed with silica (Merck, 70-230 mesh). The purities of the compounds 
were determined via HPLC using a Shimadzhu LCMS-IT-TOF system with a 
Phenomenex Luma C18 column (50 x 3.0mm, 5µm). Detection was conducted 
at 220 nm and integration was obtained with a Shimadzhu LCMS solution 
software. The mobile phase was a gradient with solvent B from 30% to 100% 
over 9 minutes and a flow rate of 0.8 mL/min. Solvent A was 0.1% 
trifluoroacetic acid in water, and solvent B was 0.1% trifluoroacetic acid in 
acetonitrile. Compounds used in biological assays have purity of at least 95%. 
1
H NMR and 
13
C NMR spectra were measured on a Bruker ACF 300 or AMX 
500 Fourier Transform spectrometer. Chemical shifts were reported in parts per 
million (ppm), relative to the internal standard of tetramethylsilane (TMS). The 
signals observed were described as follows: s (singlet), d (doublet), t (triplet), 
m (multiplet). The number of protons (n) for a given resonance was indicated 
as nH. Mass spectra were performed on a Finnigan/MAT LCQ mass 
spectrometer under electron spray ionization (ESI). Optical rotations were 
determined with a JASCO DCP-1000 digital polarimeter and were the average 
of at least 10 measurements with an RSD value of less than -100%.  
 
Synthesis of (S)-tert-Butyl-4-((R)-1-hydroxyhexadec-2-ynyl)-2,2-
dimethyloxazolidine-3-carboxylate (3-3a).  
Garner’s aldehyde 3-2 (0.432 mL, 2.00 mmol) in tetrahydrofuran (10 mL) was 
added, via a cannula, to a solution of  heptadec-1-yne (2.72 mmol) and BuLi 
(1.45 mL, 2.32 mmol, 1.6 M in hexanes) in tetrahydrofuran (15 mL) at -40 ºC. 
The reaction mixture was stirred under nitrogen for 5 h at -40 ºC. When TLC 
monitoring indicated the complete consumption of the starting materials, the 
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reaction mixture was quenched slowly with dropwise addition of distilled water 
(10 mL) and extracted with ethyl acetate (3×20 mL). The combined organic 
layer was washed with saturated ammonium chloride solution followed by 
saturated sodium chloride solution, dried over magnesium sulfate, filtered, 
concentrated and purified by column chromatography (silica gel; ethyl acetate: 
hexane = 1:7 with 2% acetic acid) to yield 3-3a.   
[α]25 = -67.6° (c = 9.55 x 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.50-4.68 (m, 1H, OCH2CH), 3.89-4.10 (m, 3H, OCH2CH, CH(OH) ), 2.16 (dt, 
2H, J = 1.9 Hz, 6.9 Hz, C≡CCH2), 1.56 (s, 3H, OCCH3), 1.47-1.49 (m, 12 H, 
NCCH3, OC(CH3)3), 1.23-1.33 (m, 30H, CH2(CH2)15CH3), 0.85 (m, 3H, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (154.0, 94.9, 86.5, 811, 77.9, 65.0, 
64.0, 62.8, 31.9, 29.6, 29.5, 29.3, 29.1, 28.8, 28.5, 28.3, 25.7, 25.1, 22.6, 18.7, 
14.0); HRMS (ESI, M + Na) calcd for C30H55O4NNa, 516.4023; found, 
516.4045. Yield: 68%. 
 
Synthesis of (S)-tert-butyl 2,2-dimethyl-4-octadec-2-ynoyloxazolidine-3-
carboxylate (3-4a). 
Compound 3-3a (0.43 g, 0.92 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous dichloromethane 
(15 mL). Sodium bicarbonate (0.39g, 4.62 mmol) and Dess-Martin periodinane 
(0.47g, 1.11 mmol) were added in the stated order and the reaction mixture was 
stirred at room temperature for 1 h. After which, the reaction mixture was 
quenched slowly with dropwise addition of saturated sodium bicarbonate 
solution and extracted with dichloromethane (3×20 mL). The combined 
organic layer was washed with saturated sodium chloride solution, dried over 
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magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:15) to yield 3-4a.  
[α]25 = +133.26° (c = 4.45 x 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) 
δ 4.03-4.50 (m, 3H, OCH2CH), 2.36 (t, 2H, J = 7.3 Hz, C≡CCH2), 1.68 (s, 3H, 
OCCH3), 1.52-1.63 (m, 12 H, NCCH3, OC(CH3)3), 1.24-1.49 (m, 30H, 
CH2(CH2)15CH3), 0.86 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (1186.1, 151.2, 98.1, 95.3, 94.6, 80.6, 78.7, 66.6, 65.7, 31.9, 29.6, 
29.5, 29.3, 28.9, 28.3, 28.1, 27.5, 26.1, 25.2, 24.2, 22.6, 19.1, 14.0); HRMS 
(ESI, M + Na) calcd for C30H53O4NNa, 514.3867; found, 514.3883. Yield: 
70%. 
 
Synthesis of (S)-tert-butyl 4-((R)-1-hydroxy-3-(4-pentylphenyl)prop-2-
ynyl)-2,2-dimethyloxazolidine-3-carboxylate (3-3b).  
Garner’s aldehyde 3-2 (0.432 mL, 2 mmol) in tetrahydrofuran (10 mL) was 
added, via a cannula, to a solution of  1-ethynyl-4-pentylbenzene (2.72 mmol) 
and BuLi (1.45 mL, 2.32 mmol, 1.6 M in hexanes) in tetrahydrofuran (15 mL) 
at -40 ºC. The reaction mixture was stirred under nitrogen for 5 h at -40 ºC. 
When TLC monitoring indicated the complete consumption of the starting 
materials, the reaction mixture was quenched slowly with dropwise addition of 
distilled water (10 mL) and extracted with ethyl acetate (3×20 mL). The 
combined organic layer was washed with saturated ammonium chloride 
solution followed by saturated sodium chloride solution, dried over magnesium 
sulfate, filtered, concentrated and purified by column chromatography (silica 
gel; ethyl acetate: hexane = 1:4 with 2% acetic acid) to 3-3b. 
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[α]25 = -32.62° (c = 10.7 x 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
7.07-7.31 (m, 4H, C≡CC6H4), 5.26 (d, 1H, J = 3.2 Hz, CH(OH)), 4.69-4.71 (m, 
1H, OCH2CH), 3.95-4.22 (m, 2H, OCH2CH), 2.55 (t, 2H, J = 7.6 Hz, 
C6H4CH2), 1.55-1.59 (m, 6H, OCCH3, NCCH3), 1.47 (s, 9 H, OC(CH3)3), 
1.21-1.31 (m, 6H, CH2(CH2)3CH3), 0.87 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C 
NMR (125 MHz, CDCl3) δ (170.97, 154.2, 143.4, 131.5, 128.2, 119.7, 94.9, 
86.4, 81.3, 64.6, 62.8, 60..2, 53.3, 35.7, 30.8, 28.3, 25.7, 25.3, 22.4, 20.9, 13.9); 
Yield: 87%. 
 
Synthesis of (S)-tert-butyl 2,2-dimethyl-4-(3-(4-pentylphenyl)propioloyl)-
oxazolidine-3-carboxylate (3-4b) 
Compound 3-3b (0.37 g, 0.92 mmol) was placed in n a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous dichloromethane 
(15 mL). Sodium bicarbonate (0.39 g, 4.62 mmol) and Dess-Martin 
periodinane (0.47 g, 1.11 mmol) were added in the stated order and the reaction 
mixture was stirred at room temperature for 1 h. After which, the reaction 
mixture was quenched slowly with dropwise addition of saturated sodium 
bicarbonate solution and extracted with dichloromethane (3×20 mL). The 
combined organic layer was washed with saturated sodium chloride solution, 
dried over magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:10) to yield 3-4b. 
[α]25 = -111.33° (c = 89.6 x 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.17-7.49 (m, 4H, C≡CC6H4), 4.10-4.61 (m, 3H, OCH2CH), 2.61 (t, 2H, J = 
7.7 Hz, C6H4CH2), 1.28-1.77 (m, 21H, OCCH3, NCCH3, OC(CH3)3, 
CH2(CH2)3CH3), 0.87 (t, 3H, J = 6.7 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) 
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δ (187.0, 151.3, 147.0, 133.4, 128.9, 116.5, 98.3, 86.0, 80.8, 66.5, 66.1, 36.0, 
31.3, 30.6, 28.3, 26.2, 25.2, 25.0, 24.2, 22.4, 13.9); Yield: 78%. 
 
Synthesis of (S)-tert-butyl 4-((R)-1-hydroxy-13-(tetrahydro-2H-pyran-2-
yloxy)tridec-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate (3-6) 
Garner’s aldehyde 3-2 (3.40 g, 14.82 mmol) in tetrahydrofuran (6 mL) was 
added, via a cannula, to a solution of 2-(dodec-11-ynyloxy)-tetrahydro-2H-
pyran 5 (4.14 g, 15.56 mmol) and BuLi (10.2 mL, 16.3 mmol, 1.6 M in hexane) 
in tetrahydrofuran (15 mL) at -40 ºC. The reaction mixture was stirred under 
nitrogen for 5 h at -40 ºC. When TLC monitoring indicated the complete 
consumption of the starting materials, the reaction mixture was quenched 
slowly with dropwise addition of distilled water (10 mL) and extracted with 
ethyl acetate (3×20 mL). The combined organic layer was washed with 
saturated ammonium chloride solution followed by saturated sodium chloride 
solution, dried over magnesium sulfate, filtered, concentrated and purified by 
column chromatography (silica gel; ethyl acetate: hexane = 1:6 with 2% acetic 
acid) to yield 3-6. 
[α]25 = -8.21° (c = 10.6 x 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.52-4.54 (m, 1H, OCHOCH2), 4.47 (br s, 1H, CHOH), 3.98-4.09 (m, 2H, 
OCH2CHN), 3.77-3.86 (m, 2H, OCH2CH2 – THP ring), 3.61-3.69 (m, 1H, 
OCH2CHN), 3.27-3.47 (m, 2H, OCH2CH2), 2.10-2.14 (m, 2H, C≡CCH2), 
1.64-1.79 (m, 1H, CHOH), 1.52 (s, 6H, OCCH3, NCCH3), 1.37-1.46 (m, 10H, 
OCH(CH2)3O – THP ring, OCH2CH2, C≡CCH2CH2), 1.43 (s, 9H, OC(CH3)3), 
1.18-1.27 (m, 12H, CH2(CH2)6CH2); 
13
C NMR (125 MHz, CDCl3) δ 153.9, 
98.5, 94.7, 86.4, 81.0, 77.7, 67.4, 64.8, 63.7, 62.6, 62.0, 53.2, 30.5, 29.5, 29.3, 
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29.2, 28.9, 28.6, 28.3, 28.2, 26.0, 25.5, 20.5, 19.4, 18.5; HRMS (ESI, M + Na) 
calcd for C28H49O6NNa: 518.3452; found, 518.3469. Yield: 74%. 
 
Synthesis of (4S)-tert-butyl 2,2-dimethyl-4-(13-(tetrahydro-2H-pyran-2-
yloxy)tridec-2-ynoyl)oxazolidine-3-carboxylate (3-7) 
Compound 3-6 (0.46 g, 0.92 mmol) was placed in n a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous dichloromethane 
(15 mL). Sodium bicarbonate (0.39g, 4.62 mmol) and Dess-Martin periodinane 
(0.47g, 1.11 mmol) were added in the stated order and the reaction mixture was 
stirred at room temperature for 1 h. After which, the reaction mixture was 
quenched slowly with dropwise addition of saturated sodium bicarbonate 
solution and extracted with dichloromethane (3×20 mL). The combined 
organic layer was washed with saturated sodium chloride solution, dried over 
magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:10) to yield 3-7. 
 [α]25 = -30.04° (c = 156.4 x 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) 
δ 4.43-4.45 (m, 1H, OCHOCH2), 4.22-4.24 (m, 1H, OCH2CHN), 3.92-4.05 (m, 
2H, OCH2CHN), 3.57-3.76 (m, 2H, CH2OCO), 3.23-3.38 (m, 2H, OCH2CH2), 
2.22-2.28 (m, 2H, C≡CCH2), 1.69-1.72 (m, 1H, OCHC(H)H – THP ring) , 1.58 
(s, 3H, OCCH3), 1.52-1.55 (m, 1H, OCHCH2C(H)H – THP ring), 1.41-1.47 
(m, 10H, OCHC(H)HC(H)HCH2 - THP ring, OCH2(CH2)2,  C≡CCH2CH2), 
1.38 (s, 3H, NCCH3), 1.30 (s, 9H, OC(CH3)3), 1.11-1.28 (m, 10H, 
CH2(CH2)5CH2); 
13
C NMR (125 MHz, CDCl3) δ 185.6, 150.9, 98.4, 94.9, 80.2, 
78.4, 67.2, 66.3, 65.4, 61.9, 59.9, 30.5, 29.4, 29.2, 29.1, 28.6, 28.5, 28.0, 27.8, 
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27.2, 25.9, 25.2, 24.8, 23.9, 19.3, 18.7; HRMS (ESI, M + Na) calcd for 
C28H47O6NNa: 516.3296; found, 516.3303. Yield: 77%. 
 
Synthesis of (S)-tert-butyl 4-(13-hydroxytridec-2-ynoyl)-2,2-dimethyl-
oxazolidine-3-carboxylate (3-8)  
Compound 3-7 (0.22 g, 0.45 mmol) was placed in n a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous ethanol (8 mL). 
Pyridinium p-toluenesulfonate (11.2 mg, 0.045 mmol) was added and the 
reaction mixture was warmed and stirred at 55 °C for 12 h. After which, the 
solvent was removed under vacuum and the liquid obtained was re-dissolved in 
ethyl acetate. The solution was washed with saturated sodium chloride solution, 
dried over magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:4) to yield 3-8. 
[α]25 = -31.67° (c = 166.7 x 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.26-4.28 (m, 1H, OCH2CHN), 3.96-4.09 (m, 2H, OCH2CHN), 3.51-3.54 (m, 
2H, CH2OH), 2.29-2.32 (m, 2H, C≡CCH2), 1.61 (m, 2H, OCH2CH2) , 1.56 (s, 
1H, CH2OH), 1.47-1.51 (m, 4H, HOCH2CH2CH2,  C≡CCH2CH2), 1.45 (s, 3H, 
OCCH3), 1.42 (s, 3H, NCCH3), 1.34 (s, 9H, OC(CH3)3), 1.17-1.32 (m, 10H, 
CH2(CH2)5CH2); 
13
C NMR (125 MHz, CDCl3) δ 186.0, 151.0, 98.0, 95.1, 80.5, 
78.5, 66.4, 65.5, 62.5, 32.5, 29.2, 29.1, 29.0, 28.7, 28.6, 28.1, 27.9, 27.3, 25.5, 
24.9, 24.0, 18.8; HRMS (ESI, M + Na) calcd for C23H39O5NNa: 432.2720; 





Synthesis of (S)-tert-butyl 4-(13-acetoxytridec-2-ynoyl)-2,2-dimethyl-
oxazolidine-3-carboxylate (3-9) 
(S)-tert-butyl 4-(13-hydroxytridec-2-ynoyl)-2,2-dimethyloxazolidine-3-
carboxylate 3-8 (103 mg, 0.25 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in triethylamine (10 mL). 4-
Dimethylaminopyridine (18.4 mg, 0.15 mmol) and acetic anhydride (0.0594 
mL, 0.63 mmol) were added in the stated order and the reaction mixture was 
stirred at room temperature for 17 h. The reaction mixture was quenched with 
saturated ammonium chloride solution (15 mL) and extracted with ethyl acetate 
(3×20 mL). The combined organic phases was washed with saturated sodium 
chloride solution, dried with magnesium sulphate, filtered, concentrated and 
purified by column chromatography (silica gel; ethyl acetate: hexane = 1:12) to 
yield pure 3-9. 
[α]25 = -32.53° (c = 19.8 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.31-4.51 (m, 1H, OCH2CHN), 4.00- 4.17 (m, 4H, OCH2CH, 
C≡C(CH2)9CH2O), 2.36 (t, 2H, J = 7 Hz C≡CCH2), 2.02 (s, 3H, COOCH3) 
1.67 (s, 3H, OCCH3), 1.50-1.62 (m, 3H, NCCH3), 1.40 (s, 9H, OC(CH3)3), 
1.25-1.36 (m, 16 H, C≡CCH2(CH2)8CH2O); 
13
C NMR (125 MHz, CDCl3) δ 
(186.2, 171.2, 151.1, 97.8, 95.3, 80.6, 78.7, 66.5, 65.7, 64.5, 29.3, 29.2, 28.9, 
28.3, 27.5, 26.1, 25.8, 25.0, 20.1, 19.0); HRMS (ESI, M + Na) calcd for 







Synthesis of (S)-tert-butyl 2,2-dimethyl-4-(13-(methylsulfonyloxy)tridec-2-
ynoyl)oxazolidine-3-carboxylate (3-10) 
(S)-tert-butyl 4-(13-hydroxytridec-2-ynoyl)-2,2-dimethyloxazolidine-3-
carboxylate 3-8 (2.99 g, 7.30 mmol) was placed in a 50 mL round-bottom flask 
containing a magnetic stirrer and dissolved in dichloromethane (15 mL). 
Triethylamine (5.08 mL, 36.50 mmol) and methanesulfonyl chloride (1.44 mL, 
18.50 mmol) were added in the stated order and the reaction mixture was 
stirred at room temperature for 17 h. The reaction mixture was quenched with 
saturated ammonium chloride solution (15 mL) and extracted with 
dichloromethane (3×20 mL). The combined organic phases was washed with 
saturated sodium chloride solution, dried with magnesium sulphate, filtered, 
concentrated and purified by column chromatography (silica gel; ethyl acetate: 
hexane = 1:3) to yield pure 3-10. 
 [α]25 = -6.35° (c = 247.6 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
4.23 (m, 1H, OCH2CHN), 3.95-4.11 (m, 4H, OCH2CH, C≡C(CH2)9CH2O), 
2.27 (t, 2H, J = 6.3 Hz C≡CCH2), 1.52-1.64 (m, 6H, OCCH3, NCCH3), 1.35 (s, 
9H, OC(CH3)3), 1.17-1.29 (m, 16 H, C≡CCH2(CH2)8CH2O); 
13
C NMR (75 
MHz, CDCl3) δ (185.7, 150.8, 97.7, 94.8, 80.2, 78.4, 70.0, 66.3, 65.3, 36.9, 
28.9, 28.7, 28.4, 28.0, 27.8, 27.1, 25.8, 25.0, 24.9, 24.7, 23.9, 18.7); HRMS 








Synthesis of (S)-tert-butyl 4-((R)-1-hydroxy-13-methoxytridec-2-ynyl)-2,2-
dimethyloxazolidine-3-carboxylate (3-12) 
Garner’s aldehyde, 3-2, (0.0976 g, 0.43 mmol) in tetrahydrofuran (5 mL) was 
added, via a cannula, to a solution of 12-methoxydodec-1-yne 3-11 (0.1003 g, 
0.51 mmol) and BuLi (0.293 mL, 0.47 mmol, 1.6 M in hexane) in 
tetrahydrofuran (15 mL) at -40 ºC. The reaction mixture was stirred under 
nitrogen for 5 h at -40 ºC. When TLC monitoring indicated the complete 
consumption of the starting materials, the reaction mixture was quenched 
slowly with dropwise addition of distilled water (10 mL) and extracted with 
ethyl acetate (3×15 mL). The combined organic layer was washed with 
saturated ammonium chloride solution followed by saturated sodium chloride 
solution, dried over magnesium sulfate, filtered, concentrated and purified by 
column chromatography (silica gel; ethyl acetate: hexane = 1:8) to yield 3-12. 
[α]25 = -27.58° (c = 12.3 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
3.88-4.11 (m, 4H, OCH2CHN, CH(OH)), 3.29-3.34 (m, 5H, 
C≡C(CH2)9CH2OCH3), 2.15 (t, 2H, J = 6.3 Hz C≡CCH2), 1.54-1.62 (m, 6H, 
OCCH3, NCCH3), 1.21-1.53 (m, 25H, OC(CH3)3, C≡CCH2(CH2)8CH2O); 
13
C 
NMR (125 MHz, CDCl3) δ (154.0, 95.0, 86.5, 81.1, 81.0, 77.9, 72.9, 65.0, 64.7, 
63.9, 62.7, 60.3, 58.4, 29.5, 29.4, 29.3, 29.0, 28.8, 28.4, 28.2, 26.0, 25.7, 25.3, 
20.9, 18.7, 14.1); HRMS (ESI, M + Na) calcd for C24H43NO5Na, 448.3033, 






Synthesis of (S)-tert-butyl 4-(13-methoxytridec-2-ynoyl)-2,2-dimethyl-
oxazolidine-3-carboxylate (3-13) 
Compound 3-12 (0.0984 g, 0.23 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous dichloromethane 
(10 mL). Sodium bicarbonate (0.0970 g, 1.16 mmol) and Dess-Martin 
periodinane (0.147g, 0.347 mmol) were added in the stated order and the 
reaction mixture was stirred at room temperature for 1 h. After which, the 
reaction mixture was quenched slowly with dropwise addition of saturated 
sodium bicarbonate solution and extracted with dichloromethane (3×15 mL). 
The combined organic layer was washed with saturated sodium chloride 
solution, dried over magnesium sulfate, filtered, concentrated and purified by 
column chromatography (silica gel; ethyl acetate: hexane = 1:12) to yield 3-13. 
[α]25 = -66.23° (c = 28.4 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.31-4.33 (m, 1H, OCH2CHN), 4.03-4.14 (m, 2H, OCH2CH), 3.28-3.34 (m, 
5H, C≡C(CH2)9CH2OCH3), 2.34 (t, 2H, J = 7.3 Hz C≡CCH2), 1.66 (s, 3H, 
OCCH3), 1.54 (s, 3H, NCCH3), 1.39 (s, 9H, OC(CH3)3), 1.24-1.35 (m, 16 H, 
C≡CCH2(CH2)8CH2O); 
13
C NMR (125 MHz, CDCl3) δ (186.1, 151.1, 98.0, 
95.2, 80.8, 78.7, 72.8, 66.6, 65.6, 58.4, 29.5, 29.4, 29.2, 28.9, 28.3, 27.5, 26.1, 
25.1, 24.2, 19.0); HRMS (ESI, M + Na) calcd for C24H41O5NNa, 446.2877; 
found, 446.2866. Yield: 62%. 
 
Synthesis of (S)-tert-butyl 4-((R)-1-acetoxy-13-(tetrahydro-2H-pyran-2-
yloxy)tridec-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate (3-14)  
Compound 3-6 (1.74 g, 3.50 mmol) was placed in a 25 mL round-bottom flask 
containing a magnetic stirrer and dissolved in triethylamine (10 mL). 4-
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Dimethylaminopyridine (85.6 mg, 0.70 mmol) and acetic anhydride (0.663 mL, 
7.01 mmol) were added in the stated order and the reaction mixture was stirred 
at room temperature for 17 h. The reaction mixture was quenched with 
saturated ammonium chloride solution (15 mL) and extracted with ethyl acetate 
(3×20 mL). The combined organic phases was washed with saturated sodium 
chloride solution, dried with magnesium sulphate, filtered, concentrated and 
purified by column chromatography (silica gel; ethyl acetate: hexane = 1:12) to 
yield pure 3-14. 
[α]25 = -42.34° (c = 73.6 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
5.85 (d, 1H, J = 15.2 Hz, CHOC(O)CH3), 4.55 (s, 1H, OCHO), 3.98-4.24 (m, 
3H, OCH2CHN), 3.34-3.84 (m, 4H, CH2OCHOCH2), 2.07-2.15 (m, 2H, 
C≡CCH2), 2.02 (s, 3H, C(O)CH3), 1.71-1.83 (m, 6H, OCHOCH2CH2CH2CH2), 
1.52-1.56 (m, 6H, NCCH3, OC(CH3)3), 1.25-1.46 (m, 25H, OC(CH3)3, 
C≡CCH2(CH2)8CH2O); 
13
C NMR (125 MHz, CDCl3) δ (169.8, 151.5, 98.8, 
94.9, 87.9, 80.5, 75.3, 67.6, 64.3, 63.9, 63.0, 62.3, 60.3, 59.9, 30.7, 29.7, 29.5, 
29.4, 29.0, 28.7, 28.2, 26.5, 26.2, 25.7, 25.5, 24.5, 23.3, 21.1, 19.6, 18.6); 
HRMS (ESI, M + Na) calcd for C30H51NO7Na, 560.3558; found, 560.3552 
Yield: 71%. 
 
Synthesis of (S)-tert-butyl 4-((R)-1-acetoxy-13-hydroxytridec-2-ynyl)-2,2-
dimethyloxazolidine-3-carboxylate (3-15)  
Compound 3-14 (0.241 g, 0.45 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous ethanol (10 mL). 
Pyridinium p-toluenesulfonate (11.2 mg, 0.045 mmol) was added and the 
reaction mixture was warmed and stirred at 55 °C for 12 h. After which, the 
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solvent was removed under vacuum and the liquid obtained was re-dissolved in 
ethyl acetate. The solution was washed with saturated sodium chloride solution, 
dried over magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel, ethyl acetate: hexane = 1:3) to yield 3-15. 
[α]25 = -58.37° (c = 25.8 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.85 (d, 1H, J = 14.5 Hz, CHOC(O)CH3), 3.82-4.09 (m, 3H, OCH2CHN), 3.40 
(t, 2H, J = 6.95, CH2OH), 2.00 (t, 2H, J = 6.93, C≡CCH2), 1.90 (s, 3H, 
C(O)CH3), 1.31-1.38 (m, 6H, NCCH3, OC(CH3)3), 1.10-1.29 (m, 25H, 
OC(CH3)3, C≡CCH2(CH2)8CH2O); 
13
C NMR (125 MHz, CDCl3) δ (169.3, 
151.1, 94.5, 87.5, 80.2, 75.0, 63.9, 63.4, 62.6, 62.1, 59.6, 32.3, 30.4, 29.1, 29.0, 
28.6, 28.3, 27.9, 26.1, 25.4, 25.3, 24.1, 22.9, 20.6, 18.2); HRMS (ESI, M + Na) 
calcd for C25H43NO6Na, 476.2983; found, 476.2975. Yield: 82%. 
 
Synthesis of (S)-tert-butyl 4-((R)-1-acetoxy-13-(methylsulfonyloxy)tridec-
2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate (3-16)  
Compound 3-15 (0.244 g, 0.42 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in dichloromethane (15 mL). 
Triethylamine (0.293 mL, 2.11 mmol) and methanesulfonyl chloride (0.0830 
mL, 1.07 mmol) were added in the stated order and the reaction mixture was 
stirred at room temperature for 17 h. The reaction mixture was quenched with 
saturated ammonium chloride solution (15 mL) and extracted with 
dichloromethane (3×20 mL). The combined organic phases was washed with 
saturated sodium chloride solution, dried with magnesium sulphate, filtered, 
concentrated and purified by column chromatography (silica gel; ethyl acetate: 
hexane = 1:3) to yield pure 3-16. 
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[α]25 = -45.94° (c = 42.9 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.82-5.87 (m, 1H, CHOC(O)CH3), 3.97-4.25 (m, 5H, OCH2CHN, CH2OS), 
2.97 (s, 3H, CH2SO2CH3), 2.15 (m, 2H, C≡CCH2), 2.06 (s, 3H, C(O)CH3), 
1.69-1.75 (m, 2H, CH2CH2OS), 1.45-1.51 (m, 15H, NCCH3, OC(CH3)3, 
OC(CH3)3), 1.23-1.37 (m, 14H, C≡CCH2(CH2)7(CH2)2O); 
13
C NMR (125 MHz, 
CDCl3) δ (169.1, 151.0, 94.3, 87.3, 80.0, 75.0, 69.9, 63.8, 62.4, 59.5, 36.6, 31.2, 
28.8, 28.6, 28.5, 28.4, 28.2, 27.8, 26.1, 25.6, 24.9, 22.8, 20.5, 18.1); HRMS 
(ESI, M + Na) calcd for C26H45NO8SNa, 554.2758; found, 554.2743. Yield: 
70%. 
 
Synthesis of (S)-tert-butyl 4-((R)-1-acetoxy-13-azidotridec-2-ynyl)-2,2-
dimethyloxazolidine-3-carboxylate (3-17)  
Compound 3-16 (0.392 g, 0.74 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in dimethylformamide (15 
mL). Sodium azide (73 mg, 1.11 mmol) was added and the reaction mixture 
was stirred at 80
o
C for 4 h. After which, the solvent was removed under 
vacuum and the liquid obtained was re-dissolved in ethyl acetate. The solution 
was washed with saturated sodium chloride solution, dried over magnesium 
sulfate, filtered, concentrated and purified by column chromatography (silica 
gel; ethyl acetate: hexane = 1:6) to yield 3-17. 
[α]25 = -61.36° (c = 25.0 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.75-5.79 (m, 1H, CHOC(O)CH3), 3.89-4.16 (m, 3H, OCH2CHN), 3.15 (t, 2H, 
J = 6.9 Hz, CH2N3), 2.05-2.08 (m, 2H, C≡CCH2), 1.97 (s, 3H, C(O)CH3), 1.47-
1.51 (m, 2H, CH2CH2N3), 1.34-1.46 (m, 15H, NCCH3, OC(CH3)3, OC(CH3)3), 
1.18-1.24 (m, 14H, , C≡CCH2(CH2)7(CH2)2O); 
13
C NMR (125 MHz, CDCl3) δ 
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(169.2, 151.2, 94.6, 87.5, 80.2, 75.2, 64.0, 63.6, 62.7, 59.7, 51.1, 29.1, 28.8, 
28.7, 28.5, 28.4, 28.0, 26.4, 26.3, 25.4, 23.0, 20.7, 18.3); HRMS (ESI, M + Na) 
calcd for C25H42N4O5, 501.3047; found, 501.3048. Yield: 68%. 
 
Synthesis of (S)-tert-butyl 4-((R)-13-azido-1-hydroxytridec-2-ynyl)-2,2-
dimethyloxazolidine-3-carboxylate (3-18)  
Compound 3-17 (0.240 g, 0.50 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in methanol (8 mL). 
Potassium carbonate (0.200 g, 1.45 mmol) was added and the reaction mixture 
was stirred at room temperature for 24 h. After which, the solvent was removed 
under vacuum and the liquid obtained was re-dissolved in ethyl acetate. The 
solution was washed with saturated sodium chloride solution, dried over 
magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:3) to yield 3-18. 
[α]25 = -12.91° (c = 15.8 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.44 (s, 1H, CHOH), 3.84-4.05 (m, 3H, OCH2CHN), 3.16 (t, 2H, J = 6.95 Hz, 
CH2N3), 2.09-2.11 (m, 2H, C≡CCH2), 1.39-1.52 (m, 15H, NCCH3, OC(CH3)3, 
OC(CH3)3), 1.15-1.28 (m, 16H, , C≡CCH2(CH2)8CH2N3); 
13
C NMR (125 MHz, 
CDCl3) δ (153.7, 94.6, 80.8, 77.9, 64.8, 63.6, 62.5, 51.2, 29.2, 29.1, 28.9, 28.8, 
28.6, 28.3, 28.1, 26.4, 25.5, 18.5); HRMS (ESI, M + Na) calcd for 






Synthesis of (S)-tert-butyl 4-(13-azidotridec-2-ynoyl)-2,2-dimethyl-
oxazolidine-3-carboxylate (3-19)  
Compound 3-18 (0.401 g, 0.92 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous dichloromethane 
(15 mL). Sodium bicarbonate (0.39 g, 4.62 mmol) and Dess-Martin 
periodinane (0.47 g, 1.11 mmol) were added in the stated order and the reaction 
mixture was stirred at room temperature for 2 h. After which, the reaction 
mixture was quenched slowly with dropwise addition of saturated sodium 
bicarbonate solution and extracted with dichloromethane (3×20 mL). The 
combined organic layer was washed with saturated sodium chloride solution, 
dried over magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:4) to yield 3-19. 
[α]25 = -41.39° (c = 10.1 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
3.97-4.44 (m, 3H, OCH2CHN), 3.18 (t, 2H, J = 6.95 Hz, CH2N3), 2.28-2.32 (m, 
2H, C≡CCH2), 1.34-1.62 (m, 15H, NCCH3, OC(CH3)3, OC(CH3)3), 1.21-1.30 
(m, 16H, , C≡CCH2(CH2)8CH2N3); 
13
C NMR (125 MHz, CDCl3) δ (185.9, 
151.0, 97.8, 95.1, 80.4, 78.8, 78.6, 66.5, 65.5, 51.2, 29.1, 29.0, 28.9, 28.6, 28.1, 
28.0, 27.4, 27.3, 26.5, 25.9, 25.0, 24.8, 24.0, 18.9 ); HRMS (ESI, M + Na) 
calcd for C23H38N4O4Na, 457.2785; found, 457.2790. Yield: 82%. 
 
Synthesis of (S)-tert-butyl 4-((R,E)-1-hydroxyhexadec-2-enyl)-2,2-
dimethyloxazolidine-3-carboxylate (3-21)  
Compound 3-20 (0.507 g, 1.16 mmol) was placed in a 25 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous tetrahydrofuran 









for 10 minutes before being 
transferred to room temperature and stirred for another 2 h. After which, the 
reaction mixture was quenched slowly with dropwise addition of saturated 
ammonium chloride at 0
o
C. The quenched mixture was filtered and the filtrate 
collected, washed with saturated sodium chloride solution, dried over 
magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:9 with 2% acetic acid) to 
yield 3-21. 
[α]25 = -13.28° (c = 34.8 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.41-5.75 (m, 2H, CH=CH), 3.82-4.12 (m, 4H, OCH2CH, OCH2CHN, 
CH(OH)), 2.01-2.05 (m, 2H,  C≡CCH2), 1.56 (s, 3H, OCCH3), 1.27-1.48 (m, 
16H, NCCH3, CH2(CH2)9CH2CH3, OC(CH3)3), 1.24 (s, 18 H, 
CH2(CH2)9CH2CH3), 0.87 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (154.2, 133.4, 128.0, 94.4, 81.0, 73.9, 64.9, 62.2, 32.3, 31.8, 29.6, 
29.5, 29.4, 29.3, 29.2, 29.1, 28.3, 24.6, 22.6, 20.6, 14.0); HRMS (ESI, M + Na) 
calcd for C26H49NO4, 462.3554; found, 462.3533. Yield: 47%. 
 
Synthesis of (S,E)-tert-butyl 4-hexadec-2-enoyl-2,2-dimethyloxazolidine-3-
carboxylate (3-22)  
Compound 3-21 (88.5 mg, 0.20 mmol) was placed in a 25 mL round-bottom 
flask containing a magnetic stirrer and dissolved in anhydrous dichloromethane 
(10 mL). Sodium bicarbonate (84.4 mg, 1.01 mmol) and Dess-Martin 
periodinane (0.128 g, 0.30 mmol) were added in the stated order and the 
reaction mixture was stirred at room temperature for 2 h. After which, the 
reaction mixture was quenched slowly with dropwise addition of saturated 
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sodium bicarbonate solution and extracted with dichloromethane (3×15 mL). 
The combined organic layer was washed with saturated sodium chloride 
solution, dried over magnesium sulfate, filtered, concentrated and purified by 
column chromatography (silica gel; ethyl acetate: hexane = 1:15) to yield 3-22. 
[α]25 = -34.00° (c = 22.0 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
6.94 (m, 1H, C(O)CH=CH), 6.20-6.30 (m, 1H,  4H, C(O)CH=CH), 4.46-4.47 
(m, 1H, OCH2CHN), 3.85-4.17 (m, 2H, OCH2CH), 2.20 (t, 2H, 6.6 Hz, 
C≡CCH2), 1.62 (s, 3H, OCCH3), 1.52 (s, 2H, CH2CH3), 1.34-1.49 (m, 14H, 
NCCH3, CH2(CH2)9CH2CH3, OC(CH3)3), 1.23 (s, 18 H, CH2(CH2)9CH2CH3), 
0.85 (t, 3H, J = 6.7 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ (196.5, 151.4, 
149.6, 125.2 80.7, 65.8, 64.1, 32.6, 31.8, 29.6, 29.4, 29.3, 29.1, 28.3, 28.2, 27.9, 
25.1, 24.1, 22.6, 14.0); HRMS (ESI, M + Na) calcd for C26H47NO4Na, 
460.3397; found, 460.3383. Yield: 81%. 
 
Synthesis of (S)-tert-butyl 4-heptadecanoyl-2,2-dimethyloxazolidine-3-
carboxylate (3-23) 
Compound 1 (229 mg, 0.53 mmol) was placed in a 25 mL round-bottomed 
flask containing a magnetic stirrer and dissolved in anhydrous methanol (4mL). 
10% Pd/C powder (0.0029 g, 10% wt. eq.) and diphenyl sulfide (0.15μL, 
0.00094 mmol) were added in the stated order and the reaction mixture was 
purged twice with hydrogen gas. The mixture was stirred at room temperature 
under hydrogen for 24 h. After which, the reaction mixture was filtered through 
Celite powder and purified by column chromatography (silica gel; ethyl acetate: 
hexane = 1:15) to yield 3-23. 
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[α]25 = -29.95° (c = 111.9 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.33 (m, 1H, OCH2CHN), 3.82-4.12 (m, 2H, OCH2CH), 2.41-2.47 (m, 2H,  
C≡CCH2), 1.65 (s, 3H, OCCH3), 1.52-1.60 (m, 2H, CH2CH3), 1.48 (s, 3H, 
NCCH3), 1.45 (s, 9H, OC(CH3)3), 1.21-1.36 (m, 24H, CH2(CH2)12CH2CH3), 
0.83 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (208.4, 151.3, 
95.0, 80.4, 65.6, 65.2, 65.1, 38.9, 38.3, 31.8, 29.6, 28.5, 29.3, 29.2, 29.1, 28.2, 
26.1, 25.2, 24.8, 23.6, 23.0, 23.0, 22.6, 14.0); HRMS (ESI, M + Na) calcd for 
C26H49NO4Na, 462.3554; found, 462.3566. Yield: 91%. 
 
General procedure for synthesis of (R)-tert-butyl 4-(1-(alkylimino)-
hexadec-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate compound (3-24a-
e) 
Compound 3-1 (229 mg, 0.53 mmol) and the respective amine (3.154 mmol) 
were placed in a 50 mL round-bottomed flask containing a magnetic stirrer and 
dissolved in dry diethyl ether (15 mL). To this solution was added drop-wise 
titanium(IV) chloride (0.315 mL, 0.32 mmol, 1 M in dichloromethane) at room 
temperature over 5 minutes. After stirring for 24 h at room temperature, the 
reaction mixture was quenched with 1 M sodium hydroxide (15 mL). The 
aqueous phase was extracted with diethyl ether (3×20 mL) and the combined 
organic phases was dried over magnesium sulfate, filtered, concentrated and 
purified by column chromatography (alumina; ethyl acetate: hexane = 1:20) to 






dine-3-carboxylate (3-24a)  
[α]25 = -32.14° (c = 114.8 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
4.33-4.37 (m, 1H, OCH2CH), 4.03-4.13 (m, 1H, =NCH(CH3)2), 3.84-3.97 (m, 
2H, OCH2CH), 2.31 (t, 2H, J = 7.0 Hz, C≡CCH2), 1.63 (s, 3H, OCCH3), 1.53 
(s, 3H, NCCH3), 1.49 (m, 4H, CH2(CH2)9CH2), 1.44 (s, 9H, OC(CH3)3), 1.21 
(s, 18 H, CH2(CH2)9CH2), 1.09 (dd, 6H, J = 6.2 Hz, 15.6 Hz, C=NCH(CH3)3, 
0.83 (t, 3H, J = 6.7 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (152.7, 128.2, 
125.9, 100.5, 94.9, 79.6, 72.4, 67.5, 63.5, 60.2, 55.2, 31.8, 29.5, 29.4, 29.2, 
28.9, 28.8, 28.2, 28.0, 24.9, 23.2, 23.1, 22.6, 20.9, 19.2, 14.0; HRMS (ESI, M 




[α]25 = -25.86° (c = 87.0 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
4.43 (dd, 1H, J = 4.6 Hz, 6.6 Hz, OCH2CH), 3.93-4.19 (m, 2H, OCH2CH), 
3.54 (t, 2H, J = 6.2 Hz, 7.1 Hz, C=NCH2C3H7), 2.37 (t, 2H, J = 7.1 Hz, 
C≡CCH2), 1.68 (s, 3H, OCCH3), 1.58 (s, 3H, NCCH3), 1.49 (m, 6H, 
CH2(CH2)9CH2, C=NCH2CH2CH3), 1.40 (s, 9H, OC(CH3)3), 1.26 (s, 18H, 
CH2(CH2)9CH2), 0.94 (t, 3H, J = 7.3 Hz, C=N(CH2)2CH3) 0.88 (t, 3H, J = 6.7 
Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (154.8, 153.6, 151.7, 101.1, 94.9, 
72.7, 67.5, 63.9, 57.4, 31.8, 29.6, 29.4, 29.3, 28.9, 28.3, 28.1, 22.6, 19.2, 14.0, 
12.0); HRMS (ESI, M + Na) calcd for C29H52O3N2Na, 499.3870; found, 





carboxylate (3-24c)  
[α]25 = -19.50° (c = 80.3 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
4.42 (dd, 1H, J = 5.1 Hz, 6.2 Hz, OCH2CH), 3.92-4.19 (m, 2H, OCH2CH), 
3.57 (t, 2H, J = 6.9 Hz, C=NCH2C3H7), 2.37 (t, 2H, J = 7.0 Hz, C≡CCH2), 1.67 
(s, 3H, OCCH3), 1.53 (s, 3H, NCCH3), 1.49 (s, 6H, CH2(CH2)9CH2, 
C=NCH2CH2CH2CH3), 1.41 (s, 9H, OC(CH3)3), 1.25 (s, 20H, CH2(CH2)9CH2, 
C=NCH2CH2CH2CH3), 0.85-0.95 (m, 6H, CH2CH3, C=N(CH2)3CH3); 
13
C 
NMR (125 MHz, CDCl3) δ (154.7, 153.6, 151.7, 100.3, 94.9, 79.7, 72.7, 67.4, 
63.9, 55.4, 32.5, 31.8, 29.6, 29.4, 29.3, 28.9, 28.2, 28.1, 25.3, 24.9, 22.6, 20.6, 
19.2, 14.0; HRMS (ESI, M + Na) calcd for C30H54O3N2Na, 513.4027; found, 
513.4022. Yield: 95%. 
 
(R)-tert-butyl 4-(1-(benzylimino)hexadec-2-ynyl)-2,2-dimethyloxazolidine-
3-carboxylate (3-24d)  
[α]25 = -27.06° (c = 166.0 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.17-7.27 (m, 5H, CH2C6H5), 4.74 (s, 2H, CH2C6H5), 4.45-4.46 (m, 1H, 
OCH2CH), 3.94-4.16 (m, 2H, OCH2CH), 2.37 (t, 2H, J = 6.9 Hz, C≡CCH2), 
1.66 (s, 3H, OCCH3), 1.52 (s, 3H, NCCH3), 1.48 (s, 4H, CH2(CH2)9CH2), 1.46 
(s, 9H, OC(CH3)3), 1.30 (s, 18 H, CH2(CH2)9CH2), 0.84 (t, 3H, J = 7.1 Hz, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (155.5, 151.6, 139.4, 128.2, 128.0, 
126.6, 101.7, 94.8, 79.6, 73.0, 67.1, 63.9, 59.2, 31.8, 29.5, 29.4, 29.3, 29.0, 
28.3, 28.0, 25.9, 25.2, 22.6, 19.2, 13.9; HRMS (ESI, M + Na) calcd for 






[α]25 = -55.66° (c = 10.5 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.05 (dd, 1H, J = 3.8 Hz, 6.9 Hz, OCH2CH), 3.90-4.20 (m, 2H, OCH2CH), 
2.31 (t, 2H, J = 7.3 Hz, C≡CCH2), 1.68 (s, 3H, OCCH3), 1.54 (s, 3H, NCCH3), 
1.50 (s, 4H, CH2(CH2)9CH2), 1.43 (s, 9H, OC(CH3)3), 1.24 (s, 18H, 
CH2(CH2)9CH2), 0.87 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (151.4, 149.6, 95.5, 94.7, 80.2, 73.7, 66.9, 54.8, 31.9, 29.6, 29.4, 29.3, 
29.1, 28.4, 28.2, 28.1, 25.1, 24.1, 22.7, 19.4, 14.1); HRMS (ESI, M + Na) calcd 
for C26H46O4N2Na, 473.3350; found, 473.3340. Yield: 60%. 
 
General procedure for synthesis of (S)-tert-butyl 4-((R)-1-alkoxyhexadec-
2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate (3-25a-d) 
Compound 3-20 (122 mg, 0.28 mmol) was placed in a 25 mL round-bottom 
flask containing a magnetic stirrer and dissolved in dimethyl sulfoxide (5 mL). 
Sodium hydride (22.4 mg, 0.56 mmol) was added and the reaction mixture was 
allowed to stir for half an h at room temperature. After which the alkyl halide 
(1.4 mmol) was added and the stirring was continued for another 17 h. The 
reaction mixture was quenched with saturated ammonium chloride solution (10 
mL) and extracted with ethyl acetate (3×15 mL). The combined organic phases 
was washed with saturated sodium chloride solution, dried with magnesium 
sulphate, filtered, concentrated and purified by column chromatography (silica 






[α]25 = -32.99° (c = 33.5 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.18 (d, 1H, J = 2.5 Hz, CHOCH3), δ 4.16-4.17 (m, 1H, OCH2CHN), 3.95-3.98 
(m, 2H, OCH2CHN), 3.39 (s, 3H, OCH3) 2.17 (s, 2H, C≡CCH2), 1.67 (s, 3H, 
OCCH3), 1.53 (s, 3H, NCCH3), 1.48 (s, 13H, CH2(CH2)9CH2, OC(CH3)3), 
1.26 (s, 18H, CH2(CH2)9CH2), 0.87 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR 
(125 MHz, CDCl3) δ (152.3, 151.7, 129.0, 128.2, 125.3, 94.2, 87.7, 80.1, 71.4, 
70.2, 64.2, 61.0, 60.3, 57.2, 31.9, 29.7, 29.6, 29.3, 28.5, 26.1, 25.1, 23.6, 22.7, 
18.7, 14.1); HRMS (ESI, M + Na) calcd for C27H49O4NNa, 474.3554; found, 




[α]25 = -47.27° (c = 66.3 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.34-4.57 (m, 1H, OCH2CHN), 4.09 (d, 1H, J = 6.3 Hz, CHOC3H7), 3.63-3.66 
(m, 2H, OCH2CH2CH3) 3.27-3.66 (m, 2H, OCH2CHN), 2.15 (t, 2H, J = 7.3 Hz, 
C≡CCH2), 1.55 (s, 6H, OCCH3, NCCH3 ), 1.49 (s, 13H, CH2(CH2)9CH2, 
OC(CH3)3), 1.45 (s, 2H, OCH2CH2CH3), 1.27 (s, 18H, CH2(CH2)9CH2), 0.84-
0.89 (m, 6H, C≡C(CH2)12CH3, OCH2CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ 
(152.2, 151.6, 94.8, 86.9, 79.9, 71.1, 69.0, 67.5, 64.7, 31.8, 29.6, 29.3, 28.7, 
28.3, 25.7, 25.5, 23.9, 22.6, 18.7, 14.0); HRMS (ESI, M + Na) calcd for 







[α]25 = -46.41° (c = 39.6 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.34-4.59 (m, 1H, OCH2CHN), 4.18 (d, 1H, J = 8.9 Hz, CHOC4H9), 3.92-4.03. 
(m, 2H, OCH2(CH2)2CH3) 3.32-3.72 (m, 2H, OCH2CHN), 2.17 (t, 2H, J = 6.0 
Hz, C≡CCH2), 1.52-1.56 (m, 6H, OCCH3, NCCH3 ), 1.51 (s, 13H, 
CH2(CH2)9CH2, OC(CH3)3), 1.47 (s, 2H, OCH2CH2CH2CH3), 1.25 (s, 20H, 
CH2(CH2)9CH2, OCH2CH2CH2CH3), 0.85-0.90 (m, 6H, C≡C(CH2)12CH3, 
OCH2(CH2)2CH3); 
13
C NMR (125 MHz, CDCl3) δ (152.2, 151.7, 94.3, 87.0, 
79.6, 69.2, 69.0, 67.6, 64.2, 60.9, 31.9, 29.7, 29.6, 29.3, 29.1, 28.7, 28.4, 25.8, 
22.7, 19.3, 18.7, 14.1); HRMS (ESI, M + Na) calcd for C30H55O4NNa, 




[α]25 = -64.34° (c = 50.9 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
7.18-7.26 (m, 5H, CH2C6H5), 3.88-4.76 (m, 6H, OCH2CHN, CHOCH2C6H5, 
OCH2CHN, CHOCH2C6H5), 2.17 (m, 2H, C≡CCH2), 1.39-1.54 (m, 37H, 
OCCH3, NCCH3, OC(CH3)3,  CH2(CH2)11CH3), 0.79-0.82 (t, 3H, J = 7.3 Hz, 
C≡C(CH2)12CH3); 
13
C NMR (125 MHz, CDCl3) δ (152.2, 138.2, 128.3, 128.1, 
127.7, 94.9, 94.3, 87.8, 80.0, 70.6, 67.3, 64.2, 60.9, 31.9, 29.6, 29.5, 29.1, 28.6, 
28.3, 25.5, 23.7, 22.6, 18.8, 14.1); HRMS (ESI, M + Na) calcd for 




Synthesis of (S)-tert-butyl 4-((R)-1-acetoxyhexadec-2-ynyl)-2,2-
dimethyloxazolidine-3-carboxylate (3-26) 
Compound 3-20 (101 mg, 0.23 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and dissolved in triethylamine (10 mL). 4-
Dimethylaminopyridine (16.8 mg, 0.14 mmol) and acetic anhydride (0.0543 
mL, 0.57 mmol) were added in the stated order and the reaction mixture was 
stirred at room temperature for 17 h. Thereafter, the reaction mixture was 
quenched with saturated ammonium chloride solution (15 mL) and extracted 
with ethyl acetate (3×20 mL). The combined organic phases was washed with 
saturated sodium chloride solution, dried with magnesium sulphate, filtered, 
concentrated and purified by column chromatography (silica gel; ethyl acetate: 
hexane = 1:10) to yield pure 3-26. 
[α]25 = -51.81° (c = 63.5 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.86 (d, 1H, J = 25.9 Hz, CH(OCOCH3), δ 4.18-4.26 (m, 1H, OCH2CH), 3.98-
4.14 (m, 2H, OCH2CH), 2.16 (t, 2H, J = 7.0 Hz, C≡CCH2), 2.07 (s, 3H, 
CH(OCOCH3)), 1.68 (s, 3H, OCCH3), 1.46 (s, 7H, CH2(CH2)9CH2, NCCH3), 
1.24 (m, 27H, CH2(CH2)9CH2, OC(CH3)3), 0.86 (t, 3H, J = 7 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (169.7, 152.3, 151.5, 94.9, 87.9, 80.5, 75.3, 
64.3, 63.0, 60.3, 60.0, 31.8, 29.6, 29.4, 29.3, 28.3, 26.5, 25.7, 24.5, 22.6, 21.0, 
18.6, 14.1); HRMS (ESI, M + Na) calcd for C28H49O5NNa, 502.3503; found, 






Synthesis of (R)-tert-butyl 4-(heptadec-1-en-3-yn-2-yl)-2,2-dimethyl-
oxazolidine-3-carboxylate (3-27) 
CH3PPh3Br (1.33 g, 3.72 mmol) was placed in a 50 mL round-bottom flask 
containing a magnetic stirrer and dissolved in dry THF (2 mL). t-BuOK (332 
mg, 2.98 mmol) was added and the solution was stirred at 0
o
C for 30 min. 
Thereafter, the temperature was lowered to -78
o
C and compound 1 (0.324 g, 
0.74 mmol) dissolved in THF (2 mL) was added. The mixture was warmed to 
0
o
C and quenched with distilled water. The aqueous layer was extracted with 
diethyl ether (3×20 mL). The combined organic layer was washed with 
saturated sodium chloride solution, dried over magnesium sulfate, filtered, 
concentrated and purified by column chromatography (silica gel; ethyl acetate: 
hexane = 1:20) to yield 3-27. 
[α]25 = -4.17° (c = 59.9 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.26-5.40 (m, 2H, C=CH2, δ 4.28-4.41 (m, 1H, OCH2CH), 3.94-4.06 (m, 2H, 
OCH2CH), 2.28 (m, 2H, C≡CCH2), 1.49-1.64 (m, 6H, OCCH3, NCCH3), 1.42 
(s, 9H, OC(CH3)3), 1.24-1.41 (m, 22H, CH2(CH2)11CH3), 0.87 (t, 3H, J = 6.9 
Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (151.9, 135.8, 131.8, 128.2, 
125.5, 119.7, 94.6, 92.3, 798, 78.3, 67.9, 61.9, 31.9, 30.3, 29.6, 29.5, 29.3, 29.1, 
28.9, 28.6, 28.4, 28.3, 25.6, 24.0, 22.7, 19.3, 14.1); Yield: 56%. 
 
General procedure for synthesis of 1-arylhexadec-2-yn-1-ol (3-29a-l) 
Aldehyde 3-28 (1.80 mmol) in tetrahydrofuran (6 mL) was added, via a 
cannula, to a solution of 1-pentadecyne (0.520 mL, 1.98 mmol) and BuLi (1.24 
mL, 1.98 mmol, 1.6 M in hexanes) in tetrahydrofuran (15 mL) at -23 ºC. The 
reaction mixture was stirred under nitrogen for 4 h at -23 ºC. When TLC 
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monitoring indicated the complete consumption of the aldehyde, the reaction 
mixture was quenched slowly with dropwise addition of distilled water (10 mL) 
and extracted with ethyl acetate (3×20 mL). The combined organic layer was 
washed with saturated ammonium chloride solution followed by saturated 
sodium chloride solution, dried over magnesium sulfate, filtered, concentrated 
and purified by column chromatography (silica gel; ethyl acetate: hexane = 
1:10) to yield 3-29. 
1-phenylhexadec-2-yn-1-ol (3-29a) 
1
H NMR (500 MHz, CDCl3) δ 7.18-7.42 (m, 5H, C6H5), 5.31 (s, 1H, CHOH), 
2.14 (td, 2H, J = 1.9 Hz, 7.6 Hz C≡CCH2), 1.43 (m, 2H, CH2(CH2)10CH3), 
1.27-1.30 (m, 2H, CH2CH3), 1.17 (s, 18H, CH2(CH2)9CH2), 0.80 (t, 3H, J = 6.9 
Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (141.2, 128.3, 127.9, 126.5, 87.4, 
80.0, 64.5, 31.9, 29.6, 29.5, 29.4, 29.3, 29.0, 28.8, 28.5, 22.6, 18.7, 14.0); 




H NMR (300 MHz, CDCl3) δ 7.36 (d, 2H, J = 8.5 Hz, CHCHC(Cl)CHC 
HCCH(OH)), 7.22 (d, 2H, J = 8.5 Hz, CHCHC(Cl)CHCHCCH(OH)), 5.30 (d, 
1H, J = 5.8 Hz, CH(OH)), 2.57 (d, 1H, J = 5.8 Hz, CH(OH)), 2.16 (td, 2H,  J = 
1.8 Hz, 7.0 Hz, C≡CCH2), 1.39-1.46 (m, 2H, CH2(CH2)10CH3), 1.26-1.28 (m, 
2H, CH2CH3), 1.18 (s, 18H, CH2(CH2)9CH2), 0.80 (t, 3H, J = 6.6 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ (139.7, 133.8, 128.5, 127.9, 87.9, 79.6, 63.9, 
31.9, 29.6, 29.5, 29.3, 29.1, 28.9, 28.5, 22.6, 18.7, 14.0); HRMS (EI) calcd for 






H NMR (300 MHz, CDCl3) δ 7.44 (d, 2H, J = 8.5 Hz, CHCHC(OCH3) 
CHCHCCH(OH)), 6.87 (d, 2H, J = 8.5 Hz, CHCHC(OCH3)CHCHCCH(OH)), 
5.37 (d, 1H, J = 5.0 Hz, CH(OH)), 3.78 (s, 3H, CHCHC(OCH3)CHCH), 2.73 
(d, 1H, J = 5.9 Hz, CH(OH)), 2.23-2.28 (m, 2H, C≡CCH2), 1.54-1.57 (m, 2H, 
CH2(CH2)10CH3), 1.52 (s, 2H, CH2CH3), 1.28 (s, 18H, CH2(CH2)9CH2), 0.90 (t, 
3H, J = 6.6 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ (159.2, 133.6, 127.9, 
113.6, 87.1, 80.2, 64.1, 55.0, 31.8, 29.6, 29.4, 29.2, 29.0, 28.8, 28.5, 22.6, 18.7, 




H NMR (500 MHz, CDCl3) δ 8.16 (d, 2H, J = 8.9 Hz, CHCHC(NO2) 
CHCHCCH(OH)), 7.67 (d, 2H, J = 8.2 Hz, CHCHC(NO2)CHCHCCH(OH)), 
5.51 (s, 1H, CH(OH)), 2.95 (d, 1H, J = 5.7 Hz, CH(OH)), 2.21-2.24 (m, 2H, 
C≡CCH2), 1.49-1.52 (m, 2H, CH2(CH2)10CH3), 1.33-1.36 (m, 2H, CH2CH3), 
1.23 (s, 18H, CH2(CH2)9CH2), 0.85 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR 
(125 MHz, CDCl3) δ (148.2, 147.4, 127.2, 123.5, 88.7, 78.9, 63.5, 31.8, 29.6, 
29.5, 29.4, 29.2, 29.0, 28.8, 28.3, 22.6, 18.6, 14.0); HRMS (EI) calcd for 




H NMR (500 MHz, CDCl3) δ 8.39 (d, 1H, J = 4.4 Hz, NCHC3H3), 7.57-7.60 
(m, 1H, NCHCHCHCH), 7.48 (d, 1H, J = 7.6 Hz, NCHCHCHCH), 7.07-7.10 
(m, 1H, CHCHCHNCH), 5.43 (s, 1H, CHOH), 2.12 (td, 2H, J = 1.9 Hz, 7.0 Hz, 
C≡CCH2), 1.37-1.43 (m, 2H, CH2(CH2)10CH3), 1.11-1.26 (m, 20H, 
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CH2(CH2)10CH2), 0.77 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (159.2, 147.9, 136.8, 122.4, 120.5, 86.4, 79.4, 63.9, 60.0, 31.6, 29.4, 
29.3, 29.2, 29.0, 28.8, 28.6, 28.2, 22.3, 18.5, 13.8, 13.7); HRMS (EI) calcd for 




H NMR (500 MHz, CDCl3) δ 8.57 (d, 1H, J = 1.9 Hz, C3H3NCH), 8.30 (dd, 
1H, J = 1.9 Hz, 4.8 Hz, C2H2CHNCH), 7.82-7.83 (m, 1H, CHC2H2NCH), 7.16 
(dd, 1H, J = 4.8 Hz, 7.9 Hz, CHCHCHNCH), 5.42 (s, 1H, CHOH), 2.14 (td, 
2H, J = 1.9 Hz, 6.9 Hz, C≡CCH2), 1.40-1.42 (m, 2H, CH2(CH2)10CH3), 1.24-
1.26 (m, 2H, CH2CH3), 1.16 (s, 18H, CH2(CH2)9CH2), 0.79 (t, 3H, J = 7.4 Hz, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (147.9, 147.5, 137.9, 134.6, 123.2, 
87.2, 79.6, 61.6, 31.7, 29.4, 29.3, 29.1, 28.9, 28.7, 28.4, 22.4, 18.6, 13.8); 




H NMR (500 MHz, CDCl3) δ 8.41-8.42 (m, 2H, CHCHNCHCH), 7.44 (d, 2H, 
J = 5.7 Hz, CHCHNCHCH), 5.42 (s, 1H, CHOH), 2.17 (td, 2H, J = 1.9 Hz, 7.6 
Hz, C≡CCH2), 1.43-1.46 (m, 2H, CH2(CH2)10CH3), 1.20-1.31 (m, 20H, 
CH2(CH2)10CH2), 0.82 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (151.6, 148.9, 121.4, 87.3, 79.3, 65.5, 31.8, 29.5, 29.4, 29.2, 28.9, 
28.8, 28.4, 22.5, 18.6, 13.9); HRMS (EI) calcd for C21H33ON 315.2562; found, 







H NMR (500 MHz, CDCl3) δ 7.31 (d, 1H, J = 1.3 Hz, OCHC2H2C), 6.25-6.34 
(m, 2H, OCHC2H2C), 5.36 (d, 1H, J = 5.0 Hz, CHOH), 2.45-2.46 (m, 1H, 
CHOH), 2.16-2.19 (m, 2H, C≡CCH2), 1.45-1.48 (m, 2H, CH2(CH2)10CH3), 
1.32 (m, 2H, CH2CH3), 1.18 (s, 18H, CH2(CH2)9CH2), 0.81 (t, 3H, J = 7.0 Hz, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (153.7, 142.7, 110.2, 107.3, 86.8, 
77.5, 58.2, 31.9, 29.6, 29.4, 29.3, 29.0, 28.8, 28.4, 22.6, 18.7, 14.0); (EI) calcd 




H NMR (500 MHz, CDCl3) δ 6.13 (s, 2H, C(OCH3)CHC(OCH3) 
CHC(OCH3)CH(OH)), 5.76-5.77 (m, 2H, C(OCH3)CHC(OCH3) CHC(OCH3) 
CH(OH)), 3.78-3.83 (m, 9H, (OCH3)CHC(OCH3) CHC(OCH3)CH(OH)), 
2.15-2.17 (m, 2H, C≡CCH2), 1.43-1.47 (m, 2H, CH2(CH2)10CH3), 1.24-1.34 
(m, 20H, CH2(CH2)10CH3), 0.87 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 
MHz, CDCl3) δ (160.7, 158.0, 111.2, 91.17, 83.3, 81.2, 56.3, 55.8, 55.2, 31.8, 
29.6, 29.5, 29.4, 29.2, 29.1, 28.7, 28.6, 22.6, 18.8, 14.0); HRMS (EI) calcd for 




H NMR (500 MHz, CDCl3) δ 6.29 (d, 1H, J = 2.5 Hz, OC(CH3)CHCHC), 
5.90 (d, 2H, J = 2.5 Hz, OC(CH3)CHCHC), 5.36 (d, 1H, J = 5.0 Hz, CHOH), 
2.28 (s, 3H, OC(CH3)CHCHC), 2.23-2.26 (m, 2H, C≡CCH2), 1.50-1.56 (m, 
2H, CH2(CH2)10CH3), 1.37-1.40 (m, 2H, CH2CH3), 1.26 (s, 18H, 
CH2(CH2)9CH2), 0.88 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR (125 MHz, 
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CDCl3) δ (152.5, 151.9, 108.2, 106.1, 86.5, 77.6, 58.2, 31.8, 29.6, 29.4, 29.3, 
29.0, 28.8, 28.4, 22.6, 18.7, 14.0, 13.5); HRMS (EI) calcd for C21H34O2, 




H NMR (300 MHz, CDCl3) δ 7.17 (d, 1H, J = 5.0 Hz, SCHC2H2C), 7.05 (d, 
1H, J = 3.2 Hz, SCHCHCHC), 6.86 (t, 1H, J = 4.3 Hz, SCHCHCHC), 5.53 (d, 
1H, J = 6.7 Hz, CH(OH)), 2.60 (d, J = 6.2 Hz, CH(OH))  2.15-2.20 (m, 2H, 
C≡CCH2), 1.41-1.49 (m, 2H, CH2(CH2)10CH3), 1.31 (s, 2H, CH2CH3), 1.18 (s, 
18H, CH2(CH2)9CH2), 0.80 (t, 3H, J = 6.6 Hz, CH2CH3); 
13
C NMR (75 MHz, 
CDCl3) δ (145.5, 126.5, 125.6, 125.2, 87.0, 79.4, 60.2, 31.8, 29.6, 29.4, 29.3, 
29.0, 28.8, 28.4, 22.6, 18.6, 14.0); HRMS (EI) calcd for C20H32OS, 320.2174; 




H NMR (500 MHz, CDCl3) δ 8.69 (d, 1H, J = 4.5 Hz, NCHCHC), 8.26 (d, 1H, 
J = 8.8 Hz, CHCHCC), 8.09 (d, 1H, J = 8.2 Hz, CHCN), 7.68 (d, 1H, J = 4.5 
Hz, NCHCHC), 7.64 (dd, 1H, J = 8.2 Hz, J = 15.2 Hz, CHCHCHCN), 7.52 (dd, 
1H, J = 6.3 Hz, J = 8.2 Hz, CHCHCHCN), 6.10 (s, 1H, CH(OH)), 2.15-2.18 
(m, 2H, C≡CCH2), 1.41-1.44 (m, 2H, CH2(CH2)10CH3), 1.17-1.27 (m, 20H, 
CH2(CH2)10CH2), 0.86 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (149.8, 147.7, 147.1, 129.3, 129.1, 126.5, 125.6, 124.1, 117.9, 88.3, 
79.3, 61.0, 31.8, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 28.8, 28.3, 22.6, 18.7, 14.0); 




General procedure for synthesis of 1-arylhexadec-2-yn-1-one (3-30a–h,l) 
Compound 3-29 (0.49 mmol) was placed in a 25 mL round-bottom flask 
containing a magnetic stirrer and dissolved in anhydrous dichloromethane (10 
mL). Sodium bicarbonate (0.206 g, 2.45 mmol) and Dess-Martin periodinane 
(0.312 g, 0.74 mmol) were added in the stated order and the reaction mixture 
was stirred at room temperature for 2 h. After which, the reaction mixture was 
quenched slowly with dropwise addition of saturated sodium bicarbonate 
solution and extracted with dichloromethane (3×15 mL). The combined 
organic layer was washed with saturated sodium chloride solution, dried over 
magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:15) to yield 3-30. 
1-phenylhexadec-2-yn-1-one (3-30a) 
1
H NMR (500 MHz, CDCl3) δ 7.35-8.05 (m, 5H, C6H5), 2.39 (t, 2H, J = 7.3, 
C≡CCH2), 1.56-1.59 (m, 2H, CH2(CH2)10CH3), 1.37-1.39 (m, 2H, CH2CH3), 
1.17 (s, 18H, CH2(CH2)9CH2), 0.78 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR 
(125 MHz, CDCl3) δ (178.0, 136.9, 133.7, 129.4, 128.3, 96.7, 79.6, 31.8, 29.6, 
29.5, 29.4, 29.2, 28.9, 27.7, 22.6, 19.1, 14.0); HRMS (EI) calcd for C22H32O, 




H NMR (500 MHz, CDCl3) δ 7.97 (d, 2H, J = 8.8 Hz, CHCHC(Cl)CH 
CHCC(O)H), 7.34 (d, 2H, J = 8.8 Hz, CHCHC(Cl)CHC HCC(O)H)), 2.16 (t, 
2H,  J = 7.3 Hz, C≡CCH2), 1.57-1.60 (m, 2H, CH2(CH2)10CH3), 1.36-1.39 (m, 
2H, CH2CH3), 1.17 (s, 18H, CH2(CH2)9CH2), 0.80 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ (176.6, 140.3, 135.3, 130.7, 128.7, 97.3, 79.3, 
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31.8, 29.6, 29.5, 29.4, 29.3, 29.0, 28.9, 27.7, 22.6, 19.1, 14.0); HRMS (EI) 




H NMR (500 MHz, CDCl3) δ 8.09 (d, 2H, J = 8.9 Hz, CHCHC(OCH3) 
CHCHCC(O)), 6.92 (d, 2H, J = 8.9 Hz, CHCHC(OCH3) CHCHCC(O)), 3.86 
(s, 3H, CHCHC(OCH3)CHCH), 2.46 (t, 2H, J = 6.9 Hz, C≡CCH2), 1.62-1.67 
(m, 2H, CH2(CH2)10CH3), 1.46 (m, 2H, CH2CH3), 1.25 (s, 18H, 
CH2(CH2)9CH2), 0.87 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (176.9, 164.2, 131.8, 130.4, 113.7, 95.9, 79.6, 55.5, 31.9, 29.6, 29.5, 
29.4, 29.3, 28.9, 27.8, 22.6, 19.1, 14.0); HRMS (EI) calcd for C23H34O2, 




H NMR (500 MHz, CDCl3) δ 8.27 (d, 2H, J = 9.5 Hz, CHCHC(NO2) 
CHCHCC(O)), 8.24 (d, 2H, J = 9.5 Hz, CHCHC(NO2) CHCHCC(O)), 2.51 (t, 
2H, J = 7 Hz, C≡CCH2), 1.63-1.69 (m, 2H, CH2(CH2)10CH3), 1.41-1.46 (m, 2H, 
CH2CH3), 1.21-1.31 (m, 18H, CH2(CH2)9CH2), 0.83 (t, 3H, J = 6.9 Hz, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (175.8, 150.6, 141.0, 130.2, 123.6, 
99.3, 79.3, 31.8, 29.6, 29.5, 29.3, 29.2, 28.9, 28.9, 27.6, 22.5, 19.2, 13.9); 




H NMR (300 MHz, CDCl3) δ 8.68 (m, 1H, , NCHC3H3), 8.02 (d, 1H, J = 7.7 
Hz, NCHCHCHCH), 7.76 (td, 1H, J = 1.7 Hz, 7.7 Hz, NCHCHCHCH), 7.38-
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7.42 (m, 1H, CHCHCHNCH), 2.44 (t, 2H, J = 7.1 Hz, C≡CCH2), 1.56-1.61 (m, 
2H, CH2(CH2)10CH3), 1.35-1.40 (m, 2H, CH2CH3), 1.16 (s, 18H, 
CH2(CH2)9CH2), 0.78 (t, 3H, J = 6.7 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) 
δ (177.9, 153.0, 149.5, 136.7, 127.1, 123.0, 99.2, 80.3, 31.7, 29.4, 29.3, 29.2, 
29.1, 28.8, 28.7, 27.5, 22.4, 19.3, 13.8); HRMS (EI) calcd for C21H31ON, 




H NMR (500 MHz, CDCl3) δ 9.24 (s, 1H, C3H3NCH), 8.71 (d, 1H, J = 4.4 Hz, 
C2H2CHNCH), 8.25 -8.27 (m, 1H, CHC2H2NCH), 7.32-7.35 (m, 1H, 
CHCHCHNCH), 2.43 (t, 2H, J = 7.0 Hz, C≡CCH2), 1.57-1.61 (m, 2H, 
CH2(CH2)10CH3), 1.35-1.38 (m, 2H, CH2CH3), 1.16 (s, 18H, CH2(CH2)9CH2), 
0.78 (t, 3H, J = 6.6 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (176.3, 153.8, 
151.2, 140.0, 132.0, 123.2, 98.4, 79.0, 31.7, 29.5, 29.4, 29.2, 28.8, 27.6, 22.5, 





H NMR (500 MHz, CDCl3) δ 8.77 (d, 2H, J = 5.7 Hz, CHCHNCHCH), 7.84-
7.85 (m, 2H, CHCHNCHCH), 2.47 (m, 2H, C≡CCH2), 1.61-1.66 (m, 2H, 
CH2(CH2)10CH3), 1.40-1.45 (m, 2H, CH2CH3), 1.20-1.25 (m, 18H, 
CH2(CH2)9CH2), 0.82 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3) 
δ (176.8, 150.6, 142.4, 121.9, 98.9, 79.1, 31.8, 29.5, 29.4, 29.3, 29.2, 28.9, 28.8, 
27.6, 22.5, 19.1, 14.0); HRMS (EI) calcd for C21H31ON, 313.2406; found, 





H NMR (500 MHz, CDCl3) δ 7.56 (s, 1H, OCHC2H2C), 7.21-7.24 (m, 1H, 
OCHCHCHC), 6.48-6.49 (m, 1H, OCHCHCHC), 2.38 (t, 2H, J = 7.3 Hz, 
C≡CCH2), 1.54-1.59 (m, 2H, CH2(CH2)10CH3), 1.36-1.37 (m, 2H, CH2CH3), 
1.19 (s, 18H, CH2(CH2)9CH2), 0.80 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR 
(125 MHz, CDCl3) δ (165.0, 153.3, 147.6, 120.5, 112.4, 95.5, 79.0, 31.9, 29.6, 
29.5, 29.4, 29.3, 29.0, 28.8, 27.6, 22.6, 19.1, 14.0); HRMS (EI) calcd for 




H NMR (500 MHz, CDCl3) δ 9.06 (d, 1H, J = 4.5 Hz, NCHCHC), 8.89 (d, 1H, 
J = 8.8 Hz, CHCHCC), 8.14 (d, 1H, J = 8.9 Hz, CHCN), 8.10 (d, 1H, J = 4.6 
Hz, NCHCHC), 7.73 (dd, 1H, J = 7.6, J = 15.2 Hz, CHCHCHCN), 7.63 (dd, 
1H, J = 7.6 Hz , J = 15.2 Hz, CHCHCHCN), 2.48 (t, 2H, J = 7.0 Hz, C≡CCH2), 
1.62-1.68 (m, 2H, CH2(CH2)10CH3), 1.40-1.46 (m, 2H, CH2CH3), 1.22 (s, 18H, 
CH2(CH2)9CH2), 0.84 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (179.0, 149.8, 149.1, 139.5, 129.9, 129.7, 128.8, 125.5, 124.0, 123.9, 
97.6, 80.9, 31.8, 29.6, 29.5, 29.4, 29.3, 28.9, 28.8, 27.6, 22.6, 19.1, 14.0); 
HRMS (ESI, M+1) calcd for C25H34NO, 364.2635; found, 364.2639. Yield: 
80%. 
 
General procedure for synthesis of 1-arylhexadec-2-yn-1-one (3-30i–k) 
Compound 29 (0.1182 mmol) was placed in a 25 mL round-bottom flask 
containing a magnetic stirrer and dissolved in anhydrous dichloromethane (4 
mL). Manganese dioxide (2.369 mmol) was added and the reaction mixture 
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was stirred at room temperature for 3 h. The reaction mixture was then filtered 
through Celite powder and purified by column chromatography (ethyl acetate: 
hexane = 1:10) to yield 3-30. 
1-(2,4,6-trimethoxyphenyl)hexadec-2-yn-1-one (3-30i) 
1
H NMR (500 MHz, CDCl3) δ 6.05 (s, 2H, C(OCH3)CHC(OCH3) 
CHC(OCH3 )C(O)), 3.75 (s, 9H, C(OCH3)CHC(OCH3) CHC(OCH3)C(O)), 
2.30 (t, 2H, J = 7.3 Hz, C≡CCH2), 1.49-1.52 (m, 2H, CH2(CH2)10CH3), 1.35 (m, 
2H, CH2CH3), 1.21 (s, 18H, CH2(CH2)9CH2), 0.83 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (177.1, 163.1, 159.6, 112.5, 93.0, 90.6, 83.1, 
55.7, 55.2, 31.7, 29.4, 29.3, 29.1, 28.9, 28.6, 27.7, 22.4, 19.0, 13.9); HRMS (EI) 




H NMR (500 MHz, CDCl3) δ 7.16 (d, 1H, J = 3.8 Hz, OC(CH3)CHCHC), 
6.11 (d, 2H, J = 3.2 Hz, OC(CH3)CHCHC), 2.35 (t, 2H, J = 7.3 Hz, C≡CCH2), 
2.32 (s, 3H, OC(CH3)CHCHC), 1.54-1.57 (m, 2H, CH2(CH2)10CH3),  1.35-
1.38 (m, 2H, CH2CH3), 1.18 (s, 18H, CH2(CH2)9CH2), 0.79 (t, 3H, J = 6.9 Hz, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (164.2, 159.2, 152.1, 122.9, 109.2, 
94.4, 78.8, 31.8, 29.5, 29.4, 29.3, 29.2, 28.9, 28.8, 27.6, 22.5, 18.9, 13.9); 




H NMR (500 MHz, CDCl3) δ 7.64-7.87 (m, 2H, J = 5.0 Hz, SCHCHCHC), 
7.12 (t, 1H, J = 4.1 Hz, SCHCHCHC), 2.45 (t, 2H, J = 6.9 Hz, C≡CCH2), 1.61-
1.67 (m, 2H, CH2(CH2)10CH3), 1.42-1.47 (m, 2H, CH2CH3), 1.24 (s, 18H, 
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CH2(CH2)9CH2), 0.86 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR (125 MHz, 
CDCl3) δ (169.9, 145.0, 134.7, 134.7, 128.1, 95.3, 79.3, 31.8, 29.6, 29.5, 29.4, 
29.3, 28.8, 27.7, 22.6, 19.0, 14.0); HRMS (EI) calcd for C20H30OS, 318.2017; 
found, 318.2016. Yield: 70%. 
 
General procedure for synthesis of (S)-tert-butyl 3-oxo-alkyl-octadec-4-yn-
2-ylcarbamate (3-30m-p) 
Aldehyde 3-28 (0.2 g, 0.7 mmol) in tetrahydrofuran (5 mL) was added, via a 
cannula, to a solution of 1-pentadecyne (0.2 mL, 0.8 mmol) and BuLi (0.6 mL, 
0.9 mmol, 1.6 M in hexanes) in tetrahydrofuran (15 mL) at -40 ºC. The 
reaction mixture was stirred under nitrogen for 4 h at -40 ºC. When TLC 
monitoring indicated the complete consumption of the aldehyde, the reaction 
mixture was quenched slowly with dropwise addition of distilled water (10 mL) 
and extracted with ethyl acetate (3×20 mL). The combined organic layer was 
washed with saturated ammonium chloride solution followed by saturated 
sodium chloride solution, dried over magnesium sulfate, filtered, concentrated. 
It was then placed in a 25 mL round-bottom flask containing a magnetic stirrer 
and dissolved in anhydrous dichloromethane (10 mL). Sodium bicarbonate (0.2 
g, 2.5 mmol) and Dess-Martin periodinane (0.3 g, 0.7 mmol) were added in the 
stated order and the reaction mixture was stirred at room temperature for 2 h. 
After which, the reaction mixture was quenched slowly with dropwise addition 
of saturated sodium bicarbonate solution and extracted with dichloromethane 
(3×15 mL). The combined organic layer was washed with saturated sodium 
chloride solution, dried over magnesium sulfate, filtered, concentrated and 
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H NMR (500 MHz, CDCl3) δ 8.29 (d, 1H, J = 5.1 Hz, NCHCHC), 8.89 (d, 1H, 
J = 5.7 Hz, NCHCHC), 7.36 (s, 1H, C(OCH3)CHC), 3.97 (s, 3H, OCH3), 2.48 
(t, 2H, J = 7.0 Hz, C≡CCH2), 1.64-1.67 (m, 2H, CH2(CH2)10CH3), 1.27-1.29 
(m, 2H, CH2CH3), 1.24 (s, 18H, CH2(CH2)9CH2), 0.86 (t, 3H, J = 6.9 Hz, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (176.8, 165.0, 147.8, 145.6, 114.5, 
111.1, 98.5, 79.3, 53.9, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.0, 28.9, 27.7, 22.6, 
19.2, 14.1); HRMS (ESI, M+1) calcd for C22H34NO2, 344.2584; found, 




H NMR (500 MHz, CDCl3) δ 8.69 (s, 1H, CHC(Cl)C), 8.62 (d, 1H, J = 8.2 Hz, 
NCHCHC), 7.71 (d, 1H, J = 8.2 Hz, NCHCHC), 2.47 (t, 2H, J = 11.8 Hz, 
C≡CCH2), 1.60-1.65 (m, 2H, CH2(CH2)10CH3), 1.38-1.44 (m, 2H, CH2CH3), 
1.24 (s, 18H, CH2(CH2)9CH2), 0.86 (t, 3H, J = 11.5 Hz, CH2CH3); 
13
C NMR 
(125 MHz, CDCl3) δ (175.4, 151.5, 148.2, 141.9, 124.1, 100.5, 80.6, 31.9, 29.7, 
29.6, 29.5, 29.4, 29.3, 29.0, 28.9, 27.4, 22.6, 19.3, 14.1); HRMS (ESI, M+1) 




H NMR (500 MHz, CDCl3) δ 8.60 (s, 1H, CHC(F)C), 8.56 (d, 1H, J = 5.1 Hz, 
NCHCHC), 7.76 (d, 1H, J = 5.7 Hz, NCHCHC), 2.47 (t, 2H, J = 7.0 Hz, 
C≡CCH2), 1.60-1.65 (m, 2H, CH2(CH2)10CH3), 1.31-1.44 (m, 2H, CH2CH3), 
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1.23 (s, 18H, CH2(CH2)9CH2), 0.85 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR 
(125 MHz, CDCl3) δ (173.0, 146.1, 146.0, 140.6, 140.4, 130.9, 130.8, 123.3, 
99.7, 99.6, 80.8, 31.8, 29.6, 29.5, 29.4, 29.3, 29.2, 28.9, 28.8, 27.5, 22.6, 19.3, 





H NMR (500 MHz, CDCl3) δ 9.36 (s, 1H, NCHN), 9.33 (s, 2H, NCHC, 
CCHN), 2.52 (t, 2H, J = 6.9 Hz, C≡CCH2), 1.64-1.69 (m, 2H, 
CH2(CH2)10CH3), 1.42-1.48 (m, 2H, CH2CH3), 1.24 (s, 18H, CH2(CH2)9CH2), 
0.85 (t, 3H, J = 6.9 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (175.5, 161.6, 
157.8, 129.7, 100.4, 78.7, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.9, 27.6, 22.6, 
19.2, 14.0); HRMS (ESI, 2M-1) calcd for C40H59N4O2, 627.4644; found, 
627.4627. Yield: 30%. 
 
General procedure for synthesis of (S)-methyl 2-(alkoxycarbonyl)-3-
hydroxypropanoate (3-32a-b) 
L-Serine methyl ester hydrochloride, 3-31 (0.5 g, 3.22 mmol) was placed in a 
50 mL round-bottom flask containing a magnetic stirrer and was dissolved in a 
mixture of tetrahydrofuran (6 mL) and water (3 mL). The respective 
chloroformate (4.83 mmol) and sodium carbonate (1.71 g, 16.10 mmol) were 
added in the stated order and the mixture was stirred at room temperature 
overnight. After which, the reaction mixture was quenched with saturated 
ammonium chloride solution and extracted with ethyl acetate (3×15 mL). The 
combined organic layer was washed with saturated sodium chloride solution, 
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dried over magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:3) to yield 3-32. 
(S)-methyl 2-(benzyloxycarbconyl)-3-hydroxypropanoate (3-32a) 
[α]25 = +7.43° (c = 22.2 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.31 (s, 5H, OCH2C6H5), 5.08 (s, 2H, OCH2C6H5), 4.41 (t, 1H, J = 3.9 Hz, 
(OH)CH2CHN), 3.68-3.92 (m, 2H, (OH)CH2CHN), 3.68 (s, 3H, OCH3); 
13
C 
NMR (75 MHz, CDCl3) δ (171.0, 156.2, 135.8, 128.1, 127.8, 127.7, 66.7, 62.4, 
55.8, 52.2); HRMS (ESI, M + Na) calcd for C12H15O5NNa, 276.0842; found, 
276.0849. Yield: 63%. 
 
 (S)-methyl 3-hydroxy-2-(phenoxycarbonyl)propanoate (3-32b) 
[α]25 = -8.11° (c = 228.9 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
7.10-7.35 (m, 5H, OC6H5), 4.43-3.46 (m, 1H, (OH)CH2CHN), 3.83-3.95 (m, 
2H, (OH)CH2CHN), 3.74 (s, 3H, OCH3); 
13
C NMR (125 MHz, CDCl3) δ 
(170.9, 154.7, 150.6, 129.2, 125.4, 121.4, 62.5, 56.0, 52.6); HRMS (ESI, M + 
Na) calcd for C11H13O5NNa, 262.0686; found, 262.0699. Yield: 82%. 
 
General procedure for synthesis of (S)-4-methyl 3-alkyl 2,2-
dimethyloxazolidine-3,4-dicarboxylate (3-33a-b) 
Compound 3-32 (1.65 mmol) was placed in a 50 mL round-bottom flask 
containing a magnetic stirrer and was dissolved in acetone (15 mL). 2,2-
Dimethoxypropane (0.406 mL, 3.30 mmol) and boron trifluoride diethyt 
etherate (0.0122 mL, 0.099 mmol) were added in the stated order and the 
mixture was stirred at room temperature for 17 h. After which, the reaction 
mixture was quenched with saturated sodium bicarbonate solution and 
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extracted with ethyl acetate (3×15 mL). The combined organic layer was 
washed with saturated sodium chloride solution, dried over magnesium sulfate, 
filtered, concentrated and purified by column chromatography (silica gel; ethyl 
acetate: hexane = 1:6) to yield 3-33. 
 (S)-3-benzyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (3-33a) 
(rotamers) 
[α]25 = -46.79° (c = 36.4 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.21-7.26 (m, 5H, OCH2C6H5), 5.08 (d, 1H, J = 12.3 Hz, OCHHC6H5), 4.93 (d, 
1H, J = 12.3 Hz, OCHHC6H5),  4.37-4.46 (m, 1H, OCH2CHN), 3.97-4.09 (m, 
2H, OCH2CHN), 3.53-3.66 (s, 3H, OCH3), 1.55-1.61 (s, 3H, OCCH3), 1.39-
1.47 (s, 3H, NCCH3) ; 
13
C NMR (75 MHz, CDCl3) δ (171.0, 151.5, 136.1, 
128.3, 127.9, 127.5, 95.2, 67.3, 66.3, 58.6, 52.1, 30.5, 24.7, 23.9); HRMS (ESI, 
M + Na) calcd for C15H19O5NNa, 316.1166; found, 316.1169. Yield: 98%. 
 
(S)-4-methyl 3-phenyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (3-33b) 
(rotamers) 
[α]25 = -30.95° (c = 11.6 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
6.94-7.22 (m, 5H, OC6H5), 4.42-4.53 (m, 1H, OCH2CHN), 3.91-4.10 (m, 2H, 
OCH2CHN), 3.61 (s, 3H, OCH3), 1.60-1.67 (s, 3H, OCCH3), 1.45-1.51 (s, 3H, 
NCCH3) ; 
13
C NMR (75 MHz, CDCl3) δ (170.5, 150.4, 128.9, 125.1, 121.4, 
95.2, 66.2, 58.7, 52.1, 25.7, 24.5, 23.5); HRMS (ESI, M + Na) calcd for 





General procedure for synthesis of (R)-alkyl 4-(hydroxymethyl)-2,2-
dimethyloxazolidine-3-carboxylate (3-34a-b) 
Compound 33 (1.71 mmol) was placed in a 50 mL round-bottom flask 
containing a magnetic stirrer and was dissolved in tetrahydrofuran (5 mL). 
Lithium borohydride (2.69 mmol) was added at 0
o
C and the mixture was 
stirred at 0
o
C for 2 h. After which, the reaction mixture was quenched slowly 
with dropwise addition of saturated ammonium chloride solution and extracted 
with ethyl acetate (3×15 mL). The combined organic layer was washed with 
saturated sodium chloride solution, dried over magnesium sulfate, filtered, 
concentrated and purified by column chromatography (silica gel; ethyl acetate: 
hexane = 1:2) to yield 3-34. 
(R)-benzyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (3-
34a) 
[α]25 = -15.87° (c = 93.0 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.21 (m, 5H, OCH2C6H5), 4.99 (s, 2H, OCH2C6H5), 3.93-4.00 (m, 3H, 
OCH2CHN, CH2OH), 3.63-3.83 (m, 2H, OCH2CHN), 1.40 (m, 6H, OCCH3, 
NCCH3); 
13
C NMR (75 MHz, CDCl3) δ (153.4, 136.0, 127.9, 127.4, 93.9, 66.3, 
64.9, 62.2, 57.8, 26.1, 22.6); HRMS (ESI, M + Na) calcd for C14H19O4NNa, 




[α]25 = -20.36° (c = 53.5 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.07-7.35 (m, 5H, OC6H5), 3.93-4.04 (m, 3H, OCH2CHN, CH2OH), 3.48-3.75 
(m, 2H, OCH2CHN), 1.51-1.65 (m, 6H, OCCH3, NCCH3); 
13
C NMR (75 MHz, 
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CDCl3) δ (151.9, 150.4, 129.0, 125.2, 121.4, 94.2, 65.1, 61.5, 58.1, 26.0, 22.6); 
HRMS (ESI, M + Na) calcd for C13H17O4NNa, 274.1050; found, 274.1056. 
Yield: 54%. 
 
General procedure for synthesis of (S)-alkyl 4-formyl-2,2-
dimethyloxazolidine-3-carboxylate (3-35a-b) 
Compound 3-34 (1.02 mmol) was placed in a 25 mL round-bottom flask 
containing a magnetic stirrer and was dissolved in anhydrous dichloromethane 
(10 mL). Sodium bicarbonate (0.428 g, 5.10 mmol) and Dess-Martin 
periodinane (0.649 g, 1.53 mmol) were added in the stated order and the 
reaction mixture was stirred at room temperature for 1 h. After which, the 
reaction mixture was quenched slowly with dropwise addition of saturated 
sodium bicarbonate solution and extracted with dichloromethane (3×15 mL). 
The combined organic layer was washed with saturated sodium chloride 
solution, dried over magnesium sulfate, filtered, concentrated and purified by 
column chromatography (silica gel; ethyl acetate: hexane = 1:5) to yield 3-35. 
 
(S)-benzyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate (3-35a) 
[α]25 = -42.67° (c = 38.5 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
9.45-9.51 (rotamers) (s, 1H, C(O)H), 7.20-7.27 (m, 5H, OCH2C6H5), 5.02-5.17 
(m, 2H, OCH2C6H5), 4.24 (m, 1H, OCH2CHN), 4.02 (m, 2H, OCH2CHN), 
1.41-1.58 (m, 6H, OCCH3, NCCH3); 
13
C NMR (75 MHz, CDCl3) δ (198.6, 
151.7, 135.8, 128.1, 127.9, 95.3, 66.9, 64.3, 63.9, 25.5, 23.3); HRMS (ESI, M 




(S)-phenyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate (3-35b) 
(rotamers) 
[α]25 = -51.27° (c = 6.3 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
9.58 (s, 1H, C(O)H), 6.99-7.27 (m, 5H, OC6H5), 4.37-4.46 (m, 1H, 
OCH2CHN), 3.96-4.11 (m, 2H, OCH2CHN), 1.50-1.65 (m, 6H, OCCH3, 
NCCH3); 
13
C NMR (75 MHz, CDCl3) δ (197.5, 150.4, 150.1, 129.1, 125.4, 
121.4, 95.5, 64.6, 63.6, 25.2, 23.2); HRMS (ESI, M + Na) calcd for 
C13H15O4NNa, 272.0893; found, 272.0899. Yield: 75%. 
 
General procedure for synthesis of (S)-alkyl 4-((R)-1-hydroxyhexadec-2-
ynyl)-2,2-dimethyloxazolidine-3-carboxylate (3-36a-b) 
Aldehyde 35 (2.803 mmol) in tetrahydrofuran (6 mL) was added, via a cannula, 
to a solution of 1-pentadecyne (1.00 mL, 3.812 mmol) and BuLi (2.032 mL, 
3.25 mmol, 1.6 M in hexanes) in tetrahydrofuran (15 mL) at -40 ºC. The 
reaction mixture was stirred under nitrogen for 4 h at -40 ºC. When TLC 
monitoring indicated the complete consumption of the aldehyde, the reaction 
mixture was quenched slowly with dropwise addition of distilled water (10 mL) 
and extracted with ethyl acetate (3×20 mL). The combined organic layer was 
washed with saturated ammonium chloride solution followed by saturated 
sodium chloride solution, dried over magnesium sulfate, filtered, concentrated 
and purified by column chromatography (silica gel; ethyl acetate: hexane = 1:5 







[α]25 = -26.69° (c = 49.0 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.35 (s, 5H, CH2C6H5), 5.18 (s, 2H, CH2C6H5), 4.63 (s, 1H, CHOH), 4.29 (s, 
1H, OCH2CHN), 4.03-4.17 (m, 2H, OCH2CH), 2.14-2.18 (m, 2H, C≡CCH2), 
1.44-1.66 (m, 8H, OCCH3, NCCH3, C≡CCH2CH2(CH2)10CH3), 1.25-1.32 (m, 
20 H, C≡CCH2CH2(CH2)10CH3), 0.87 (t, 3H, J = 6.6 Hz, CH2CH3); 
13
C NMR 
(75 MHz, CDCl3) δ (128.5, 128.0, 95.2, 87.0, 67.6, 65.0, 62.9, 61.2, 31.8, 29.6, 
29.4, 29.3, 29.0, 28.8, 28.4, 25.7, 25.4, 23.1, 22.6, 18.6, 14.0); HRMS (ESI, M 




[α]25 = -42.34° (c = 73.6 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
6.71-7.10 (m, 5H, C6H5),  5.11-5.16 (m, 1H, CHOH), 4.19-4.34 (m, 1H, 
OCH2CHN), 3.88-3.98 (m, 2H, OCH2CH), 2.13 (t, 2H, J = 6.9 Hz, C≡CCH2), 
1.61 (s, 1H, OCCH3), 1.18-1.41 (m, 25H, NCCH3, C≡CCH2(CH2)11CH3), 0.80 
(m, 3H, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ (156.2, 129.0, 119.5, 115.1, 
94.9, 92.0, 72.2, 66.0, 65.6, 60.2, 31.6, 29.3, 29.17, 29.0, 28.7, 28.5, 27.8, 27.0. 
23.0, 22.4, 18.3, 13.8); HRMS (ESI, M + Na) calcd for C28H43O4NNa, 






General procedure for synthesis of (S)-alkyl 4-hexadec-2-ynoyl-2,2-
dimethyloxazolidine-3-carboxylate (3-37a-b) 
Compound 36 (1.15 mmol) was placed in a 25 mL round-bottom flask 
containing a magnetic stirrer and was dissolved in anhydrous dichloromethane 
(10 mL). Sodium bicarbonate (0.484 g, 5.76 mmol) and Dess-Martin 
periodinane (0.732 g, 1.73 mmol) were added in the stated order and the 
reaction mixture was stirred at room temperature for 2 h. After which, the 
reaction mixture was quenched slowly with dropwise addition of saturated 
sodium bicarbonate solution and extracted with dichloromethane (3×15 mL). 
The combined organic layer was washed with saturated sodium chloride 
solution, dried over magnesium sulfate, filtered, concentrated and purified by 
column chromatography (silica gel; ethyl acetate: hexane = 1:8) to yield 37. 
 
(S)-benzyl 4-hexadec-2-ynoyl-2,2-dimethyloxazolidine-3-carboxylate (37a) 
[α]25 = -29.9° (c = 282.1 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
7.17-7.27 (m, 5H, CH2C6H5), 4.97-5.10 (m, 2H, CH2C6H5), 4.37-4.50 (m, 1H, 
OCH2CHN), 4.04 (m, 2H, OCH2CH), 2.20 (m, 2H, C≡CCH2), 1.63 (s, 3H, 
OCCH3), 1.55 (s, 3H, NCCH3), 1.40-1.47 (m, 2H, C≡CCH2CH2(CH2)9CH2), 
1.18-1.27 (m, 20 H, CH2(CH2)10CH3), 0.79 (t, 3H, J = 6.6 Hz, CH2CH3); 
13
C 
NMR (125 MHz, CDCl3) δ (185.2, 151.7, 135.9, 128.3, 128.0, 127.7, 98.7, 
95.5, 78.5, 67.3, 66.8, 66.7, 66.0, 65.3, 61.7, 29.4, 29.2, 29.1, 28.8, 28.7, 27.4, 
2.0, 24.9, 23.7, 22.5, 18.8, 13.9); HRMS (ESI, M + Na) calcd for 






[α]25 = -37.2° (c = 45.7 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.01-7.29 (m, 5H, CH2C6H5), 4.61 (t, 1H, J = 5.0 Hz, OCH2CHN), 4.16-4.19 
(m, 2H, OCH2CH), 2.33 (t, 2H, J = 7.2 Hz, C≡CCH2), 1.67 (s, 3H, OCCH3), 
1.53 (s, 3H, NCCH3), 1.48 (s, 2H, C≡CCH2CH2(CH2)10CH3), 1.18-1.30 (m, 20 
H, CH2(CH2)10CH3), 0.81 (t, 3H, J = 6.6 Hz, CH2CH3); 
13
C NMR (75 MHz, 
CDCl3) δ (184.7, 150.3, 129.3, 125.5, 121.6, 99.3, 96.0, 78.7, 67.0, 66.5, 66.1, 
31.8, 29.6, 29.3, 28.8, 27.5, 25.0, 23.8, 22.6, 19.1, 14.0); HRMS (ESI, M + Na) 
calcd for C28H41O4NNa, 478.2928; found, 478.2939. Yield: 51%. 
 
General procedure for synthesis of (S)-tert-butyl 1-hydroxy-alkyl-
carbamate (3-39a-f) 
Carboxylic acid 3-38 (0.5 g, 1.9 mmol) was placed in a 50 mL round-bottom 
flask containing a magnetic stirrer and was dissolved in tetrahydrofuran (15 
mL). Lithium aluminium hydride (1.4 mL, 2.8 mmol, 2M in THF solution) was 
added dropwise at 0
o
C and the mixture was then stirred at room temperature 
overnight. After which, the reaction mixture was quenched slowly with 
dropwise addition of saturated ammonium chloride solution, filtered and 
washed with ethyl acetate. The combined organic layer was washed with 
saturated sodium chloride solution, dried over magnesium sulfate, filtered, 
concentrated and purified by column chromatography (silica gel; ethyl acetate: 





(S)-tert-butyl 1-hydroxypropan-2-ylcarbamate (3-39a) 
[α]25 = -4.1° (c = 156.9 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
4.98 (br s, 1H, NHC(O)OC(CH3)3), 3.64 (br s, 1H, CH2OH), 3.38-3.53 (m, 3H, 
CH3CH, CH2OH), 1.36 (s, 9H, C(O)OC(CH3)3), 1.05-1.07 (d, 2H, J = 6.7 Hz, 
CH3CH); 
13
C NMR (75 MHz, CDCl3) δ (156.1, 79.3, 66.4, 48.3, 28.2, 17.2); 
HRMS (ESI, M + Na) calcd for C8H17O3NNa, 198.1101; found, 198.1109. 
Yield: 51%. 
 
(S)-tert-butyl 1-hydroxy-3-methylbutan-2-ylcarbamate (3-39b) 
[α]25 = -11.6° (c = 274.2 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.96 (br s, 1H, NHC(O)OC(CH3)3), 3.49-3.52 (m, 3H, (CH3)2CHCH, 
CH(H)OH, CH2OH), 3.28 (s, 1H, CH(H)OH), 1.74 (s, 1H, (CH3)2CH), 1.36 (s, 
9H, C(O)OC(CH3)3), 0.83-0.85 (d, 3H, J = 7.0 Hz, (CH3)(CH3)CH), 0.81-0.83 
(d, 3H, J = 7.0 Hz, (CH3)(CH3)CH); 
13
C NMR (125 MHz, CDCl3) δ (156.6, 
79.0, 63.1, 57.6, 29.0, 28.2, 19.3, 18.3); HRMS (ESI, M + Na) calcd for 
C10H21O3NNa, 226.1414; found, 226.1404. Yield: 59%. 
 
(S)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (3-39c) 
[α]25 = -27.9° (c = 217.7 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
3.94 (s, 1H, CH2OH), 3.79 (s, 1H, CH(H)OH), 3.46-3.48 (m, 2H, CHCH2OH, 
CH(H)N), 3.19-3.31 (m, 2H, CH(H)OH, CH(H)N), 1.53-1.86 (m, 4H, 
NCH2(CH2)2CH), 1.34 (s, 9H, C(O)OC(CH3)3); 
13
C NMR (75 MHz, CDCl3) δ 
(156.5, 79.7, 66.5, 59.6, 47.1, 28.2, 23.6); HRMS (ESI, M + Na) calcd for 




(S)-tert-butyl 1-hydroxy-3-phenylpropan-2-ylcarbamate (3-39d) 
[α]25 = -15.5° (c = 121.7 × 10-3 g/mL, CH2Cl2); 
1
H NMR (300 MHz, CDCl3) δ 
7.11-7.22 (m, 5H, ArH), 4.93 (br s, 1H, NHC(O)OC(CH3)3), 3.76 (s, 1H, 
CH2CH), 3.40-3.53 (m, 2H, CH2OH, CH(H)OH), 3.15 (s, 1H, CH(H)OH), 
2.73-2.75 (d, 2H, J = 7.0 Hz, CH2CH), 1.31 (s, 9H, C(O)OC(CH3)3); 
13
C NMR 
(75 MHz, CDCl3) δ (156.1, 137.9, 129.2, 128.3, 126.2, 79.5, 63.6, 53.5, 37.4, 
28.2); HRMS (ESI, M + Na) calcd for C14H21O3NNa, 274.1414; found, 
274.1427. Yield: 70%. 
 
(S)-tert-butyl 1-hydroxy-4-methylpentan-2-ylcarbamate(3-39e) 
[α]25 = -14.0° (c = 267.3 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.89 (br s, 1H, NHC(O)OC(CH3)3), 3.50-3.60 (m, 3H, (CH3)2CHCH2CH, 
CH(H)OH, CH2OH), 3.40 (s, 1H, CH(H)OH), 1.55-1.60 (m, 1H, (CH3)2CH), 
1.35 (s, 9H, C(O)OC(CH3)3), 1.23-1.35 (m, 2H, (CH3)2CHCH2), 0.83-0.84 (d, 
6H, J = 6.3 Hz, (CH3)2CH); 
13
C NMR (125 MHz, CDCl3) δ (156.3, 79.1, 65.6, 
50.6, 40.4, 28.2, 24.6, 22.8, 22.0); HRMS (ESI, M + Na) calcd for 
C11H23O3NNa, 240.1570; found, 240.1578. Yield: 59%. 
 
(R)-tert-butyl 1-(benzyloxy)-3-hydroxypropan-2-ylcarbamate (3-39f) 
[α]25 = +10.4° (c = 211.7 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
7.19-7.26 (m, 5H, ArH), 5.17 (s, 1H, NHC(O)OC(CH3)3), 4.41 (s, 2H, 
ArCH2O), 3.48-3.67 (m, 5H, OCH2CH, OCH2CH, CH2OH, CH(H)OH), 3.02 
(s, 1H, CH(H)OH), 1.35 (s, 9H, C(O)OC(CH3)3); 
13
C NMR (125 MHz, CDCl3) 
δ (155.9, 137.6, 128.3, 127.6, 127.5, 79.4, 73.2, 69.9, 63.0, 51.5, 28.2); HRMS 
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(ESI, M + Na) calcd for C15H23O4NNa, 304.1543; found, 304.1536. Yield: 
44%. 
 
General procedure for synthesis of (S)-tert-butyl 1-oxo-alkyl-carbamate 
(3-40a–f) 
Compound 3-39 (0.3 g, 1.3 mmol) was placed in a 25 mL round-bottom flask 
containing a magnetic stirrer and dissolved in anhydrous dichloromethane (10 
mL). Sodium bicarbonate (0.6 g, 6.7 mmol) and Dess-Martin periodinane (0.9 
g, 2.0 mmol) were added in the stated order and the reaction mixture was 
stirred at room temperature for 1.5 h. After which, the reaction mixture was 
quenched slowly with dropwise addition of saturated sodium bicarbonate 
solution and extracted with dichloromethane (3×15 mL). The combined 
organic layer was washed with saturated sodium chloride solution, dried over 
magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:7) to yield 3-40. 
(S)-tert-butyl 1-oxopropan-2-ylcarbamate (3-40a) 
[α]25 = +9.3° (c = 168.5 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
9.46 (s, 1H, CHO), 5.33 (br s, 1H, NHC(O)OC(CH3)3), 4.09-4.11 (m, 1H, 
CH3CH), 1.35 (s, 9H, C(O)OC(CH3)3), 1.22-1.24 (d, 2H, J = 7.0 Hz, CH3CH); 
13
C NMR (125 MHz, CDCl3) δ (200.0, 155.3, 79.7, 55.3, 28.1, 14.4); HRMS 
(ESI, M + Na) calcd for C8H15O3NNa, 196.0944; found, 196.0953. Yield: 47%. 
 
(S)-tert-butyl 3-methyl-1-oxobutan-2-ylcarbamate (3-40b) 
[α]25 = 48.9° (c = 210.7 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
9.54 (s, 1H, CHO), 5.18 (br s, 1H, NHC(O)OC(CH3)3), 4.12 (s, 1H, 
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(CH3)2CHCH), 2.17-2.18 (m, 1H, (CH3)2CH), 1.34 (s, 9H, C(O)OC(CH3)3), 
0.92-0.93 (d, 3H, J = 7.0 Hz, (CH3)(CH3)CH), 0.84-0.85 (d, 3H, J = 7.0 Hz, 
(CH3)(CH3)CH); 
13
C NMR (125 MHz, CDCl3) δ (200.3, 155.7, 79.6, 64.5, 28.8, 
28.1, 18.8, 17.4); HRMS (ESI, M + Na) calcd for C10H19O3NNa, 224.1257; 
found, 224.1264. Yield: 78%. 
 
(S)-tert-butyl 2-formylpyrrolidine-1-carboxylate (3-40c) (rotamers) 
[α]25 = -57.6° (c = 124.2 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
9.39-9.48 (s, 1H, CHO), 3.97-4.11 (s, 1H, CHCHO), 3.37-3.47 (m, 2H, CH2N), 
1.77-2.08 (m, 4H, NCH2(CH2)2CH), 1.35-1.40 (s, 9H, C(O)OC(CH3)3); 
13
C 
NMR (125 MHz, CDCl3) δ (200.2, 153.8, 80.4, 64.9, 46.7, 28.2, 27.8, 23.8); 
HRMS (ESI, M + Na) calcd for C10H17O3NNa, 222.1101; found, 222.1111. 
Yield: 58%. 
 
(S)-tert-butyl 1-oxo-3-phenylpropan-2-ylcarbamate (3-40d) 
[α]25 = +13.9° (c = 285.4 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
9.49 (s, 1H, CHO), 7.06-7.20 (m, 5H, ArH), 5.15-5.17 (m, 1H, 
NHC(O)OC(CH3)3), 4.27-4.28 (m, 1H, CH2CH), 2.93-3.04 (m, 2H, CH2CH), 
1.32 (s, 9H, C(O)OC(CH3)3); 
13
C NMR (125 MHz, CDCl3) δ (199.3, 155.2, 
135.8, 129.1, 128.4, 126.7, 79.8, 60.6, 35.0, 28.0); HRMS (ESI, M + Na) calcd 
for C14H19O3NNa, 272.1257; found, 272.1254. Yield: 64%. 
 
(S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate (3-40e) 
[α]25 = -5.5° (c = 155.6 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
9.52 (s, 1H, CHO), 5.06 (br s, 1H, NHC(O)OC(CH3)3), 4.16 (s, 1H, 
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(CH3)2CHCH2CH), 1.68-1.74 (m, 2H, (CH3)2CHCH2CH), 1.30-1.41 (m, 10H, 
(CH3)2CH,  C(O)OC(CH3)3), 1.23-1.35 (m, 2H, (CH3)2CHCH2), 0.90-0.91 (d, 
6H, J = 7.0 Hz, (CH3)2CH); 
13
C NMR (125 MHz, CDCl3) δ (200.4, 155.6, 79.8, 
58.3, 37.9, 28.2, 24.5, 23.0, 21.8); HRMS (ESI, M + Na) calcd for 
C11H21O3NNa, 238.1414; found, 238.1417. Yield: 59%. 
 
(S)-tert-butyl 1-(benzyloxy)-3-oxopropan-2-ylcarbamate (3-40f) 
[α]25 = +4.8° (c = 125.2 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
9.53 (s, 1H, CHO), 7.17-7.27 (m, 5H, ArH), 5.39 (s, 1H, NHC(O)OC(CH3)3), 
4.42 (s, 2H, ArCH2O), 4.22 (br s, 1H, OCH2CH), 3.60-3.63 (m, 1H, 
OCH(H)CH), 3.88-3.90 (m, 1H, OCH(H)CH), 1.37 (s, 9H, C(O)OC(CH3)3); 
13
C NMR (125 MHz, CDCl3) δ (199.0, 155.5, 137.2, 128.4, 127.8, 127.6, 80.0, 
73.4, 67.7, 60.0, 28.2); HRMS (ESI, M + Na) calcd for C15H21O4NNa, 
302.1363; found, 302.1372. Yield: 60%. 
 
General procedure for synthesis of (S)-tert-butyl 3-oxo-alkyl-octadec-4-yn-
2-ylcarbamate (3-41a-f) 
Aldehyde 3-40 (0.2 g,  0.7 mmol) in tetrahydrofuran (5 mL) was added, via a 
cannula, to a solution of 1-pentadecyne (0.2 mL, 0.8 mmol) and BuLi (0.6 mL, 
0.9 mmol, 1.6 M in hexanes) in tetrahydrofuran (15 mL) at -40 ºC. The 
reaction mixture was stirred under nitrogen for 4 h at -40 ºC. When TLC 
monitoring indicated the complete consumption of the aldehyde, the reaction 
mixture was quenched slowly with dropwise addition of distilled water (10 mL) 
and extracted with ethyl acetate (3×20 mL). The combined organic layer was 
washed with saturated ammonium chloride solution followed by saturated 
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sodium chloride solution, dried over magnesium sulfate, filtered, concentrated. 
It was then placed in a 25 mL round-bottom flask containing a magnetic stirrer 
and dissolved in anhydrous dichloromethane (10 mL). Sodium bicarbonate (0.2 
g, 2.5 mmol) and Dess-Martin periodinane (0.3 g, 0.7 mmol) were added in the 
stated order and the reaction mixture was stirred at room temperature for 2 h. 
After which, the reaction mixture was quenched slowly with dropwise addition 
of saturated sodium bicarbonate solution and extracted with dichloromethane 
(3×15 mL). The combined organic layer was washed with saturated sodium 
chloride solution, dried over magnesium sulfate, filtered, concentrated and 
purified by column chromatography (silica gel; ethyl acetate: hexane = 1:12) to 
yield 3-41. 
(S)-tert-butyl 3-oxooctadec-4-yn-2-ylcarbamate (3-41a) 
[α]25 = +15.0° (c = 57.5 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.19 (br s, 1H, NHC(O)OC(CH3)3), 4.36 (br s, CH3CH), 2.37 (t, 2H, J = 7.0 Hz, 
C≡CCH2), 1.55-1.58 (m, 2H, C≡CCH2CH2), 1.24-1.43 (m, 32H,  
C(O)OC(CH3)3, CH3CH, CH2(CH2)10CH3), 0.86 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (187.0, 155.0, 98.2, 79.8, 78.8, 56.9, 36.6, 31.9, 
29.7, 29.6, 29.5, 29.4, 29.3, 29.0, 28.8, 28.3, 27.6, 22.6, 19.1, 17.8, 14.0); 
HRMS (ESI, M + Na) calcd for C23H41O3NNa, 402.2979; found, 402.2970. 
Yield: 37%. 
 
(S)-tert-butyl 2-methyl-4-oxononadec-5-yn-3-ylcarbamate (3-41b) 
[α]25 = +34.5° (c = 113.7 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.07 (br s, 1H, NHC(O)OC(CH3)3), 4.32 (br s, 1H, (CH3)2CHCH), 2.36 (t, 2H, 
J = 7.0 Hz, C≡CCH2), 1.51-1.58 (m, 2H, C≡CCH2CH2), 1.40 (s, 9H, 
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C(O)OC(CH3)3), 1.34-1.37 (m, 1H, (CH3)2CH), 1.22 (s, 20H, CH2(CH2)10CH3), 
0.98-0.99 (d, 3H, J = 7.0 Hz, (CH3)(CH3)CH), 0.84 (t, 3H, J = 7.0 Hz, 
CH2CH3), 0.77-0.79 (d, 3H, J = 7.0 Hz, (CH3)(CH3)CH); 
13
C NMR (125 MHz, 
CDCl3) δ (186.9, 155.7, 97.9, 79.6, 65.8, 31.8, 30.3, 29.6, 29.529.4, 29.3, 29.2, 
28.9, 28.8, 28.2, 27.5, 22.6, 19.6, 19.0, 16.5, 14.0); HRMS (ESI, M + Na) calcd 
for C25H45O3NNa, 430.3292; found, 430.3298. Yield: 27%. 
 
(S)-tert-butyl 2-hexadec-2-ynoylpyrrolidine-1-carboxylate (3-41c) 
(rotamers) 
[α]25 = -41.2° (c = 82.4 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ, 
4.16-4.19 (m, 1H, CH2NCH), 3.48-3.51 (m, 2H, CH2NCH), 2.30-2.33 (m, 2H, 
C≡CCH2), 1.80-2.33 (m, 4H, NCH2(CH2)2CH), 1.51-1.54 (m, 2H, 
C≡CCH2CH2) 1.42 (s, 2H, C≡CCH2CH2CH2), 1.38 (s, 9H, C(O)OC(CH3)3), 
1.21 (s, 18H, CH2(CH2)9CH3), 0.84 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (75 
MHz, CDCl3) δ (188.2, 153.7, 96.8, 80.2, 78.4, 66.6, 46.7, 31.8, 30.2, 29.6, 
29.5, 29.4, 29.3, 29.2, 29.0, 28.9, 28.8, 28.1, 27.6, 24.1, 23.6, 22.6, 19.0, 18.9, 
14.0); HRMS (ESI, M + Na) calcd for C25H43O3NNa, 428.3135; found, 
428.3130. Yield: 35%. 
 
(S)-tert-butyl 3-oxo-1-phenyloctadec-4-yn-2-ylcarbamate (3-41d) 
[α]25 = +14.0° (c = 151.6 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
7.07-7.20 (m, 5H, ArH), 5.00-5.02 (m, 1H, NHC(O)OC(CH3)3), 4.56-4.58 (m, 
1H, CH2CH), 3.09-3.16 (m, 2H, CH2CH), 2.30 (t, 2H, J = 7.0 Hz, C≡CCH2), 
1.48-1.51 (m, 2H, C≡CCH2CH2), 1.18-1.33 (m, 29H,  C(O)OC(CH3)3, 
CH2(CH2)10CH3), 0.80 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, 
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CDCl3) δ (185.7, 154.9, 135.7, 129.4, 128.3, 126.8, 98.5, 79.6, 79.3, 61.9, 37.2, 
31.8, 29.6, 29.5, 29.4, 29.3, 29.2, 28.9, 28.8, 28.2, 27.5, 22.5, 19.0, 14.0); 
HRMS (ESI, M + Na) calcd for C29H45O3NNa, 478.3292; found478.3291. 
Yield: 32%. 
 
(S)-tert-butyl 2-methyl-5-oxoicos-6-yn-4-ylcarbamate (3-41e) 
[α]25 = +28.3° (c = 46.7 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.95 (br s, 1H, NHC(O)OC(CH3)3), 4.37 (br s, 1H, (CH3)2CHCH2CH), 2.37 (t, 
2H, J = 7.0 Hz, C≡CCH2), 1.73-1.76 (m, 2H, (CH3)2CHCH2CH), 1.55-1.66 (m, 
2H, C≡CCH2CH2), 1.37-1.40 (m, 12H,  C(O)OC(CH3)3, (CH3)2CH,  
CH2(CH2)8CH3) 1.24, (s, 16H, CH2(CH2)8CH3), 0.92-0.96 (m, 6H, (CH3)2CH), 
0.86 (t, 3H, J = 7.0 Hz, CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (187.6, 155.4, 
98.0, 90.3, 79.7, 65.8, 59.9, 54.6, 40.8, 31.9, 30.4, 29.6, 29.4, 29.3, 29.0, 28.8, 
28.2, 27.6, 23.1, 22.6, 21.8, 19.6, 19.1, 14.0); HRMS (ESI, M + Na) calcd for 
C26H47O3NNa, 444.3448; found, 444.3442. Yield: 50%. 
 
(S)-tert-butyl 1-(benzyloxy)-3-oxooctadec-4-yn-2-ylcarbamate (3-41f) 
[α]25 = +0.8° (c = 72.7 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
7.19-7.27 (m, 5H, ArH), 5.42-5.44 (m, 1H, NHC(O)OC(CH3)3), 4.36-4.49 (m, 
3H, ArCH2O, OCH2CH), 4.00-4.02 (m, 1H, OCH(H)CH), 3.65-3.68 (m, 1H, 
OCH(H)CH), 2.26 (t, 2H, J = 7.0 Hz, C≡CCH2), 1.45-1.48 (m, 2H, 
C≡CCH2CH2), 1.38 (s, 9H,  C(O)OC(CH3)3), 1.29-1.31 (m, 2H, 
CH2(CH2)9CH3), 1.18 (s, 18H, CH2(CH2)9CH3), 0.81 (t, 3H, J = 7.0 Hz, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (184.7, 154.7, 137.4, 128.3, 127.7, 
127.6, 98.1, 79.9, 78.9, 73.4, 69.2, 61.5, 36.6, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 
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29.0, 28.8, 28.3, 27.5, 24.6, 22.6, 19.0, 14.0); HRMS (ESI, M + Na) calcd for 
C30H47O4NNa, 508.3397; found, 508.3381. Yield: 33%. 
 
Synthesis of (2S,3R)-methyl 2-(tert-butoxycarbonylamino)-3-hydroxy-
butanoate (3-43) 
(2S,3R)-Threonine methyl esther (1.0 g, 5.9 mmol) was placed in a 50 mL 
round-bottom flask containing a magnetic stirrer and was dissolved in 
tetrahydrofuran (15 mL). Triethylamine (1.8 mL, 12.7 mmol) was added and 
the reaction mixture was allowed to stir at 0 ºC for 5 minutes, before di-tert-
butyl dicarbonate (1.5 mL, 6.5 mmol) was added drop-wise. The reaction 
mixture was subsequently warmed to 55 ºC and stirred for 2 h, before it was 
quenched slowly with dropwise addition of saturated ammonium chloride 
solution and extracted with ethyl acetate (3×15 mL). The combined organic 
layer was washed with saturated sodium chloride solution, dried over 
magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:1) to yield 3-43. 
[α]25 = -6.3° (c = 159.3 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
5.45-5.46 (d, 1H, J = 8.2 Hz, NHC(O)OC(CH3)3), 4.18-4.25 (m, 2H, 
(CH3)CHCHN, (CH3)CHCHN), 3.71 (s, 3H, C(O)OCH3), 2.85 (br s, 1H, 
CHOH), 1.40 (s, 9H, C(O)OC(CH3)3), 1.18-1.19 (d, 3H, J = 6.3 Hz, 
(CH3)CHCHN); 
13
C NMR (125 MHz, CDCl3) δ (172.0, 156.1, 80.0, 67.8, 58.8, 
52.3, 28.2, 19.7); HRMS (ESI, M + Na) calcd for C10H19O5NNa, 256.1155; 




Synthesis of (4S,5R)-3-tert-butyl 4-methyl 2,2,5-trimethyloxazolidine-3,4-
dicarboxylate (3-44) (rotamers) 
Compound 3-43 (1.6 g, 6.7 mmol) was placed in a 50 mL round-bottom flask 
containing a magnetic stirrer and was dissolved in acetone (10 mL). 2,2-
Dimethoxypropane (7.2 mL, 58.4 mmol) and boron trifluoride diethyt etherate 
(0.05 mL, 0.4 mmol) were added in the stated order and the mixture was stirred 
at room temperature for 17 h. After which, the reaction mixture was quenched 
with saturated sodium bicarbonate solution and extracted with ethyl acetate 
(3×15 mL). The combined organic layer was washed with saturated sodium 
chloride solution, dried over magnesium sulfate, filtered, concentrated and 
purified by column chromatography (silica gel; ethyl acetate: hexane = 1:4) to 
yield 3-44. 
[α]25 = -47.2° (c = 26.2 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
3.86-4.11 (m, 2H, (CH3)CHCHN, (CH3)CHCHN), 3.73 (s, 3H, C(O)OCH3), 
1.61 (s, 3H, (CH3)CO), 1.55 (s, 3H, (CH3)CN), 1.45 (s, 3H, (CH3)CHCHN), 
1.35 (s, 9H, C(O)OC(CH3)3); 
13
C NMR (125 MHz, CDCl3) δ (171.2, 150.9, 
95.1, 80.2, 73.8, 66.1, 52.1, 28.3, 26.4, 24.0, 18.8); HRMS (ESI, M + Na) calcd 
for C13H23O5NNa, 296.1492; found, 256.1482. Yield: 45%. 
 
Synthesis of (4R,5R)-tert-butyl 4-(hydroxymethyl)-2,2,5-trimethyl-
oxazolidine-3-carboxylate (3-45) 
Compound 3-44 (0.7 g, 2.6 mmol) was placed in a 50 mL round-bottom flask 
containing a magnetic stirrer and was dissolved in tetrahydrofuran (15 mL). 
Lithium aluminium hydride (3 mL, 5.2 mmol, 2M in THF solution) was added 
dropwise at 0
o
C and the mixture was then stirred at room temperature for 2 h. 
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After which, the reaction mixture was quenched slowly with dropwise addition 
of saturated ammonium chloride solution, filtered and washed with ethyl 
acetate. The combined organic layer was washed with saturated sodium 
chloride solution, dried over magnesium sulfate, filtered, concentrated and 
purified by column chromatography (silica gel; ethyl acetate: hexane = 1:3) to 
yield 3-45. 
[α]25 = -17.4° (c = 38.2 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.70 (br s, 1H,  (CH3)CHCHN), 3.63 (br s, 1H, CH2OH), 3.44 (br s, 2H, 
(CH3)CHCHN, C(H)HOH), 3.25 (br s, 1H, C(H)HOH), 1.33 (s, 3H, (CH3)CN), 
1.26 (s, 9H, C(O)OC(CH3)3), 1.23 (s, 3H, (CH3)CO), 1.10-1.11 (d, 3H, J = 6.3 
Hz, (CH3)CHCHN); 
13
C NMR (125 MHz, CDCl3) δ (153.4, 93.4, 80.4, 71.9, 
66.3, 63.1, 59.8, 27.9, 25.6); HRMS (ESI, M + Na) calcd for C12H23O4NNa, 
268.1519; found, 268.1529. Yield: 82%. 
 
Synthesis of (4S,5R)-tert-butyl 4-formyl-2,2,5-trimethyloxazolidine-3-
carboxylate (3-46) (rotamers) 
Compound 3-45 (0.5 g, 2.1 mmol) was placed in a 25 mL round-bottom flask 
containing a magnetic stirrer and dissolved in anhydrous dichloromethane (10 
mL). Sodium bicarbonate (0.9 g, 10.7 mmol) and Dess-Martin periodinane (1.4 
g, 3.2 mmol) were added in the stated order and the reaction mixture was 
stirred at room temperature for 1.5 h. After which, the reaction mixture was 
quenched slowly with dropwise addition of saturated sodium bicarbonate 
solution and extracted with dichloromethane (3×15 mL). The combined 
organic layer was washed with saturated sodium chloride solution, dried over 
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magnesium sulfate, filtered, concentrated and purified by column 
chromatography (silica gel; ethyl acetate: hexane = 1:5) to yield 3-46. 
[α]25 = -34.6° (c = 477.1 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
9.22 (s, 1H, CHO), 3.89-3.90 (m, 1H,  (CH3)CHCHN), 3.52-3.62 (m, 1H, 
(CH3)CHCHN), 1.41 (s, 3H, (CH3)CN), 1.33 (s, 3H, (CH3)CO), 1.26 (s, 9H, 
C(O)OC(CH3)3), 1.17-1.19 (d, 3H, J = 6.3 Hz, (CH3)CHCHN); 
13
C NMR (125 
MHz, CDCl3) δ (197.0 150.6, 94.6, 81.0, 70.7, 69.8, 27.9, 25.9, 24,7, 17.4); 
HRMS (ESI, M + Na) calcd for C12H21O4NNa, 266.1363; found, 266.1376. 
Yield: 92%. 
 
Synthesis of (4S,5R)-tert-butyl 4-hexadec-2-ynoyl-2,2,5-trimethyl-
oxazolidine-3-carboxylate (3-47) (rotamers) 
Aldehyde 3-46 (0.5 g, 2.0 mmol) in tetrahydrofuran (5 mL) was added, via a 
cannula, to a solution of 1-pentadecyne (0.6 mL, 2.4 mmol) and BuLi (1.7 mL, 
2.7 mmol, 1.6 M in hexanes) in tetrahydrofuran (15 mL) at -40 ºC. The 
reaction mixture was stirred under nitrogen for 4 h at -40 ºC. When TLC 
monitoring indicated the complete consumption of the aldehyde, the reaction 
mixture was quenched slowly with dropwise addition of distilled water (10 mL) 
and extracted with ethyl acetate (3×20 mL). The combined organic layer was 
washed with saturated ammonium chloride solution followed by saturated 
sodium chloride solution, dried over magnesium sulfate, filtered, concentrated. 
It was then placed in a 25 mL round-bottom flask containing a magnetic stirrer 
and dissolved in anhydrous dichloromethane (10 mL). Sodium bicarbonate (0.3 
g, 3.0 mmol) and Dess-Martin periodinane (0.4 g, 0.9 mmol) were added in the 
stated order and the reaction mixture was stirred at room temperature for 2 h. 
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After which, the reaction mixture was quenched slowly with dropwise addition 
of saturated sodium bicarbonate solution and extracted with dichloromethane 
(3×15 mL). The combined organic layer was washed with saturated sodium 
chloride solution, dried over magnesium sulfate, filtered, concentrated and 
purified by column chromatography (silica gel; ethyl acetate: hexane = 1:15) to 
yield 3-47. 
[α]25 = -39.6° (c = 228.3 × 10-3 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 
4.06-4.09 (m, 1H, (CH3)CHCHN), 3.77-3.78 (d, 1H, J = 8.2 Hz, 
(CH3)CHCHN), 2.29 (t, 2H, J = 7.0 Hz, C≡CCH2), 1.56 (s, 3H, (CH3)CN), 
1.54 (s, 3H, (CH3)CO), 1.47-1.50 (m, 2H, C≡CCH2CH2), 1.41-1.43 (m, 2H, 
CH2(CH2)9CH3), 1.33 (s, 9H, C(O)OC(CH3)3), 1.27-1.28 (d, 3H, J = 6.3 Hz, 
(CH3)CHCHN), 1.17 (s, 18H, CH2(CH2)9CH3), 0.80 (t, 3H, J = 7.0 Hz, 
CH2CH3); 
13
C NMR (125 MHz, CDCl3) δ (184.9, 150.7, 96.8, 94.9, 80.8, 78.2, 
73.1, 72.2, 31.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 28.8, 28.7, 28.2, 28.0, 27.5, 
27.4, 26.2, 25.1, 24.4, 22.5, 18.9, 18.0, 13.9); HRMS (ESI, M + Na) calcd for 
C27H47O4NNa, 472.3397; found, 472.3380. Yield: 56%. 
 
3.5.2 Sphingosine kinase 1 or 2 DNA plasmid preparation 
Culture Growing: SphK 1 and 2 bacteria cells were removed from the freezer, 
and warmed to room temperature. 200 μL of LB medium was transferred into 
50mL Falcon Tubes and then 20μL of the warmed bacteria cells (SphK 1 and 2) 
were added. The mixtures were shaken gently and 50 μL of each of the mixture 
was pipetted into individually prepared culture plates (pre-coated with AMP) 
and evenly spread out using a bent glass pipette. The culture plates (containing 
SphK 1 and 2 cells individually) were then turned upside down and placed 
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overnight in an incubator at 37°C, 5% CO2 in a water saturated environment. 
This environment will allow the cells to grow into single colonies. After the 
single cell colonies have grown, a single colony was picked using a 
micropipette tip and dropped into a falcon tube containing LB medium. The 
tube was placed in an incubator shaker set at 270 rpm for 7 h or more. The tube 
was then checked for cloudiness before more medium was added to the tube 
and the shaking was continued at 280 rpm for an additional 17 h or more. 
Extraction and Purification: The cultured bacteria (containing the DNA-
plasmids encoding for SphK 1 and SphK 2 genes) were centrifuged down and 
the supernatant liquid poured away. The pellet obtained was re-dissolved in 
medium and purified using QIAfilter Plasmid Maxi kit, following the protocol 
listed in the kit, yielding the DNA plasmids for SphK 1 and 2. The 
concentration of the DNA plasmids is obtained using the Thermo Scientific 
NanoDrop
TM
 1000 Spectrophotometer. 
 
3.5.3 Mammalian Cell Transfection 
Cell line used for the transfection process in this project was the HCT 116 cell 
line. The cell line was cultured using McCoy 5A media supplemented with 
10% Fetal Bovine Serum (FBS), 1% 2mM L-glutamine, 10 mg/mL 
streptomycin and 10 µL/mL penicillin. The cell line was maintained in an 
incubator at 37°C, with 5% CO2 in a water saturated environment. 1 x 10
6
 cells 
were plated in a 10 cm well plate in 15 mL of 10% McCoy media (Media with 
10% FBS only) a day before actual transfection. On day of transfection, the 
medium in the cell culture was removed, the cells washed with sterile 
phosphate buffered saline (PBS) and 15 mL of 10% McCoy medium was 
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added as medium. SphK 1 or 2 DNA plasmids obtained were diluted in Opti-
MEM I Reduced Serum Medium and mixed gently (24 µg plasmid in 1.5 mL 
Opti-MEM/ per 10 cm plate). Lipofectamine 2000 reagent was diluted in Opti-
MEM, mixed gently and incubated for 5 minutes (60 µL Lipofectamine 2000 
reagent in 1.5 mL Opti-MEM/ per 10 cm plate). The diluted DNA and 
Lipofectamine reagent were combined, shaken gently and incubated for 20 
minutes. 3.0 mL of the combined DNA-Lipofectamine 2000 complex was 
added to the culture plate and was then placed in the incubator for 17 h at 37°C 
with 5% CO2 in a water saturated environment. After 17 h, the cells were 
scrapped and transferred to 2.0 mL eppendorf tubes. Cell lysates are obtained 
by freeze-thawing the eppendorf tubes using liquid nitrogen for at least 10 
times consecutively. The tubes were then centrifuged at 13000 rpm for about 5 
minutes and the supernatant liquid was transferred to a 2.0 mL centrifuge tube. 
Concentrations of the cell lysates were measured using the Bradford Test 
template, following the protocol listed for Bradford Test.
30
   
 
3.5.4 Fluorescence based Sphingosine Kinase (SphK) Assay 
Proteins, 80 µg of cell lysates (SphK 1 or 2), in 2 µL of sonicated 1 mM of 
FluoroTag-BSA solution (which was prepared by mixing 1 mL bovine serum 
albumin solution (4mg/L) with 40 µL 2mM of 15-NBD-Sph in ethanol) and 5 
µL of 20 mM ATP solution were added in the stated order into an eppendorf 
tube. A reaction mixture containing no SphK served as blank. The reaction 
mixture was then topped up to 100 µL volume with SphK buffer solution. The 
mixture was vortexed vigorously before placing in a 37 °C water bath for 30 
minutes. After which, 100 µL of potassium phosphate buffer (1M, pH 8.5), 
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followed by 500 µL of chloroform/methanol (2:1, v/v) were added. The 
mixture was then vortexed vigorously and centrifuged for 5 minutes at 5000 
rpm. 75 µL of the upper aqueous layer obtained was added into the respective 
wells of a 96 wells black micro-plate. Thereafter, 75 µL of dimethylformamide 
was added into the respective wells. The fluorescence intensity was measured 
using a fluoro-spectrometer at 485 nm (excitation) and 535 nm (emission). 
 
3.5.5 MTT Assay 
U937 cells/ HL60 cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 media containing 10% Fetal Bovine Serum (FBS) and 1% L-
glutamine. 50000 cells were placed in wells of three 96 wells plates with a cell 
density of 1x10
6
 cells/ mL. The compound of interest was added into each well 
at concentration of 10 μM. Dimethylsphingosine was also added in at the 10 
μM to serve as a control. Wells containing plain DMSO served as a vehicular 
control. The plate was then placed in the incubator for 24, 48 and 72 h of 
incubation timing at 37 °C with 5% CO2 in a water saturated environment. At 
the end of each individual incubation time point, MTT reagent solution (For 
200 samples) was prepared by dissolving 4 mg of 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) in 1 mL of plain RPMI 1640 
medium and 50 μL of the MTT solution was added into each sample well. The 
plate was then incubated again in the dark for 2 h and centrifuged at 3000 rpm 
for 5 minutes. The supernatant was removed using a pipette and care was taken 
not to disturb the crystal formation. The crystals were then dissolved in 200 μL 
(per well) of DMSO/ glycine buffer solution (190 μL of DMSO + 10 μL of 
glycine buffer). The plate was then gently shaken using a vortemp machine for 
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5 minutes to ensure equal mixing and absorbance at 570 nm was taken using a 
spectrometer.  For HCT 116 cell line, McCoy 5A media is used. For MCF 10A 
cell line, MEM media is used. 
 
3.5.6 Protein Kinase C (PKC) Assay 
Protein Kinase C (PKC) Alpha protein and PKC protein were diluted to 2.5 
μg/uL. The PKC 5X Solution was activated using probe sonicator for 25 
seconds. Master mix containing PKC Reaction 5X Buffer, C1 Peptide, PKC 
Activator 5X Solution and Peptide Protection Solution was prepared. The 
master mix solution was then aliquot into individual 0.6 mL eppendorf tubes 
(16 μL each) and kept on ice till PKC enzyme is added. Inhibitors of various 
concentrations were added and deionised water is used to top up volume of 
solution in eppendorf to 21 μL. (25 μL for negative control assay). The 
eppendorfs was incubated in 30 degrees water bath for 2 minutes. 4 μL of PKC 
alpha or PKC protein was then added into eppendorfs to Standard or Positive 
Control Assay respectively. The eppendorfs were further incubated in 30 ºC 
water bath for 30 minutes. Upon end of the incubation time, the eppendorfs 
were placed in a 95 ºC heating block for 10 minutes to stop the reaction. The 
eppendorfs were placed on ice and in dark till loading begins. Add 1 μL of 
80% glycerol to each eppendorfs before loading onto gel. Gel Preparation/ 
Separation: The horizontal agarose gel apparatus was assembled accordingly. 
0.8% agarose solution (1.6 g in 200 mL 50 mM Tris-HCl, pH 8.0) was 
prepared and heated in microwave for 2 minutes and 10 seconds until all the 
agarose has been dissolved. The mixture was allowed to cool to 60 degrees and 
subsequently poured into gel tray, ensuring no bubble was formed in the 
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process. The gel was allowed to solidify before the comb was removed. The 
gel was placed in the electrophoresis chamber and 50 mM Tris-HCl (pH 8.0) 
solution was poured onto the gel. The PKC assay samples was then loaded into 
the well (10 µL per well) and the electrophoresis was started at 120 V for about 
30 minutes or till the separation was completed. The gel was then removed and 
the photo of the gel was taken using Kodax Imaging Machine.  
 
3.5.7 Annexin V Apoptosis Assay 
U937/ Monocyte cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 media containing 10% Fetal Bovine Serum (FBS) and 1% L-
glutamine. 1 million cells were placed in wells of a six wells plate with a cell 
density of 0.5 x 10
6
 cells/ mL. The compound of interest was added into each 
well at various concentrations with maximum of 10 µL. Wells containing only 
cells and with only DMSO added to serve as a vehicular control were also 
prepared. The plate was then placed in the incubator for 48 h of incubation 
timing at 37 °C with 5% CO2 in a water saturated environment. At the end of 
the incubation time point, the cells were removed into separate falcon tubes 
and centrifuged at 2000 rpm for 5 minutes. The supernatant was removed using 
a pipette and care was taken not to disturb the cell pellet. 1 mL of PBS was 
added to resuspend the cell pellets and centrifuged at 2000 rpm for 5 minutes. 
Supernatant was removed and the tubes were placed on ice. The cell pellet was 
resuspended with 100 µL of the diluted Annexin V reagent purchased from BD 
Biosciences in the dark and incubated at room temperature for 15 minutes. 400 
µL of PBS was then added and mixed well. The solution was then filtered and 
analyzed by flow cytometry. 
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3.5.8 BrdU Cell Proliferation Assay 
U937 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 
media containing 10% Fetal Bovine Serum (FBS) and 1% L-glutamine. 100 µL 
of cells (cell density of 0.2 x 10
6
 cells/ mL) were placed in 96-wells plate. The 
compound of interest was added into each well at various concentrations with 
maximum of 0.5 µL. Wells containing only cells and with only DMSO added 
to serve as a vehicular control were also prepared. 10 µL of BrdU labelling 
reagent was added to each well, before the plate was placed in the incubator for 
16 h of incubation timing at 37 °C with 5% CO2 in a water saturated 
environment. At the end of the incubation time point, the plate was centrifuged 
at 1200 rpm for 5 minutes. The supernatant was removed using a pipette and 
care was taken not to disturb the cell pellet. 200 µL of the BrdU Fixation 
Liquid was added to resuspend the cell pellets and the plate was incubated at 
room temperature for 30 minutes. The plate was then centrifuged at 1200 rpm 
for 5 minutes and the supernatant was removed. 100 µL of the Anti-BrdU 
solution was added to each well and the plate was again incubated at room 
temperature for 60 minutes. The plate was then centrifuged at 1200 rpm for 5 
minutes and the supernatant was removed. 200 µL of the washing solution was 
added and the plate was was then centrifuged at 1200 rpm for 5 minutes and 
the supernatant was removed. This washing procedure was repeated for two 
more times. 100 µL of the BrdU substrate was then added to each well and 
incubated for about 5 minutes (or till an aqua blue color developed). 10 µL of 
1M H2SO4 was added and the plate was shaken for 1 minute. The plate was 
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Chapter 4: Synthesis of Fluorescence-tagged Sphingosine-based 
Compounds and Method for Screening the Activities and Modulators 
of Sphingosine Kinases 
 
4.1 Introduction 
Sphingosine-1-phosphate (S1P) is an important signaling molecule in the 
sphingomyelin signaling pathway, involved in critical cellular processes 
including cell differentiation, apoptosis and proliferation.
1, 2 
S1P is formed 
when sphingosine is readily phosphorylated by sphingosine kinases (SphKs) to 
produce S1P. The amount of S1P generated is dictated by the activity of 
cellular SphKs. Earlier research by our group has shown that SphKs are 
involved in the signalling pathway of mast cells,
3
 regulation of pro-
inflammatory responses triggered by TNF  in primary human monocytes
4
 and 
anaphylatoxin signaling in human neutrophils.
5
 Therefore measuring the SphK 
activity would allow a deeper understanding of the roles of SphKs. 
 
SphK activity is usually measured using the radiometric assay protocol initially 
reported by Olivera et. al..
6
 This involves the generation of 
32
P-labelled S1P for 
measurement of the SphK activity using phosphor-imaging. A variant of the 
radiometric assay involves the use of 
3
H-labeled sphingosine, followed by 
quantification using liquid-scintillation counting.
7
 The use of radiometric 
assays is highly undesirable due to the hazards surrounding radioactive 
material and the labour intensive and time consuming procedures. With the 
growing interest in SphKs as novel targets for drug discovery,
8,9
 it would be 
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desirable to develop a simpler assay for the measurement of SphK activity 
without the use of radio-isotopes.  
 
Billich and coworkers have earlier reported the development of a NBD-labelled 
sphingosine compound NBD-Sph (via coupling of alkyne with Garner’s 
aldehyde)
10,11
 and several BODIPY-labelled sphingosine compounds (via a 
cross-metathesis reaction on an alkene derived from Garner’s aldehyde using 
2
nd
 generation Grubb’s catalyst)12  for the measurement of SphKs’ activities via 
a fluorescence-based assay. NBD-Sph and the BODIPY-labelled spingosine 
compounds each contain a chiral centre and chiral separation was required to 
obtain the required distereoisomer.
 
In addition, performing a SphK assay is an 
expensive experiment as each test with the fluorescence SphK assay requires 
1.0 µg of the fluorescence substrate. Thus there is a need in the academic 
laboratories for a fluorescence compound which is simple and economically 
viable to be synthesized. 
 
Our earlier works on the development of inhibitors of SphKs have resulted in 
the identification of a lead compound 3-1 (Figure 4-1) and functionalities that 
exhibited significant binding to the kinases.
13
   These functionalities generally 
contain (1) a long alkyl chain length, (2) electron donating groups at the C4 
position of the sphingosine backbone and (3) a carbonyl group at the C3 
position. Since 3-1 bears some similarities to the structure of sphingosine, 
modifying 3-1 by opening the 2,2-dimethyl-oxazolidine ring would provide a 
structure that resembles sphingosine except for the keto moiety at the C3 
position. We hypothesized that since such a compound retains the 
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pharmacophores required for good binding ability and also contains a free 
hydroxyl moiety to enable phosphorylation, it could function as a sphingosine 
mimic. Attaching a fluorescence tag to the compound would result in a 
fluorescent-labelled substrate for measuring SphKs’ activities. For our 
preliminary work, three commercially available fluorescence tags, (a) 4-fluoro-
3-nitrobenzoic acid (FNBA); (b) 2-(4-hydroxyphenyl) acetic acid (HPAA); (c) 
2-(7-hydroxy-2-oxo-2H-chromen-4-yl) acetic acid (HOCAA) were chosen 
because of their ease of attachment to compound 4-1 (Scheme 4-2). We hereby 
report the synthesis of the three new fluorescent-labelled sphingosine 
analogues and their applications in a fluorescence based SphK assay in both 96 
























Figure 4-1. Chemical structures of sphingosine, NBD-Sph and 3-1. 
 
4.2 Synthetic Strategy  
To synthesize the sphingosine analogue moiety 4-1 (Scheme 4-1), the alkyl 
backbone 4-4 was first prepared by adapting the method reported by 
Kozikowski et. al. (Scheme 4-1, part a).
14
 10-Bromodecanol 4-2 was protected 
with dihydropyran 
15
 to give 4-3 in 95% yield. Compound 4-3 was then treated 
with lithium acetylide ethylene diamine complex (LAED)
16
 in 
dimethylsulfoxide (DMSO) to provide 4-4 in 85% yield. With compound 4-4 
in hand, we proceeded to couple it with Garner’s aldehyde 4-5 to yield 
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compound 4-6 in 88% yield.
13
 Compound 4-7 was subsequently oxidised to 4-7 
using Dess-Martin Periodinane (DMP)
17,18
 in 83% yield. Finally the THP ether 
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Coupling of 4-1 with FNBA in the presence of N,N'-diisopropylcarbodiimide 
(DIC) and 4-dimethylaminopyridine (DMAP) in dimethylformamide (DMF) in 
the dark gave the fluorescence-tagged 4-8 in 74% yield (Scheme 4-2, part a).
19
 
Removal of  both the acetonide and N-Boc protecting groups with 10% HCl in 
MeOH gave 4-9 in 89% yield.
20
 However, when the same procedure was 
applied to the coupling of 4-1 to HPAA 4-10 or HOCAA 4-11, it resulted in 
many side-products. This could be attributed to the presence of the phenolic 
groups on 4-10 and 4-11. To circumvent the problem, we decided to perform 
the coupling via a Mitsunobu-type reaction. G. Appendino et. al. had earlier 
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reported that a particular Mitsunobu-type reaction was able to distinguish 
between alcohol and phenol hydroxyls in esterification reactions, thus allowing 
the coupling of the alcohol hydroxyl group and acid without any possible side 
reactions (Scheme 5-2, part b).
21
 Using diisopropyl azodicarboxylate (DIAD) 
and triphenylphosphine as reagents in the coupling between 4-1 and 4-10 or 4-
11 gave 4-12 or 4-13, respectively, in good yields. However, removal of the 
acetonide and N-Boc protecting groups with 10% HCl in MeOH resulted in 
many side products which were difficult to separate using any chromatographic 
methods. Attempts to remove the acetonide and BOC protecting groups with 
3M HCl in ethyl acetate,
22





 trifluoroacetic acid (TFA) in dichloromethane (DCM) 
and 5% water
25
 or trifluoroacetic acid and dichloromethane in 1:1 ratio
26
 
proved also to be unsuccessful. At this point, we noted that Kim et. al. had 
employed a three solvent system of TFA: DCM: H2O in a 2:2:1 ratio to 
successfully remove both N-Boc and acetonide protecting groups in good 
yield.
27
 We applied his method in our synthesis and obtained 4-14 and 4-15 in 











Scheme 4-2. Synthesis of fluorescence tagged sphingosine analogues. (a) 4-9; 














































































Unlike the fluorescent-labelled sphingosine, chiral separation was not required 
in the synthesis of our fluorescence compounds 4-9, 4-14 and 4-15 (Scheme 1, 
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synthesis of 4-8, precursor of 4-9, 4-14 and 4-15). This together with the 
shorter synthetic route are significant advantages of our fluorescence 
compounds. Furthermore, our synthetic scheme makes use of common and 
inexpensive reagents and provides a high product yield, thus making it possible 
to scale up the synthetic process to gram scale. 
 
4.3 Results and Discussions 
4.3.1 Fluorescence-based SphK Assay 
Black micro-plates instead of white micro-plates were used for our 
fluorescence-based SphK assay as this would eliminate the background 
fluorescent reading from the white coloured surface of the wells of the micro-
plate. We have also decreased the volume obtained from the upper aqueous 
layer from the standard 100 µl to 75 µl (96 wells) and 50 µl (384 wells) 
respectively. This was done to enable triplicate readings to be obtained from 
each sample and also to reduce errors. Initial trial tests of the fluorescence-
based SphK assays using purified SphK 1 and SphK 2 were conducted using 
compounds 4-9, 4-14 and 4-15 with compound NBD-Sph as a comparison 
(Figure 4-2) The excitation and emission wavelengths for each compound were 















NBD-Sph 466 527 
4-9 480 540 
4-14 345 412 
4-15 331 390 
 
4.3.2 Detection of endogenous SphK activity using the fluorescence assay  
To maximize the potential of our fluorescence assay, we decided to validate the 
compounds in a fluorescence assay setup. Compound 4-9 was chosen because 
kinetic studies (Not shown in this thesis) have shown that 4-9 is of comparable 
sensitivity in detecting SphK 1 and 2 activities as compared to NBD-Sph. The 
experiment was conducted by measuring the endogenous SphK activity from 
cell extracts. Human colorectal cancer cell line HCT 116 is known to have a 
significantly higher level of SphK expression than other cell lines. To validate 
the sensitivity of our assay in detecting endogenous SphK activity, we 
measured the SphK activity of HCT 116 cells and Chinese Hamster Ovarian 
(CHO) cells. The results obtained show, as expected, a significant higher level 
of SphK activity in HCT 116 as compared to CHO cells (Figure 4-2A). We 
then compared the sensitivity of our compound against the reference compound 
in detecting endogenous SphK activity from human cell extracts. The 
endogenous SphK activity measured using compounds 4-9 and NBD-Sph was 





Figure 4-2. Fluorescence SphK assay. A) Fluorescence assay using compound 
4-9 for the comparison of SphK activity between CHO and HCT 116 cells 
extracts. B) Fluorescence SphK assay from HCT 116 cell extracts comparing 
compound 4-9 with NBD-Sph. Note: All readings are represented as fold 
change over blank. A reaction mixture containing no SphK served as blank. 
Results shown are from three independent experiments. * refers to p-value 
<0.05, ** refers to p-value <0.005. 
 
4.3.3 Fluoro-tagged compounds in SphK inhibitory studies  
Next, we evaluated the applicability of our fluorescence assay in SphK 
inhibitory studies. Known competitive SphK inhibitors, N,N-
dimethylsphingosine (DMS) and our SphK 1-specific inhibitor compound 3-
1,
13
 were used to determine the inhibition of endogenous SphK activity. HCT 
116 cells were pre-treated with DMS and 3-1, respectively, before stimulation 
with foetal bovine serum (FBS) to stimulate the endogenous SphK activity. 
Measurement of the SphK activity was carried out using compounds 4-9 and 
NBD-Sph. Results obtained show that upon stimulation with 10% FBS, the 
SphK activity increases by 30%. However in the presence of 3-1, the increase 
in activity is reduced to basal or below basal levels. A similar trend is observed 
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with DMS (Figure 4-3). These results emphasize that compound 4-9 is 
sensitive enough to detect the inhibition of SphK activity levels, even for that 




Figure 4-3. Fluorescence SphK assay results using cell extracts showing SphK 
activity and inhibitory measurements, comparing NBD-Sph and compound 4-
9. Note: Compound NBD-Sph and compound 4-10 detect the increase as well 
as inhibition of SphK activity in HCT 116 cells. HCT 116 cells were pre-
treated with increasing doses of 3-1 or DMS before SphK activity was induced 
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with 10% FBS. Result is the representative of three independent experiments. * 
refers to p-value <0.05, ** refers to p-value <0.005, comparing cell extracts 
from 10% Serum (FBS) stimulated cells with cell extracts from cells stimulated 
with 10% FBS, but pretreated with the SphK inhibitors.  
 
4.3.4 Potential for scaling the fluorescence-based assay for high 
throughput screening 
To further extend the application of our fluorescence-based assay, we applied it 
on a 384-well micro-plate format. Results obtained (Figure 4-4) show that the 
fluorescence assay works equally well for both the 96 well and 384 well micro-
plate format, showing similar sensitivity in detecting the increase in SphK 
activity. This observation suggests that our fluorescence-based assay may 
potentially be developed for high throughput screening of modulators of SphKs. 









Figure 4-4. Fluorescence SphK assay results of compound 4-9 detects SphK 
activity in HCT 116 cells in both 96-well and 384-well micro-plate formats. 
Note: All readings are represented as fold change over blank. A reaction 
mixture containing no SphK served as blank. Result is the representative of 
three independent experiments. 
** 
refers to p-value <0.005, comparing the basal 
(Black) levels with the SphK activity from cell extracts (HCT 116).  
 
4.4 Conclusions 
In conclusion, we have developed a novel fluorescent-labelled substrate 4-9 
which effectively measures the SphK activity from lysate of cells that are 
known to have SphK 1 or SphK 2 DNA expressions. Our fluorescence assay 
could be applied to known inhibitors of SphK 1, such as DMS and compound 
3-1, using both the 96- and 384-well micro plate format. In addition, we have 
demonstrated that compound 4-9 has comparable stability and sensitivity to 
NBD-Sph in the measurement of SphK activity and with C3 being a keto 
functionality instead of a chiral hydroxyl moiety, the purification process in the 
synthesis of compound 4-9 is very much simplified, saving significant cost and 
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time. These findings lend support to compound 4-9 being an alternative fluoro-
tagged substrate for fluorescence-based SphK activity assay.  
 
4.5 Experimental Section 
4.5.1 Chemistry 
General Procedures.  All chemical reagents and solvents were obtained from 
Sigma Aldrich, Merck, Lancaster or Fluka and were used without further 
purification. Analytical TLC was carried out on pre-coated silica plates (Merck 
silica gel 60, F254) and visualized with UV light or stained with 
phosphomolybdic acid (PMA) stain. Flash column chromatography was 
performed with silica (Merck, 70-230 mesh). 
1
H NMR and 
13
C NMR spectra were measured on a Bruker ACF 300 or AMX 
500 Fourier Transform spectrometer. Chemical shifts were reported in parts per 
million (ppm), relative to the internal standard of tetramethylsilane (TMS). The 
signals observed were described as follows: s (singlet), d (doublet), t (triplet), 
m (multiplet). The number of protons (n) for a given resonance was indicated 
as nH. Mass spectra were performed on a Finnigan MAT 95/XL-T mass 
spectrometer under electron spray ionization (ESI) or fast atom bombardment 
(FAB) techniques. Optical rotations were determined with a JASCO DCP-1000 
digital polarimeter and were the average of at least 10 measurements with an 
RSD value of less than +/- 100%. 
 
Synthesis of 2-(10-bromodecyloxy)-tetrahydro-2H-pyran (4-3) 
10-bromo-1-decanol (2.52 mL, 12.65 mmol) and anhydrous dichloromethane 
(20 mL) were placed in a dry round bottom flask. Dihydropyran (1.73 mL, 
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18.97 mmol) and pyridinium p-toluenesulfonate (0.32 g, 1.26 mmol) were 
added in the stated order and the reaction mixture was stirred at room 
temperature for 5 h. After which, the reaction mixture was concentrated and 
purified by column chromatography (dichloromethane: hexane = 1:3) to yield 
4-3. 
1
H NMR (500 MHz, CDCl3) δ 4.53-4.54 (m, 1H, OC(H)CO), 3.67-3.85 
(m, 2H, OCH2CH2 – THP ring), 3.32-3.48 (m, 4H, OCH2CH2, BrCH2), 1.76-
1.84 (m, 3H, BrCH2CH2, OCHC(H)H – THP ring), 1.65-1.70 (m, 1H, 
OCHCH2C(H)H – THP ring), 1.47-1.58 (m, 6H,  OCHC(H)HC(H)H – THP 
ring, OCH2CH2 – THP ring, OCH2CH2), 1.22-1.40 (m, 12H, CH2(CH2)6CH2) ; 
13
C NMR (125 MHz, CDCl3) δ 98.7, 67.5, 62.2, 33.8, 32.7, 30.7, 29.6, 29.4, 
29.3, 29.2, 28.6, 28.0, 26.1, 25.4, 19.6; HRMS (FAB, M + H) calcd for 
C15H30BrO2: 321.1429; found, 321.1372. Yield: 95%. 
 
Synthesis of 2-(dodec-11-ynyloxy)-tetrahydro-2H-pyran (4-4)  
Compound 4-3 (4.15 g, 12.92 mmol) and dimethylsulfoxide (15 mL) were 
placed in a dry round bottom flask and the reaction mixture was cooled to 10 
o
C. Lithium acetylide-ethylene diamine complex (2.62 g, 28.42 mmol) was 
added and the reaction mixture was stirred at 0 °C for 10 minutes. Thereafter, 
the temperature was raised to room temperature and the mixture was stirred 
overnight. After which, the reaction mixture was quenched with deionised 
water (50 mL) and extracted with diethyl ether. The combined organic layer 
was washed with saturated sodium chloride solution, dried over magnesium 
sulfate, filtered, concentrated and purified by column chromatography 
(dichloromethane: hexane = 1:2) to yield 4-4.
 1
H NMR (300 MHz, CDCl3) δ 
4.50-4.51 (m, 1H, OC(H)CO), 3.62-3.83 (m, 2H, OCH2CH2 – THP ring), 3.28-
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3.45 (m, 2H, OCH2CH2), 2.08-2.14 (m, 2H, C≡CCH2), 1.87 (s, 1H, 
HC≡CCH2), 1.73-1.78 (m, 1H, OCHC(H)H – THP ring), 1.61-1.69 (m, 1H, 
OCHCH2C(H)H – THP ring), 1.41-1.52 (m, 8H,  OCHC(H)HC(H)H – THP 
ring, OCH2CH2 – THP ring, OCH2CH2,  C≡CCH2CH2), 1.23-1.32 (m, 12H, 
CH2(CH2)6CH2) ; 
13
C NMR (75 MHz, CDCl3) δ 98.6, 84.5, 67.9, 67.4, 62.0, 
30.6, 29.6, 29.3, 29.2, 28.9, 28.6, 28.3, 26.1, 25.4, 19.5, 18.2; HRMS (FAB, M 
+ H) calcd for C17H31O2: 267.2319; found, 267.2319. Yield: 85%. 
 
Synthesis of (R)-tert-butyl 4-((R)-1-hydroxy-13-(tetrahydro-2H-pyran-2-
yloxy)tridec-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate (4-6) 
Garner’s aldehyde 4-5 (3.40 g, 14.82 mmol) in tetrahydrofuran (6 mL) was 
added, via a cannula, to a solution of 4-4 (4.14 g, 15.56 mmol) and BuLi (10.2 
mL, 16.3 mmol, 1.6 M in hexanes) in tetrahydrofuran (15 mL) at -40 ºC. The 
reaction mixture was stirred under nitrogen for 4 h at -40 ºC. When TLC 
monitoring indicated the complete consumption of the starting materials, the 
reaction mixture was quenched slowly by dropwise addition of distilled water 
(10 mL) and extracted with ethyl acetate. The combined organic layer was 
washed with saturated ammonium chloride solution followed by saturated 
sodium chloride solution, dried over magnesium sulfate, filtered, concentrated 
and purified by column chromatography (ethyl acetate: hexane = 1:5 with 2% 
acetic acid) to yield 4-6. [α]25 = -8.21° (c = 10.6 x 10-3 g/mL, CH2Cl2); 
1
H 
NMR (500 MHz, CDCl3) δ 4.52-4.54 (m, 1H, OCHOCH2), 4.47 (br s, 1H, 
CHOH), 3.98-4.09 (m, 2H, OCH2CHN), 3.77-3.86 (m, 2H, OCH2CH2 – THP 
ring), 3.61-3.69 (m, 1H, OCH2CHN), 3.27-3.47 (m, 2H, OCH2CH2), 2.10-2.14 
(m, 2H, C≡CCH2), 1.64-1.79 (m, 1H, CHOH), 1.52 (s, 6H, OCCH3, NCCH3), 
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1.37-1.46 (m, 10H, OCH(CH2)3O - THP ring, OCH2CH2,  C≡CCH2CH2), 1.43 
(s, 9H, OC(CH3)3), 1.18-1.27 (m, 12H, CH2(CH2)6CH2); 
13
C NMR (125 MHz, 
CDCl3) δ 153.9, 98.5, 94.7, 86.4, 81.0, 77.7, 67.4, 64.8, 63.7, 62.6, 62.0, 53.2, 
30.5, 29.5, 29.3, 29.2, 28.9, 28.6, 28.3, 28.2, 26.0, 25.5, 20.5, 19.4, 18.5; 
HRMS (ESI, M + Na) calcd for C28H49O6NNa: 518.3452; found, 518.3469. 
Yield: 88%. 
 
Synthesis of (4R)-tert-butyl 2,2-dimethyl-4-(13-(tetrahydro-2H-pyran-2-
yloxy)tridec-2-ynoyl)oxazolidine-3-carboxylate (4-7) 
Compound 4-6 (0.46 g, 0.92 mmol) and anhydrous dichloromethane (15 mL) 
were placed in a dry round bottom flask. Dess-Martin periodinane (0.47 g, 1.11 
mmol) and sodium bicarbonate (0.39 g, 4.62 mmol) were added in the stated 
order and the reaction mixture was stirred at room temperature for 1 h. After 
which, the reaction mixture was quenched slowly by dropwise addition of 
saturated sodium bicarbonate solution and extracted with dichloromethane. The 
combined organic layer was washed with saturated sodium chloride solution, 
dried over magnesium sulfate, filtered, concentrated and purified by column 
chromatography (ethyl acetate: hexane = 1:4) to yield 4-7. [α]25 = -30.04° (c = 
156.4 x 10
-3
 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 4.43-4.45 (m, 1H, 
OCHOCH2), 4.22-4.24 (m, 1H, OCH2CHN), 3.92-4.05 (m, 2H, OCH2CHN), 
3.57-3.76 (m, 2H, CH2OCO), 3.23-3.38 (m, 2H, OCH2CH2), 2.22-2.28 (m, 2H, 
C≡CCH2), 1.69-1.72 (m, 1H, OCHC(H)H - THP ring) , 1.58 (s, 3H, OCCH3), 
1.52-1.55 (m, 1H, OCHCH2C(H)H - THP ring), 1.41-1.47 (m, 10H, 
OCHC(H)HC(H)HCH2 - THP ring, OCH2(CH2)2,  C≡CCH2CH2), 1.38 (s, 3H, 





NMR (125 MHz, CDCl3) δ 185.6, 150.9, 98.4, 94.9, 80.2, 78.4, 67.2, 66.3, 
65.4, 61.9, 59.9, 30.5, 29.4, 29.2, 29.1, 28.6, 28.5, 28.0, 27.8, 27.2, 25.9, 25.2, 
24.8, 23.9, 19.3, 18.7; HRMS (ESI, M + Na) calcd for C28H47O6NNa: 
516.3296; found, 516.3303. Yield: 83%. 
 
Synthesis of (R)-tert-butyl 4-(13-hydroxytridec-2-ynoyl)-
2,2dimethyloxazolidine-3-carboxylate (4-1)  
Compound 4-7 (0.22 g, 0.45 mmol) and anhydrous ethanol (8 mL) were placed 
in a dry round bottom flask. Pyridinium p-toluenesulfonate (11.2 mg, 0.045 
mmol) was added and the reaction mixture was warmed and stirred at 55 °C for 
12 h. After which, the solvent was removed under vacuum and the liquid 
obtained was re-dissolved in ethyl acetate. The solution was washed with 
saturated sodium chloride solution, dried over magnesium sulfate, filtered, 
concentrated and purified by column chromatography (ethyl acetate: hexane = 
1:4) to yield 4-1. [α]25 = -31.67° (c = 166.7 x 10-3 g/mL, CH2Cl2); 
1
H NMR 
(500 MHz, CDCl3) δ 4.26-4.28 (m, 1H, OCH2CHN), 3.96-4.09 (m, 2H, 
OCH2CHN), 3.51-3.54 (m, 2H, CH2OH), 2.29-2.32 (m, 2H, C≡CCH2), 1.61 
(m, 2H, OCH2CH2) , 1.56 (s, 1H, CH2OH), 1.47-1.51 (m, 4H, 
HOCH2CH2CH2,  C≡CCH2CH2), 1.45 (s, 3H, OCCH3), 1.42 (s, 3H, NCCH3), 
1.34 (s, 9H, OC(CH3)3), 1.17-1.32 (m, 10H, CH2(CH2)5CH2); 
13
C NMR (125 
MHz, CDCl3) δ 186.0, 151.0, 98.0, 95.1, 80.5, 78.5, 66.4, 65.5, 62.5, 32.5, 
29.2, 29.1, 29.0, 28.7, 28.6, 28.1, 27.9, 27.3, 25.5, 24.9, 24.0, 18.8; HRMS 





Synthesis of (R)-tert-butyl 4-(13-(4-fluoro-3-nitrobenzoyloxy)tridec-2-
ynoyl)-2,2-dimethyloxazolidine-3-carboxylate (4-8)  
Compound 4-1 (0.19 g, 0.46 mmol) and anhydrous dimethylformamide (10 
mL) were placed in a dry round bottom flask. 4-Fluoro-3-nitrobenzoic acid 
(171.5 mg, 0.93 mmol), 4-dimethylaminopyridine (11.3 mg, 0.093 mmol) and 
N,N'-diisopropylcarbodiimide (14.3 µL, 0.93 mmol) were added in the stated 
order and the reaction mixture was stirred at room temperature for 12 h in the 
dark. The reaction mixture was then warmed to 55 °C and stirred for 1 h. The 
temperature was further raised to 90 °C and stirred for another 1 h. After 
which, the reaction mixture was extracted with diethyl ether and the combined 
organic layer was washed with saturated sodium chloride solution, dried over 
magnesium sulfate, filtered, concentrated and purified by column 
chromatography (ethyl acetate: hexane = 1:3) to yield 4-8. [α]25 = -21.74° (c = 
44.8 x 10
-3
 g/mL, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) δ 8.61-8.63 (m, 1H, 
CH=CH-CNO2), 8.23-8.26 (m, 1H, CH=CH-CF),  7.31-7.35 (m, 1H, CH=CH-
CF), 4.27-4.30 (m, 3H, OCH2CHN, C(O)OCH2CH2), 3.97-4.10 (m, 2H, 
OCH2CHN), 2.28-2.33 (m, 2H, C≡CCH2), 1.70-1.72 (m, 2H, OCH2CH2) 1.61 
(s, 3H, OCCH3), 1.42-1.45 (m, 2H, C≡CCH2CH2), 1.36 (s, 3H, NCCH3), 1.34 
(s, 9H, OC(CH3)3), 1.22-1.32 (m, 12H, CH2(CH2)6CH2); 
13
C NMR (125 MHz, 
CDCl3) δ 186.2, 163.6, 158.9, 156.9, 136.5, 127.7, 118.6, 98.2, 95.3, 80.7, 
78.7, 66.5, 66.2, 65.7, 65.3, 60.3, 29.4, 29.2, 29.1, 28.9, 28.8, 28.5, 27.5, 25.8, 
25.1, 24.2, 19.1; HRMS (ESI, M + Na) calcd for C33H39O5N3F1Na: 599.2766; 




Synthesis of (R)-14-amino-15-hydroxy-13-oxopentadec-11-ynyl 4-fluoro-3-
nitrobenzoate (4-9)  
Compound 4-8 (0.10 g, 0.18 mmol) and anhydrous methanol (7 mL) were 
placed in a dry round bottom flask. 10% HCl (0.255 mL, 3M), was added and 
reaction mixture was stirred under reflux for 1 h. After which, the reaction 
mixture was allowed to cool, concentrated under vacuum and the resulting 
solid was re-dissolved in ethyl acetate. The solution obtained was dried over 
magnesium sulfate, filtered, concentrated and purified by column 
chromatography (ethyl acetate: hexane = 1:4, then dichloromethane: methanol 
= 1:10) to yield 4-9. [α]25 = +4.52° (c = 73.5 x 10-3 g/mL, CHCl3); 
1
H NMR 
(500 MHz, Acetone) δ 8.68-8.69 (m, 1H, CH=CH-CNO2), 8.41-8.44 (m, 1H, 
CH=CH-CF),  7.66-7.72 (m, 1H, CH=CH-CF), 4.31-4.65 (m, 5H, OCH2CHN, 
C(O)OCH2CH2 OCH2CHN), 2.56-2.60 (m, 2H, C≡CCH2), 1.79-1.86 (m, 2H, 
OCH2CH2), 1.62-1.69 (m, 2H, C≡CCH2CH2), 1.18-1.48 (m, 12H, 
CH2(CH2)6CH2); 
13
C NMR (125 MHz, CDCl3) δ 180.4, 163.6, 158.9, 156.8, 
137.3, 136.5, 137.6, 118.8, 101.9, 77.6, 66.1, 63.1, 59.5, 29.3, 29.2, 29.1, 29.0, 
28.9, 28.5, 27.4, 25.8, 19.3; HRMS (ESI, M + Na) calcd for C20H31O6N2F1Na: 









General Procedure for the Synthesis of (S)-tert-butyl 4-(13-(2-(4-
hydroxyphenyl)acetoxy)tridec-2-ynoyl)-2,2-dimethyloxazolidine-3-carbox-
ylate (4-12) and (S)-tert-butyl 4-(13-(2-(7-hydroxy-2-oxo-2H-chromen-4-
yl)acetoxy)tridec-2-ynoyl)-2,2-dimethyloxazolidi  -ne -3-carboxylate (4-13) 
Compound 4-1 (0.19 g, 0.46 mmol) and anhydrous tetrahydrofuran (10 mL) 
were placed in a dry round bottom flask. Thereafter, the respective acid (4-
hydroxyphenylacetic acid 4-10 or 7-hydroxy-2-oxo-2H-chromen-4-yl)acetic 
acid 4-11) (0.51 mmol), triphenylphosphine (133 mg, 0.51 mmol) and 
diisopropylazodicarboxylate (102.3 mg, 0.51 mmol) were added in the stated 
order and the reaction mixture was stirred in the dark and at room temperature 
for 48 h. After which, the solvent was removed and the residue was extracted 
with ethyl acetate and the combined organic layer was washed with saturated 
sodium bicarbonate, dried over magnesium sulfate, filtered, concentrated and 
purified by column chromatography (ethyl acetate: hexane = 1:5) to yield 4-12 
or 4-13. For 4-12: [α]25 = -1.4° (c = 2.8 x 10-3 g/mL, Acetone); 1H NMR (500 
MHz, CDCl3) δ 7.09-7.10 (d, 2H, CH=CH-CCH2), 6.75-6.77 (d, 2H, CH=CH-
COH), 4.34-4.36 (m, 1H, OCH2CHN), 4.10-4.17 (m, 2H, OCH2CHN), 4.05-
4.09 (m, 2H, C(O)OCH2CH2), 3.50 (s, 2H, CCH2C(O)OCH2), 2.34-2.38 (m, 
2H, C≡CCH2), 1.69-1.72 (m, 2H, OCH2CH2) 1.53 (s, 3H, OCCH3), 1.42-1.49 
(m, 2H, C≡CCH2CH2), 1.41 (s, 3H, NCCH3), 1.36 (s, 9H, OC(CH3)3), 1.22-
1.25 (m, 12H, CH2(CH2)6CH2); 
13
C NMR (125 MHz, CDCl3) δ 186.4, 172.3, 
155.3, 151.3, 130.2, 125.6, 115.4, 98.5, 95.3, 80.9, 78.7, 66.5, 65.7, 64.9, 60.4, 
40.6, 29.3, 29.0, 28.9, 28.4, 28.3, 28.1, 27.4, 25.7, 25.1, 24.2, 20.9, 19.0, 14.1; 
HRMS (ESI, M + Na) calcd for C34H43O4N2Na: 566.3115; found, 566.3105. 
Yield: 91%. For 4-13: [α]25 = -0.6° (c = 6.3 x 10-3 g/mL, Acetone); 1H NMR 
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(500 MHz, CDCl3) δ 7.39-7.41 (m, 1H, CH=CH-COH), 6.79-6.82 (m, 2H, 
CH=CH-COH, CH=CH-COH),  6.15 (s, 1H, CH=CH-C(O)O), 4.32-4.34 (m, 
1H, OCH2CHN), 4.01-4.14 (m, 4H, OCH2CHN, C(O)OCH2CH2), 3.69 (s, 2H, 
CCH2C(O)OCH2), 2.33-2.36 (t, 2H, C≡CCH2), 1.64-1.67 (m, 2H, OCH2CH2), 
1.59 (s, 3H, OCCH3), 1.49-1.53 (m, 2H, C≡CCH2CH2), 1.46 (s, 3H, NCCH3), 
1.36 (s, 9H, OC(CH3)3), 1.16-1.21 (m, 12H, CH2(CH2)6CH2); 
13
C NMR (125 
MHz, CDCl3) δ 186.2, 168.9, 161.6, 160.8, 155.2, 141.3, 148.9, 125.7, 113.5, 
112.7, 111.8, 103.3, 98.6, 95.2, 80.9, 66.5, 65.7, 65.2, 60.4, 38.2, 29.2, 29.0, 
28.9, 28.8, 28.7, 28.2, 28.0, 27.3, 25.6, 25.1, 24.1, 20.9, 18.9, 14.0; HRMS 
(ESI, M + Na) calcd for C41H41O4N1Na: 634.2928; found, 634.2958. Yield: 
97%. 
 
General Procedure for the Synthesis of (S)-14-amino-15-hydroxy-13-
oxopentadec-11-ynyl 2-(4-hydroxyphenyl)acetate (4-14) and (S)-14-amino-
15-hydroxy-13-oxopentadec-11-ynyl-2-(7-hydroxy-2-oxo-2H-chromen-4-
yl)acetate (4-15) 
Compound 4-12 or 4-13 (0.18 mmol), dichloromethane (2 mL) and water (1 
mL) were placed in a round bottom flask. Trifluoroacetic acid (2 mL) was 
added and the reaction mixture was stirred for 2.5 h. After which, the bottom 
aqueous layer was separated and concentrated under vacuum to yield the 
respective compound of 4-14 or 4-15. For 4-14: [α]25 = +4.52° (c = 73.5 x 10-3 
g/mL, Acetone); 
1H NMR (500 MHz, Acetone) δ 7.04-7.07 (d, 2H, 
CH=C(CH2)-CH), 6.72-6.75 (d, 2H, CH=C(OH)-CH), 4.22-4.56 (m, 2H, 
OCH2CHN0, 3.97-4.05 (m, 2H, C(O)OCH2CH2), 3.54-3.61 (m, 1H, 
OCH2CHN), 3.46 (s, 2H, CCH2C(O)OCH2), 2.47-2.51 (t, 2H, C≡CCH2), 1.54-
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1.55 (m, 4H, OCH2CH2, C≡CCH2CH2), 1.08-1.39 (m, 12H, CH2(CH2)6CH2); 
13C NMR (125 MHz, MeOD) δ 174.2, 174.1, 157.5, 131.3, 126.4, 116.3, 116.2, 
101.2, 69.5, 65.9, 61.8, 41.3, 30.7, 30.5, 30.4, 30.3, 30.2, 29.6, 26.9, 24.2; (ESI, 
M+H) calcd for C23H34O5N1: 404.2432; found, 404.2445. Yield: 58%. For 4-
15: [α]25 = -6.8° (c = 36.4 x 10-3 g/mL, Acetone); 1H NMR (500 MHz, MeOD) 
δ 7.50-7.53 (d, 1H, CH=CH-COH), 6.79-6.81 (d, 1H, CH=CH-COH), 6.70 (s, 
1H, CH=CH-COH),  6.17 (s, 1H, CH=CH-C(O)O), 4.26-4.30 (m, 2H, 
OCH2CHN), 4.07-4.11 (m, 3H, OCH2CHN, C(O)OCH2), 3.83 (s, 2H, 
CCH2C(O)O), 2.45-2.50 (t, 2H, C≡CCH2), 1.54-1.61 (m, 4H, 
C(O)OCH2(CH2)2), 1.19-1.39 (m, 12H, C≡CCH2(CH2)6CH2); 
13
C NMR (125 
MHz, MeOD) δ 180.3, 169.7, 162.2, 161.9, 155.6, 150.4, 126.4, 113.3, 112.0, 
111.8, 102.6, 100.8, 77.5, 65.5, 62.5, 59.1, 37.6, 29.3, 29.2, 29.0, 28.9, 28.7, 
28.4, 27.4, 25.7, 18.5; HRMS (ESI, M+) calcd for C26H34O7N1: 471.2257; 
found, 471.2200. Yield: 67%. 
 
4.5.2 Stimulation of cells with serum  
Human colorectal cancer cell line HCT116 and Chinese hamster ovary cell line 
CHO were purchased from American Type Culture Collection (ATCC). 
HCT116 cells were cultured in McCoy 5A modified medium containing 10% 
fetal bovine serum (FBS) and CHO cells were cultured in Dulbecco's Modified 
Eagle Medium (DMEM) containing 10% fetal bovine serum. HCT116 cells 
were plated at a density of 2x10
6
 cells per well in 6-well plates under low 
serum condition (1% FBS) overnight. Subsequently, cells were pretreated with 
SPHK inhibitors for 15 minutes before stimulation with serum (10% FBS) for 
up to 30 minutes. Samples were lysed in RIPA buffer and the protein 
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concentration was measured using Bradford reagent. Lysates were used for 
western blot analysis and measurement of sphingosine kinase activity. 
 
4.5.3 Fluorescence based Sphingosine Kinase (SphK) Assay 
Proteins, 2.5 ng of purified-recombinant SphK 1 or SphK 2 (purchased from 
BPS Bioscience, USA) or 40 µg of cell lysates, in 2 µL of sonicated 1 mM of 
FluoroTag-BSA solution (which was prepared by mixing 1 mL bovine serum 
albumin solution (4 mg/L) with 40 µL 2mM of Compound NBD-Sph/4-9/4-
14/4-15 in ethanol and 40 µL dimethylsulfoxide) and 5 µL of 20 mM ATP 
solution were added in the stated order into an eppendorf tube. A reaction 
mixture containing no SphK served as blank. The reaction mixture was then 
topped up to 100 µl volume with SphK buffer solution. The mixture was 
vortexed vigorously before placing in a 37 °C water bath for 30 min. After 
which, 100 µL of potassium phosphate buffer (1 M, pH 8.5), followed by 500 
µL of chloroform/methanol (2:1, v/v) were added. The mixture was then 
vortexed vigorously and centrifuged for 5 min at 5000 rpm. 75 uL (96 wells) or 
50 µL (384 wells) of the upper aqueous layer obtained was added into the 
respective wells of a 96 or 384 wells black micro-plate. Thereafter, 75 uL (96 
wells) or 50 µL (384 wells) of dimethylformamide was added into the 
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